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ABSTRACT 
Introduction: The relationship between HIV exposure and body composition (and the 
quality thereof) of preterm infants is not well researched. Human breast milk (HBM) is 
considered inadequate in meeting the protein requirements of very low birth weight 
(VLBW) infants, which could affect the body composition. 
Objectives: The primary objective of this study was to determine the body composition of 
HIV-exposed preterm VLBW and extremely low-birth weight (ELBW) infants. Secondary 
objectives were to evaluate the effect of the treatment duration of maternal highly active 
antiretroviral therapy (HAART) and the effect HBM has on the body composition of this 
vulnerable population. Furthermore, the effect of breast milk fortification and days infants 
were kept nil per os (NPO) has on body composition were also assessed.  
Methods: A descriptive cross-sectional study was conducted between May and October 
2016. HIV-exposed and -unexposed preterm infants (gestational age < 37 weeks) with a 
birth weight of ≤1 200 g were included. Each infant’s maternal medical background was 
recorded. Anthropometric and body composition measurements were recorded weekly 
during the 28-day follow-up period. Nutritional intakes and clinical progress was 
documented daily. 
Results: A total of 113 preterm infants were included in this study, of which thirty infants 
(27%) were HIV-exposed. HIV-exposed infants had significantly ( 𝑝 =  0.01) lower 
gestational ages than HIV-unexposed infants (25–28 weeks). HIV-exposed infants 
displayed significantly lower fat mass percentage (FM%) on day 21 and day 28 (0.9% vs. 
1.4%, 𝑝 = 0.02 and 1.0% vs. 1.5%; 𝑝 = 0.03), respectively. HIV-exposed infants whose 
mothers received HAART for ≥ 20 weeks had higher weights and FM% with lower fat-free 
mass percentages (FFM%) at birth when compared to infants whose mothers received 
treatment for shorter durations (≥ 4–< 20 weeks). In this study 110 of 113 preterm infants 
received HBM, of which 91 infants received fortified HBM. HIV-exposed and unexposed 
infants receiving fortified HBM displayed differences in (FM%) (0.88% vs. 1.36%; 𝑝 = 
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0.01) compared to (0.97% vs.1.49%; 𝑝 = 0.03) and FFM% (98.98% vs. 98.68%; 
𝑝 =  0.03) compared to (99.02% vs. 98.49%; 𝑝 = 0.02), on day 21 and 28 respectively. All 
Infants kept NPO vs. not kept NPO displayed differences in FM% on day 7, 21 and 28 of 
life (0.9% vs 1.3%; 𝑝 = 0.03), (0.99% vs 1.4%; 𝑝 = 0.02) and (0.9% vs 1.6%; 𝑝 = 0.0004) 
as well as differences in FFM% (99.1% vs 98.4%; 𝑝 = 0.0005) on day 28 of life. 
Conclusion: Body composition differs between HIV-exposed and HIV-unexposed 
preterm infants and the duration of maternal HAART affects postnatal infant body 
composition. There were no significant differences in the body composition of HIV-
exposed and HIV-unexposed infants who received HBM or fortified HBM. However, 
between the HIV-exposed infants significant differences in body composition 
measurements were found for infants who received fortified HBM and those who did not. 
Infants who were kept NPO were generally smaller, shorter, and had lower FM% and more 
FFM%.  
Key Message: The ward feeding protocols for preterm infants should be re-evaluated, 
focusing specifically on the HIV-exposed preterm infants, to improve short and long term 
outcomes of this vulnerable population. 
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OPSOMMING 
Inleiding: Die verhouding tussen blootstelling aan MIV, liggaamsamestelling (en die 
kwaliteit daarvan) en premature babas, is nie goed nagevors nie. Menslike borsmelk 
(HBM) word as onvoldoende beskou om in die proteïenvereistes van babas met 'n baie 
lae geboortegewig (VLBW) te voorsien. Dit kan 'n effek op liggaamsamestelling hê. 
Doelwitte: Die primêre doelwit van hierdie studie was om die liggaamsamestelling te 
bepaal van premature babas met baie lae geboortegewig (VLBW) en dié met uiters lae 
geboortegewig (ELBW), wat aan MIV blootgestel was. Sekondêre doelwitte was om te 
evalueer wat die effek was van die tydsduur waartydens die moeder hoogs aktiewe 
antiretrovirale behandeling (HAART) ontvang het, en ook om te bepaal wat die effek is 
van menslike borsmelk (HBM) op die liggaamsamestelling van hierdie kwesbare 
populasie. Hierbenewens, is die effek van borsmelkfortifisering, asook die dae waarop 
babas nil per os (NPO) ontvang het, op liggaamsamestelling bepaal. 
Metodes: 'n Beskrywende deursnit-studie is tussen Mei en Oktober 2016 uitgevoer. 
Premature babas (gestasie-ouderdom < 37 weke) met 'n geboortegewig van ≤  1 200 g 
wat aan MIV blootgestel was en nie aan MIV blootgestel was nie, is as populasie ingesluit. 
Die mediese agtergrond van elke baba se moeder is opgeteken. Antropometriese en 
liggaamsamestellingsmates is weekliks gedurende die opvolgperiode van 28 dae 
opgeteken. Voedings-inname en kliniese vooruitgang is daagliks gedokumenteer. 
Resultate: 'n Totaal van 113 premature babas is by hierdie studie betrek, van wie dertig 
babas (27%) aan MIV blootgestel was. Babas wat aan MIV blootgestel was, het 
beduidend (𝑝 =0.01) laer gestasie-ouderdomme gehad as dié wat nie aan MIV blootgestel 
was nie (25–28 weke). Babas wat aan MIV blootgestel was, het ‘n beduidend laer 
vetmassa-persentasie (FM%) (0.9% vs. 1.4%, 𝑝 = 0.02 en 1.0% vs. 1.5%, 𝑝 = 0.03) op 
Dag 21 en 28 getoon. Babas wat aan MIV blootgestel was en wie se moeders HAART vir 
≥ 20 weke ontvang het, het by geboorte meer geweeg en hoër FM% gehad, met 'n laer 
vetvrye massa-persentasie (FFM%) wanneer hulle vergelyk is met babas wie se moeders 
behandeling vir korter periodes (≥ 4–< 20 weke) ontvang het. In hierdie studie het 110 
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van die 113 premature babas menslike borsmelk (HBM) ontvang en 91 gefortifiseerde 
menslike borsmelk (HBM). Babas wat aan MIV blootgestel was en dié wat nie aan MIV 
blootgestel was nie, en wat gefortifiseerde menslike borsmelk (HBM) ontvang het, het 
verskille getoon in FM% (0.88% vs. 1.36%; 𝑝 = 0.01) teenoor (0.97% vs.1.49%; 𝑝 = 0.03) 
en FFM% (98.98% vs. 98.68%; 𝑝 = 0.03) teenoor (99.02% vs. 98.49%; 𝑝 = 0.02) op Dag 
21 en 28 onderskeidelik. Die babas wat nil per os (NPO) ontvang het vs. babas was nie 
NPO ontvang het nie, het geen verskille getoon in FM% (0.9% vs. 1.3%; 𝑝 = 0.03), (0.99% 
vs. 1.4%; 𝑝 = 0.02) en (0.9% vs. 1.6%; 𝑝 = 0.0004) op Dag 7, 21 en 28 van lewe, en ook 
nie in FFM% (99.1% vs. 98.4%; 𝑝 =  0.0005) op Dag 28 van lewe nie. 
Gevolgtrekking: Die liggaamsamestelling van premature babas wat aan MIV blootgestel 
was en dié wat nie aan MIV blootgestel was nie, verskil. Daarbenewens beïnvloed die 
tydsduur waartydens die moeder HAART-behandeling ontvang, die postnatale 
liggaamsamestelling van 'n baba. Daar was geen beduidende verskille in die 
liggaamsamestelling van babas wat aan MIV blootgestel was en dié wat nie aan MIV 
blootgestel was nie, en wat menslike borsmelk (HBM) of gefortifiseerde menslike 
borsmelk (HBM) ontvang het nie. In terme van die babas wat aan MIV blootgestel was, is 
daar egter beduidende verskille gevind in die liggaamsamestellingsmates van dié wat 
gefortifiseerde menslike borsmelk (HBM) ontvang het en dié wat dit nie ontvang het nie. 
Babas wat nil per os (NPO) ontvang het, was oor die algemeen kleiner, korter en het 'n 
laer FM% en meer FFM% gehad. 
 
Sleutel boodskappe: Die saal voedingsprotokolle vir premature babas moet 
geherevalueer word, met spesifieke fokus op MIV blootgestelde premature babas, om kort 
en langtermyn-uitkomste van hierdie kwesbare populasie te verbeter. 
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GLOSSARY OF TERMS  
2-Compartment model – The 2-C model separates the body into two compartments: fat 
mass (FM) and fat-free mass (FFM), the latter consisting of heterogeneous components 
comprised of carbohydrates, protein, water and minerals.1 2 3 4 5 
3-Compartment model – The 3-C model divides the human body into three 
compartments: fat mass, water and fat-free mass. The FFM compartment is divided into 
two components: body water content and remaining solids (protein and minerals), 
measuring water, fat and body solids in terms of body composition.3 
4-Compartment model – The 4-C model is an expansion of the basic 3-C model as it 
measures not only the total body water, but also the densities of total body protein and 
bone minerals. Therefore, it includes measurements of total body weight, total body 
volume, total body water and bone mineral density.1 3 4 
5/Multi-compartment model – The 5-C model stipulates a structural framework that 
divides the human body into the following compartments according to increasing 
complexity: atomic, cellular, molecular, tissue and whole body.2 3 6  
Adipose tissue – Adipose tissue is anatomically defined as tissue comprised of: 
adipocytes/fat cells, nerves, blood vessels and extracellular fluid.2 
Air displacement plethysmography – ADP is a highly accurate measuring technique 
that measures paediatric body composition in a closed chamber. ADP directly measures 
body mass and volume to calculate body density, thereby determining total body fat 
percentage.2 7 
Anthropometric measurements – A set of measurements (weight, length and head 
circumference) to assess the nutritional status of an infant.8 
Antiretroviral therapy – Specialised medication for the treatment and control of HIV 
infection. ART consists of a combination of three or more ARV medications used to kill or 
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suppress viral replication and the replication and progression of the HIV disease. Also 
known as HAART, it is usually given for life and comprises different classes of drugs, 
depending on the different stages of the HIV-cycle.9 10 
Appropriate for gestational age – Describes the size of an infant whose birth weight 
against gestational age plotted on Fenton’s-premature growth chart falls between the 10th 
and 90th percentile.9 11  
Bioelectrical impedance – BIA is a precise method for assessing body composition 
through measuring the impedance or resistance of the body by passing a weak alternating 
electrical current at a fixed frequency. BIA estimates total body water, fat-free mass, fat 
mass and body cell mass.9 12 
Biceps skinfold – BiSFT/BS is measured in the anterior midline of the left arm over the 
biceps muscle at the same level of the triceps skinfold, while the participant’s arm is placed 
at his/her side.13 14 
Body composition – Describes the percentage of fat, bone and muscle in human bodies.  
Catch-up growth – A preterm infant achieving a growth rate similar to that of a healthy 
fetus growing in utero.15 16 It can also be defined as a higher than normal growth rate after 
a period of growth suppression owing to an extent of illness or deprivation.9 
Donor breast milk – DBM is when a lactating mother donates her breast milk to be used 
for infants whose mothers do not have an adequate supply of breast milk. DBM is safe to 
use as it is pasteurised and considered the next best alternative.17 
Dual-energy x-ray absorptiometry assay – DXA is defined as a non-invasive technique 
commonly used to measure body composition in infants. The infant is removed from the 
NICU and placed in an x-ray scanning machine which measures fat mass, fat-free mass 
and bone mineral mass.2 18 
Extra cellular solids – A non-metabolising part of the human body, consisting of organic 
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compounds: collagen, reticular and elastic fibres: i.e. muscle and inorganic compounds 
(bone, bicarbonate, citrate, magnesium and sodium).19  
Extracellular water – A non-metabolising fluid made up of 94% water that surrounds 
body cells. Extra-cellular water provides a medium for gas exchange, transferring of 
nutrients and excretion of metabolic end products. It can also be used to describe fluid 
shifts and balances to determine hydration status.19 20 
Extremely low birth weight – An infant weighing < 1 000 g.9 11  
Fat-free mass – FFM is a heterogeneous component comprised of carbohydrates, 
protein, water and minerals.12 
Fat mass – The part of the human body that is comprised of fat from all of the bodily 
sources found in the brain, skeleton and adipose tissue.9 
Fat – A sub-component of adipose tissue/lipid, predominantly found at a molecular level.2 
Fixed-dose combination – Multiple antiretroviral drugs combined into one pill. FDC is 
made up of three drugs used in the first-line regimen for treating HIV. It is comprised of 
Tenofovir (TDF, 300 mg) +  Emtricitabine (FTC, 200 g) +  Efavirenz (EFV, 600 mg) to 
improve adherence and retention.10 21  
Feeding intolerance – vomit or an aspirate.  
Fortified breast milk – Supplements of protein, carbohydrates, fat, minerals, and 
vitamins added to human breast milk to meet the increased nutrient needs of preterm 
infants.9 
Gestational age – Gestational age (GA) is calculated on the basis of the date of the 
mother’s last menstrual cycle or according to the first trimester ultrasound prior to 12 
weeks.22 
Growth failure – Poor growth in infants resulting in infants not reaching weight-for-age, 
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height-for-age or both.9 23 24 
Highly active antiretroviral therapy – HAART is a triple drug combination for the 
treatment of HIV infection.25 
Human immunodeficiency virus – HIV is the retrovirus isolated and recognised in the 
etiology of AIDS.  
HIV-positive – Infected with the human immunodeficiency virus. 
HIV-negative – Not infected with the human immunodeficiency virus. 
HIV-exposed – An infant born to a woman who is HIV-positive or who becomes HIV-
positive any time during pregnancy, labour and delivery, or breastfeeding. The infant is at 
risk of acquiring the HIV infection.10 
HIV-exposed uninfected – HIV-EU is an internationally used term to describe an infant 
born to a mother who tested positive any time during pregnancy, labour and delivery, or 
breastfeeding but who has not had a positive PCR test.26 
HIV-unexposed – An infant born to a woman who is HIV negative or who does not 
become HIV positive any time during pregnancy, labour and delivery, or breastfeeding. 
The infant is not at risk of acquiring HIV. This is also known as HIV-unexposed uninfected 
(HIV-UU). 
Intrauterine growth restriction – A decrease in fetal growth rate as determined by the 
obstetrician during pregnancy.9 
Large for gestational age – Describing the size of an infant whose birth weight against 
gestational age, plotted on Fenton’s-premature growth chart, falls above the 90th 
percentile.9 11 
Lean body mass – LBM is the part of the body free that is from adipose tissue. It is 
comprised of skeletal muscle, water, bone and a small amount of essential fat found in 
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the organs, bone marrow and nerves.9 19 27  
Lipodistrophy – A change in the way the body produces, uses and distributes fat mass. 
Patients have a significant loss of fat from the extremities (arms and legs) with an increase 
in visceral fat deposits.39 
Low birth weight – LBW is the birth weight of an infant that is < 2500 g.9 
Metabolic syndrome – A medical condition or representation of a variety of syndromes 
associated with glucose intolerance, insulin resistance (often associated with type-2 
diabetes), hyperlipidemia, and hypertension; and strongly linked to abdominal obesity.9 28 
Nutritional intervention – The nutritional related activities or actions which can have an 
impact on nutrition and health outcomes.29 
Pre-eclampsia – A common complication that arises during pregnancy, characterised by 
high blood pressure.30 
Premature birth –defined as the birth of an infant before 37+0 week’s gestation.9 31 32 
Prevention of mother-to-child transmission – PMTCT is a set of guidelines derived 
from the World Health Organization (WHO) and South African National guidelines, which 
stipulates that all pregnant and breastfeeding HIV-infected women qualify for lifelong ART. 
HIV and appropriate preparation counselling must be done on the day of the HIV 
diagnosis. HIV-infected women should initiate treatment on the same day as diagnosis. 
Patients should receive ongoing counselling from trained counsellors throughout and after 
pregnancy.21 
Protease inhibitor – An antiretroviral drug that prevents the functioning of the viral 
protease enzyme and prevents viral replication.9 
Skinfold thickness – A double fold of subcutaneous adipose tissue excluding any 
underlying tissue is precisely measured by callipers at several standardised points to 
determine body fat percentage.33 34  
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Small for gestational age – Describing the size of an infant whose birth weight against 
gestational age, plotted on Fenton’s-premature growth chart, falls below the 10th 
percentile.9 11  
Subcutaneous fat – Fat that is stored directly under the skin that insulates the body, 
preserving body heat and maintaining body temperature.9 
Subscapular skinfold – SSSF/SBS is measured on the left side, below the tip of the 
inferior angle of the scapula. The SSSF/SBS is picked up on the diagonal, inclined infero-
laterally at a 45° angle versus the horizontal plane in the natural cleavage line of the skin.13 
14 
Suprailiac skinfold – SiSF/SPS is measured right above the iliac crest on the left side 
1 cm medial from the edge of the bone.13 14 
Triceps skinfold – TSF/TS is measured in the posterior midline of the left arm, over the 
triceps muscle, at the midway point between the lateral projection of the acromion process 
of the scapula and the inferior margin of the olecranon process of the ulna, while the 
participant’s arm is placed at his/her side.13 14 
Very low birth weight – An infant who weighs < 1 500 g.9 11  
Viral load – The measurement of the amount of HIV virus in the blood, stated as copies 
per millimetre.9 
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LIST OF ABBREVIATIONS AND ACRONYMS 
2-C:  Two-compartment model 
3-C:  Three-compartment model 
4-C:  Four-compartment model 
5-C:  Five-compartment model/multi-compartment model  
ADP: Air displacement plethysmography 
AGA:  Appropriate for gestational age 
ART: Antiretroviral therapy  
ANOVA:  Analysis of variance 
AZT:  Zidovudine 
BIA:  Bioelectrical impedance 
BM:  Body mass 
BCM:  Body cell mass 
BF:  Body fat 
BFHI: Baby Friendly Hospital Initiative 
CVD:  Cardiovascular disease 
DBM:  Donor breast milk 
EFV:  Efavirenz 
ELBW:  Extremely low birth weight (< 1 000 g) 
EN:  Enteral nutrition 
ESPGHAN: The European Society for Paediatric Gastroenterology, Hepatology and 
Nutrition 
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FFM: Fat-free mass 
FM:  Fat mass 
FTC:  Emtricitabine 
GA:  Gestational age 
HAART: Highly active antiretroviral therapy 
HBM:  Human breast milk 
HIV:  Human immunodeficiency virus 
HIV-EU:  HIV-exposed uninfected 
HIV-UU:  HIV-unexposed uninfected 
IUGR:  Intra-uterine growth restrictions 
IL-2:  Interleukin-2 
LBW:  Low birth weight (< 2 500 g) 
LGA: Large for gestational age 
MOM:  Mother’s own milk 
MTCT:  Mother-to-child transmission 
MUAC:  Mid-upper arm circumference 
NCPAP:  Nasal continuous positive airway pressure 
NEC:  Necrotising enterocolitis  
NHANES:  National Health and Nutrition Examination Survey 
NICU:  Neonatal intensive care unit 
NPO:  Nil per os 
NVP:  Nevirapine 
PCA:  Post-conception age 
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PCR:  Polymerase chain reaction 
PBM:  Pasteurised breast milk 
PMTCT:  Prevention of mother-to-child transmission 
TSD:  Standard deviation 
SFT:  Skinfold thickness 
SGA:  Small for gestational age 
SSSF:  Subscapular skinfold 
TBF:  Total body fat 
TAH:  Tygerberg Academic Hospital 
TBCH: Tygerberg Children’s Hospital 
TDF:  Tenofovir 
TSF:  Triceps skinfold 
TPN:  Total parenteral nutrition 
VLBW:  Very low birth weight (< 1 500 g) 
WHO:  World Health Organization 
%BF:  Body fat percentage 
%TBF:  Total body fat percentage 
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MOTIVATION FOR THE STUDY 
HIV is highly prevalent in South Africa and HIV-infected pregnant mothers have a 
considerably higher risk (13–34%) of delivering an infant preterm.1 2 The literature 
concludes that there is an evident gap in documented research in developed and 
developing countries regarding the relationship between HIV, nutritional intakes, 
pharmacological interventions, body composition and preterm infants.3 4 5 6 7 8 9 Preterm 
infants do not necessarily achieve the extra-utero growth rates or have body compositions 
similar to those of their term counterparts. Preterm infants, who experience difficulty 
achieving these growth rates could suffer from growth failure. These infants display 
increased intra-abdominal adiposity and abnormal body composition when they achieve 
catch-up growth. These factors affect the quality of weight gain, as these infants are not 
only shorter and lighter than their term counterparts, but they also have more fat mass 
and less fat-free mass, resulting in a higher total body fat percentage. This could cause 
metabolic syndrome and cardiovascular problems to develop later in a preterm infant’s 
life.  
The methods used to determine body composition in preterm infants should be simple, 
quick, and non-invasive. Available literature was reviewed and the Dauncey 
anthropometric model, which includes skinfold thickness at two primary sites and 
measures nine body dimensions, was considered in this review to be the best method to 
accurately determine body composition in preterm infants, especially in resource-poor 
countries. It is imperative to accurately assess the quality of growth and body composition 
of this fragile population to determine whether currently prescribed nutritional interventions 
are beneficial to the overall nutritional status and quality of life in the short and long term 
of the preterm infant, and to enable timely implementation of appropriate interventions, if 
required. 
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BRIEF OUTLINE OF THE THESIS 
This thesis is divided into four chapters. A brief overview of each chapter will now be given.  
Chapter 1 covers the literature review and includes the following review article: 
Factors affecting body composition in preterm infants: Assessment techniques and 
nutritional interventions. The article focuses on the body composition (in terms of fat mass 
and fat-free mass) of preterm, very- and extremely-low birth weight infants and 
concentrates on the broad assessment techniques available to accurately assess and 
determine body composition in preterm infants, especially in a resource-poor setting. This 
review also focuses on the relationship between nutritional interventions and 
pharmacological interventions and body composition of preterm infants.  
This review article was published in the journal Paediatrics and Neonatology in November 
2017.  
Strydom K, et al. Factors affecting body composition in preterm infants: Assessment techniques 
and nutritional interventions, Pediatrics and Neonatology (2017), 
https://doi.org/10.1016/j.pedneo.2017.10.007  
A literature review was conducted on different breast milk fortification strategies and the 
body composition of preterm, very- and extremely-low birth weight infants. The nutritional 
requirements are much higher in preterm infants when compared with their term 
counterparts. This review assessed which fortification strategy was most suitable for 
implementation in a resource-limited hospital to ensure preterm infants achieved their high 
nutritional requirements to ensure adequate growth and body composition.  
A literature review was conducted on the body composition of HIV-exposed and HIV-
unexposed, preterm, very- and extremely-low birth weight infants. HIV is highly prevalent 
in South Africa and HIV-infected pregnant mothers have a considerably higher risk of 
delivering an infant prematurely. However, the body composition of HIV-exposed infants 
was unclear. This review focuses on the effect that the treatment duration of maternal 
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highly active antiretroviral therapy (HAART) had on the body composition of preterm 
infants, HIV-exposed and HIV-unexposed infant outcomes and HIV-exposed infants and 
their body composition.  
Chapter 2 consists of the methodology of this cross-sectional descriptive study.  
Chapter 3 presents the study results in article format. Two articles are included in Chapter 
3: 
Article 1: The effect of maternal HIV status and treatment duration on body 
composition of HIV-exposed and HIV-unexposed preterm, very- and extremely-low 
birth weight infants. This article addresses the primary and secondary objectives of the 
study. The primary aim of this study was to determine the body composition of HIV-
exposed and HIV-unexposed preterm, VLBW and ELBW infants. The secondary objective 
was to assess the effect of the treatment duration of HAART of HIV-infected mothers on 
the body composition of these infants.  
This article was published in the journal Paediatrics and International Child Health (YPCH) 
in April 2018.  
Klara Strydom, Daniel Gerhardus Nel, Muhammad Ali Dhansay & Evette van Niekerk (2018): The 
effect of maternal HIV status and treatment duration on body composition of HIV-exposed and 
HIV-unexposed preterm, very and extremely low-birthweight infants, Paediatrics and International 
Child Health, DOI: 10.1080/20469047.2018.1466481  
Article 2: How does nutritional intake affect the body composition of HIV-exposed 
and HIV-unexposed preterm, very- and extremely-low birth weight infants? This 
article addresses the final objective of this study, which was to determine the effect 
nutritional intakes had on the body composition of HIV-exposed and HIV-unexposed 
preterm, VLBW and ELBW infants.  
This article is under review by the journal of Breastfeeding Medicine.  
Chapter 4 concludes the study objectives and findings. This chapter briefly accepts or 
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rejects the set of null hypotheses of this cross-sectional descriptive study. Limitations are 
discussed and recommendations for further research are made.  
The Vancouver referencing style has been used throughout the dissertation, unless 
otherwise stipulated by a journal’s specification.  
In this thesis, the terms HIV-exposed and HIV-exposed uninfected (HIV-EU) and HIV-
unexposed and HIV-unexposed uninfected (HIV-UU) may be used interchangeably. This 
was done in accordance with the selected journals’ specifications and standards. Refer to 
the glossary of terms on page xvi for the definitions of terms.  
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CHAPTER 1  
 
LITERATURE REVIEW 
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REVIEW ARTICLE 
1.1 FACTORS AFFECTING BODY COMPOSITION IN PRETERM INFANTS: 
ASSESSMENT TECHNIQUES AND NUTRITIONAL INTERVENTIONS 
 
Strydom K, et al. Factors affecting body composition in preterm infants: Assessment 
techniques and nutritional interventions, Pediatrics and Neonatology (2017), 
https://doi.org/10.1016/j.pedneo.2017.10.007  
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Figure 0.1Figure 1: Basic compartment model figure adapted from Ellis, “Human body 
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composition: In Vivo methods” 
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Table 0.1: Summarizing the advantages and disadvantages of different techniques for measuring body composition in preterm infants 
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For the purposes of this thesis, it was necessary to include the following subject areas in 
the literature review as they did not form part of the published review article titled Factors 
affecting body composition in preterm infants: Assessment techniques and 
nutritional interventions. They include i) fortification strategies and how they affect infant 
body composition and ii) the effects of HIV infection on body composition. 
1.2 LITERATURE OVERVIEW OF FORTIFICATION STRATEGIES AND 
BODY COMPOSITION  
In 2012, the World Health Organization (WHO) estimated that eight out of every 100 
babies were born prematurely in South Africa.1 The third trimester of pregnancy is an 
imperative period in a neonate’s life as this is when the infant undergoes rapid growth in-
utero. Compared with their term counterparts, an infant born prematurely misses out on 
this fundamental growth period and therefore their nutritional requirements are much 
higher than an infant carried to term.2  
The composition of breast milk from mothers who delivered preterm infants is initially 
higher in protein and fat, when compared with term breast milk. The composition of human 
breast milk (HBM) changes over time.2 3 4 5 A study by Hsu et al.6 examined the change 
in macronutrient composition of preterm breast milk over a four-week post-partum period. 
The results concluded that the composition of fat increased gradually and the composition 
of protein decreased slowly over the first weeks of lactation. The European Society of 
Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommends that 
very low birth weight (< 1.5 kg; VLBW) infants receive enteral and parenteral energy 
intakes of 110–135 kcal/kg/day and 110-120 kcal/kg/day, respectively and a protein 
intake of 3.5–4 g/kg/day.3 4 27 These infants are particularly challenging to feed because 
of the high recommended daily allowance of energy, protein and nutrients required to 
achieve in-utero growth rates, in conjunction with the slow feeding progressions and small 
feeding volumes tolerated, as well as the gastrointestinal immaturity of these very small 
and immature infants.1 6 8 9 10 11  
When fed in amounts that satisfy energy requirements, preterm milk only provides about 
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60% of an infant’s protein requirements.1 12 13 Therefore, HBM from mothers with preterm 
infants is not nutritionally adequate and must be fortified to ensure adequate growth and 
body composition in terms of fat mass (FM) and fat-free mass (FFM). Supplementation of 
HBM with a fortifier is common practice in many neonatal intensive care units (NICUs) to 
achieve nutritional requirements and improve intrauterine growth rates in preterm infants, 
while the many benefits of HBM, such as better neurodevelopmental outcomes, improved 
gastrointestinal function and a decrease in late-onset sepsis and necrotising enterocolitis 
(NEC) continue to be recorded.1 6 9 14  
Please refer to Chapter 3, Article 2: How does nutritional intake affect the body 
composition of HIV-exposed and HIV-unexposed preterm, very- and extremely-low birth 
weight infants?; table 1 and 2 in this thesis. Table 1 and 2 compares the breast milk 
composition, in terms of volume (ml/kg/day), energy density (kcal/kg/day) and 
macronutrient concentration, for HBM alone and fortified HBM and the nutritional intake 
of HIV-exposed and HIV-unexposed preterm infants.  
South Africa has only one commercially available fortifier, namely FM85.15 There are three 
main types of fortification strategies namely, standard, super and individualised 
fortification. 
i. Standard fortification is the method most commonly used in NICUs, and entails the 
addition of a fortifier to a volume of HBM according to the manufacturer’s 
specifications. This fortification strategy is quick and simple, but has been found to 
rarely meet the protein requirements of preterm infants.1 12 15 16  
ii. Super fortification is the addition of a dose of fortifier to a lower volume of HBM 
than that recommended by the manufacturer. This fortification strategy ensures 
that a higher protein intake is achieved. However, because the energy and 
micronutrient intake is also greater, it does not change the protein to energy ratio 
which could increase the lean body mass of these infants. Super fortification and 
standard fortification are the most commonly implemented fortifiers in NICUs 
across South Africa. 
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iii. Individualised fortification can include adjustable or targeted fortification. 
Adjustable fortification is a modified fortification method based on the preterm 
infant’s metabolic response. Periodic blood urea nitrogen values determine the 
amount of additional protein that can be supplemented by adding modular protein 
to a standard amount of fortifier.1 12  17  
iv. Targeted fortification analyses HBM by means of infrared spectrometry. This is a 
method of fortification tailored according to the macronutrient composition of HBM 
after it has been analysed and according to the individual needs of the preterm 
infant.1 12 15  
A recent review by Kemp1 critically analysed the various fortification strategies. This 
review concluded that, if implemented correctly, standard fortification was a safe and well-
tolerated method to improve in-hospital growth of preterm infants. If adequate growth of 
the preterm infant was not achieved, alternative strategies such as the super, adjustable 
or targeted fortification should be explored. A study by Natale15 concluded that targeted 
fortification is the most accurate and suitable strategy, leading to higher protein intakes 
and adequate growth. However, this strategy is expensive, labour-intensive and requires 
specialised technologies.17 
Fortification strategies can range from simple, quick, safe and inexpensive (standard 
fortification and super fortification) to complex, sophisticated and expensive (adjustable 
and targeted fortification). The standard fortification strategy is the most suitable for 
implementation in a resource-limited hospital, as it is imperative for preterm infants to 
receive their recommended nutritional requirements, to ensure the adequate growth, body 
composition and development of this fragile population.  
This study was conducted in a resource-limited area of the Western Cape, South Africa. For the 
purposes of this study, ward protocol was followed by the researcher for the fortification of HBM 
in Tygerberg Children’s Hospital (TBCH). FM85 was the fortifier used and the standard fortification 
strategy was implemented.15 18  
Stellenbosch University  https://scholar.sun.ac.za
 14 
 
REFERENCES  
1.  Kemp J, Wenhold F. Human milk fortification strategies for improved in-hospital growth of preterm 
infants. South African J Clin Nutr. 2016;29(4):157–164.  
2.  Underwood MA. Human milk for the premature infant. Pediatr Clin North Am. 2013;60(1):189–207.  
3.  Mimouni FB, Lubetzky R. Preterm human milk macronutrient and energy composition: A systematic 
review and meta-analysis. Clin Perinatol. 2017;44(1):165–172.  
4.  Mahajan S, Chawla D, Kaur J, Jain S. Macronutrients in breastmilk of mothers of preterm infants. 
Indian Paediatr. 2017;54:635–637. 
5.  Gidrewicz DA, Fenton TR. A systematic review and meta-analysis of the nutrient content of preterm 
and term breast milk. BMC Pediatr. 2014;14(216):1–14. 
6.  Hsu Y, Chen C, Lin M, Tsai C, Liang J, Wang T. Changes in preterm breast milk nutrient content in 
the first month. Pediatr Neonatol. 2014;55(6):449–454.  
7.  Liu M-Y, Chen Y-Y, Hu S-H, Chen Y-K, Chang S-J. The influence of aggressive parenteral nutrition 
to preterm and very low birth weight infants. Glob Pediatr Heal. 2015;2(0):3–8.  
8.  Ramel SE, Gray HL, Davern BA, Demerath EW. Body composition at birth in preterm infants between 
30 and 36 weeks gestation. Pediatr Obes. 2015;10(1):45–51.  
9.  Brown JVE, Embleton ND, Harding JE, Mcguire W. Multi-nutrient fortification of human milk for 
preterm infants. Cochrane Database Syst Rev. 2016;(5):1–57. 
10.  Rigo J, de Curtis M, Pieltain C. Nutritional assessment in preterm infants with special reference to 
body composition. Semin Neonatol. 2001;6(5):383–391.  
11.  Demerath EW, Johnson W, Davern BA, et al. New body composition reference charts for preterm 
infants. Am J Clin Nutr. 2017;105(1):70–77. 
12.  Radmacher PG, Adamkin DH. Fortification of human milk for preterm infants. Semin Fetal Neonatal 
Med. 2017;22(2017):30–35.  
13.  Tonkin EL, Collins CT, Miller J. Protein intake and growth in preterm infants: A systematic review. 
Glob Pediatr Heal. 2014;1:1–20.  
14.  Wauben IP, Atkinson S a, Shah JK, Paes B. Growth and body composition of preterm infants: 
Influence of nutrient fortification of mother’s milk in hospital and breastfeeding post-hospital 
discharge. Acta Paediatr. 1998;87(7):780–785. 
15.  Nestlé (South Africa). Nestlé ( South Africa ) ( Pty ) Limited Reformulation of FM85.; 2016. 
16.  Arslanoglu S. IV. Individualized fortification of human milk: Adjustable fortification. J Paediatr 
Gastroenterol Nutr. 2015;61(1):4–5. 
17.  Arslanoglu S, Moro GE, Ziegler EE. Adjustable fortification of human milk fed to preterm infants : 
does it make a difference ? J Perintology. 2006;26(October):614–621. 
18.  Western Cape Paediatric Nutrition Working Group. Clinical Guideline: Nutrition of the Premature and 
Low birthweight Infant. Metropole Pediatric Interest Group. Western Cape, 2009;1–73. 
Stellenbosch University  https://scholar.sun.ac.za
 15 
 
1.3 LITERATURE REVIEW OF THE BODY COMPOSITION OF HIV-
EXPOSED AND HIV-UNEXPOSED PRETERM INFANTS 
Almost no literature exists within the South African context regarding preterm infants, HIV, 
medication and the effects these have on growth and body composition.1 The relationship 
between HIV, prematurity and medication is an on-going global debate.2 According to the 
literature, different countries, even different health care systems provide different regimes, 
drug combinations and drug lines of HIV medication based on individual circumstances. 
HIV treatment regimes, lines and drugs are complex and specialised as they are 
constantly improved owing to increasingly sophisticated technology. 
HIV is highly prevalent in South Africa and HIV-infected pregnant mothers have a 
considerably higher risk (13–34%) of delivering an infant preterm.3 2 The Western Cape 
province of South Africa’s health department follows a set of guidelines to prevent the 
transmission of HIV from the mother to her unborn or born infant, which has produced 
favourable results.4 The most recent national consolidated guidelines, for the prevention 
of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, 
adolescents and adults released in April 2015 presented the following statistics:5 
 The coverage of HIV testing of pregnant women is close to 100%. 
 The PMTCT programme is now offered in 98% of health facilities around South 
Africa.  
 The percentage of HIV-positive pregnant women receiving antiretroviral therapy 
(ART) to reduce mother-to-child transmission (MTCT) increased from 83% in 2009 
to 87.1% 2012.  
 The percentage of MTCT had decreased to 2.7% in 2011.  
Research conducted in Africa provides evidence that HIV-exposed children have lower 
birth weights, poorer early growth and poorer health and survival rates compared with 
HIV-unexposed children. However, there is limited literature on the actual causes of poor 
growth and health of HIV-exposed infants in African countries.6 7 A combination of factors 
may contribute to the increase in morbidity among HIV-exposed infants, including a 
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reduction in maternal transfer of antibodies, increased exposure to infectious pathogens 
from the mother and an altered immunologic development.8  
Owing to the absence of literature regarding preterm infants and the effects of HIV and 
HIV medication on body composition, the literature based on children who were HIV-
positive or HIV-exposed was used for this study.1 According to this research, HIV-positive 
children who received treatment had an altered body composition when compared with 
their HIV-negative counterparts.9 1 For this reason, anthropometric measurements and 
body composition techniques are vital to assess the nutritional status of infants.  
1.3.1 Preterm HIV medication 
In a systematic review, Alemu, Yalew, Fantahun and Ashu2 compared perinatal outcomes 
of HIV-infected pregnant women who were or were not receiving ART. The study found 
that the prevalence of HIV-infected pregnant women in parts of southern Africa was ≥
  30%. This systematic review acknowledged that premature birth, low birth weight (LBW) 
and intra-uterine growth restrictions were universally seen as causes of perinatal morbidity 
and mortality. However, there is an on-going global debate regarding the role of maternal 
highly active antiretroviral therapy (HAART) in adverse pregnancy outcomes. In 
developing countries, the risk of MTCT is still very high owing to the low standards of 
health care, poor antenatal care, late diagnosis of pregnancy, shortage of ART from 
primary health care clinics and unsystematic interventions for PMTCT.  
In June 2014, a set of PMTCT guidelines were adapted from the World Health 
Organization (WHO) and South African National guidelines to include international and 
national standards, which met the needs and recommendations of the Western Cape 
Province. The 2014, PMTCT guidelines stipulated that all HIV-negative pregnant women 
needed to have routine HIV tests at: the first antenatal visit, 32 weeks of pregnancy, during 
labour, six weeks after delivery and every three months while breastfeeding.4 The recent 
2015 PMTCT guidelines differed slightly and stipulated that all pregnant women needed 
to have repeated HIV testing at: three-monthly intervals during pregnancy, during 
labour/delivery, at the six-week Expanded Programme on Immunisation (EPI) visit and 
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three-monthly during breastfeeding. The HIV-testing would be done during routine 
antenatal care, postnatal care and EPI/ follow up visits. 5 
The 2014 PMTCT guidelines required all pregnant and breastfeeding HIV-positive 
women, regardless of their CD4 lymphocyte count or viral load (VL), to qualify for lifelong 
ART.4 The most recent national consolidated guidelines for PMTCT, released in April 
2015, corresponded with this statement. However, the 2015 guidelines also included 
immediate initiation of lifelong ART for all HIV-positive women within one-year post-
partum. This guideline was validated as of January 2015.5 All patients on first-line ART 
should receive the fixed-dose combination ART, including Tenofovir (TDF, 300 mg) + 
Emtricitabine (FTC, 200 g) + Efavirenz (EFV, 600 mg) unless they were contraindicated. 
Pregnant women with contraindications to FDC should be classified as high-risk 
pregnancies. However, patients who were on the second-line ART did not change to the 
FDC ART regime. The regime combinations are complex, specific and prescribed to HIV-
positive patients depending on their individual circumstances.5 4 10  
Infants whose mothers are HIV-positive should undergo a birth polymerase chain reaction 
(PCR) test to assess whether the infant had been infected with HIV during pregnancy or 
in the postnatal period. The 2014 and 2015 guidelines stipulated that if the birth PCR test 
was negative, a prophylaxis such as Nevirapene (NVP) should be administered. The 
duration of prophylaxis treatment was dependent on whether or not the mother was 
breastfeeding. If the PCR test of the HIV-exposed infant was negative and the mother was 
breastfeeding, the administration of extended NVP should be continued up until 12 weeks. 
If the PCR test of the HIV exposed infant was negative and breastfeeding was 
discontinued, NVP should be administered up until 6 weeks. All HIV-exposed infants 
would repeat a HIV PCR test at 10 weeks and infants receiving extended NVP would have 
the repeated PCR test at 18 weeks. If an infant at any time presents to a health care facility 
with symptoms of poor health, the PCR test is repeated, even if previous PCR tests had 
a negative result. 4 5  
HIV-infected pregnant mothers have a considerably increased risk (13–34%) of delivering 
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an infant preterm. Studies have shown that women who take HAART during pregnancy 
could face such possible adverse effects.3 Grosh-Woerner, Puch, Maier, Niehues, Notheis 
and Patel et al.11 demonstrated coherent evidence from European studies, which 
confirmed an increased risk of preterm delivery when HIV-infected pregnant mothers took 
an antenatal combination of ART and HAART. The study further showed that this was 
particularly the case when a regimen containing a protease inhibitor was followed. The 
findings from a German/Austrian cohort study were confirmed by a noticeable occurrence 
of infants being born preterm for the group of HIV-infected women using HAART with a PI 
before or during pregnancy. 9 
Castetbonet al.12 and Dreyfuss, et al.13 conducted studies in Africa and found that HIV-
positive mothers were at risk of delivering preterm infants. A retrospective observational 
cohort study conducted in Johannesburg, South Africa14 stated that HIV-infected pregnant 
women receiving HAART, consisting of a triple-drug combination, prevented MTCT. In 
addition, it also decreased the incidence of maternal morbidity and mortality. However, 
this cohort study found that HIV-positive pregnant mothers, to whom HAART had been 
administered, were at increased risk of PTB in comparison with HIV-positive pregnant 
women to whom HAART had not been administered. 2  
1.3.2 HIV-exposed vs. HIV-unexposed infant outcomes 
HIV-exposed infants seem to have poorer growth and greater early mortality and morbidity 
rates than their HIV-unexposed counterparts, although HIV-exposed uninfected infants do 
not grow as poorly as HIV-infected infants.6 7 Research conducted in Africa reveals that 
HIV-exposed uninfected children have lower birth weight, poorer early growth and poorer 
health and survival rates compared with HIV-unexposed children.15 A study conducted by 
Bailey et al.16 agreed and stated that HIV-infected and HIV-exposed infants are smaller 
and have a lower birth weight than HIV-unexposed infants. There was limited literature on 
the causes of poor growth and health of HIV-exposed uninfected infants in African 
countries.6  
A retrospective cohort study conducted by Slyker et al.8 stated that a combination of 
Stellenbosch University  https://scholar.sun.ac.za
 19 
 
factors may contribute to an increase in morbidity among HIV-exposed uninfected infants 
including: a reduction in maternal transfer of antibodies, increased exposure to infectious 
pathogens from the mother and an altered immunologic development.  
It has been comprehensively documented that neonates experience a functional 
deficiency of neonatal T-cells. The immature neonatal immune system is more susceptible 
to numerous types of infections that have been associated with increased morbidity and 
mortality rates. The independent stimulation of T-cell receptors promotes corresponding 
interleukin-2 (IL-2) production and proliferation in cord blood mononuclear cells and adult 
peripheral blood mononuclear cells (PMBC).17 A study by Chougnet et al.17 concluded 
that the deficit in cytokine IL-2 production in infants born to HIV-positive mothers might be 
related to the maternal environment and/or to in-utero exposure to viral products which 
are potentially immunosuppressant. This study also reported that PMBC from HIV-
exposed infants have different production levels of IL-2 and a higher level of immune 
activation than PMBC from HIV-unexposed infants. Therefore, both HIV-infected and HIV-
exposed infants might be at a greater risk of developing infections as a result of 
intracellular pathogens. These infants may also be less responsive to conventional 
immunisation procedures. Considering the literature available on HIV, body composition 
and preterm infants, these factors could have a profound effect on the infants’ weight, 
body composition and overall development.  
1.3.3 Preterm infants, HIV and body composition 
Published literature addressing HIV-exposed preterm infants and their body composition 
is limited. As a result, this literature review incorporates studies focused on infants and 
young children.1 
It is universally known that children who are HIV-positive experience growth and metabolic 
abnormalities, which has a profound effect on their short-term survival. 1 9 18 Changes in 
body fat distribution, as well as glucose and bone metabolism in HIV positive children, can 
increase their risk of future morbidities.9  
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Chantry et al.1 reported that HIV-positive adults and children who received ART, displayed 
an altered fat distribution, especially an increase in central adiposity. This is of concern, 
as it is generally known to be a risk factor for morbidities such as cardiovascular diseases 
(CVD) and metabolic syndrome. This study also reported that children in the pre-pubertal 
stages, who received a protease inhibitor, were associated with developing lipodystrophy. 
However, limited information is available on this. Assessing body composition in the 
preterm infant population is, therefore, vital for appropriate treatment and interventions, to 
improve the future and long-term outcomes of these infants. 
A technical review for the World Health Organization (WHO)9 measured the variations in 
body composition in HIV-positive paediatric subjects. Measurements of body composition 
were conducted by means of simple anthropometric measurements such as skin fold 
thickness (SFT), as well as more sophisticated methods such as dual-energy x-
absorptiometry (DXA) techniques and indirect measurements such as bioelectrical 
impedance (BIA). This review concluded that anthropometric measurements resulted in 
HIV-positive paediatric subjects displaying a lower lean body mass when compared with 
HIV-negative controls. The use of more sophisticated methods such as DXA and BIA 
techniques yielded lower fat-free mass (FFM) and lean body mass measures in HIV-
positive paediatric subjects. This population also experienced HIV associated growth 
failure when compared with the HIV-negative control group.  
Neri et al.19 conducted a longitudinal observation study with a cross-sectional evaluation 
to compare the growth and body composition of HIV-exposed uninfected children less 
than 2 years old. This longitudinal observation study compared results to a control group 
of HIV-unexposed children less than 2 years old and to American (US) references. This 
study did not find any significant difference in the growth of HIV-exposed uninfected 
children when compared with HIV-unexposed children. However, when comparing the 
HIV-exposed uninfected group to US references, they had lower birth weights. This 
longitudinal observation study also compared body composition measurements of HIV-
exposed uninfected children with US standards. Subscapular and triceps SFT were used 
to measure the subcutaneous fat tissue of both groups. The results concluded that HIV-
Stellenbosch University  https://scholar.sun.ac.za
 21 
 
exposed uninfected children had significantly lower subcutaneous fat stores when 
compared with National Health and Nutrition Examination Survey (NHANES) standards.  
HIV is increasingly prevalent in many countries including South Africa. 2 20  According to 
the latest HIV impact assessment summary (July 2018), although the prevalence of HIV 
is high in South Africa the incidence has decreased from the 2012 estimates.21 HIV 
incidence  Adverse birth outcomes such as small for gestational age (SGA) and preterm 
infants are common to HIV-positive mothers. However, a specific relationship between 
maternal HIV, SGA and prematurity remain unclear.20 A non-randomised interventional 
cohort study20 evaluated the effects of maternal HIV on prevalent risk factors of unborn 
infants to be born SGA or preterm in rural areas of South Africa. This study comprised 
1 189 HIV-positive and 1 179 HIV-negative pregnant women in antenatal clinics in 
KwaZulu-Natal, South Africa, who were recruited from 2001 to 2004. The results 
concluded that the antenatal clinics in the province had a very high antenatal HIV 
prevalence rate of 39.5% and a very high preterm delivery rate of 21.4%. The study also 
found that 16.6% of those infants, who were born preterm, were SGA. Maternal HIV was 
correlated with a 1.2-fold-increased risk for delivering SGA infants. There is, however, 
very little information and literature available on HIV infection and its effect on body 
composition, LBW, preterm infants and intrauterine growth restriction – all of which are 
risk factors for neonatal mortality and morbidity.12 
The prevalence of HIV in South Africa is increasing, however the incidence is decreasing.2 
21 The on-going debate as to whether or not HIV increases the incidence of infants being 
born preterm is still undetermined. However, research suggested that prescribing a 
protease inhibitor to HIV-positive mothers before or during pregnancy correlates positively 
with preterm births of infants.9 11 Currently, the PMTCT guidelines are functioning well in 
the Western Cape province of South Africa as well as nationally, indicating a decrease in 
MTCT.5 4 The relationship between body fat distribution and the body composition of HIV-
infected or HIV-exposed children receiving ART prophylaxis medication has not yet been 
determined. However, it remains vital to conduct accurate and continuous anthropometric 
and body composition measurements on preterm infants to assess their nutritional status 
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in order to intervene timely and appropriately so as to prevent long-term adverse 
outcomes.  
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CHAPTER 2  
 
METHODOLOGY 
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This study formed part of a larger study, titled: 
 “Body composition, Growth and nutritional intake of HIV exposed preterm, very- and 
extremely-low birth weight infants in Tygerberg Children’s Hospital, Western Cape- The 
role of the Gut Microbiome and Human Milk Oligosaccharide composition. BIG HMO 
study.  
Two Masters in Nutrition (MSc Nutrition) students, Division of Human Nutrition, 
Stellenbosch University, conducted this large study. Each focussed on their own research 
question. Other components evaluated included: the infant gut microbiome and maternal 
Human Milk Oligosaccharide  (HMO) composition.  
Ethics reference #N15/10/102. 
2.1 RESEARCH QUESTION 
Is there a difference in the body composition and nutritional intake of HIV exposed and 
HIV-unexposed preterm, very-low birth weight (VLBW) and extremely-low birth weight 
(ELBW) infants in Tygerberg Children’s Hospital, Western Cape? 
2.2 AIM OF THE INVESTIGATION 
The aim of the study was to determine the body composition and nutritional intake of HIV-
exposed and HIV-unexposed preterm, VLBW and ELBW infants in Tygerberg Children’s 
Hospital, Western Cape. 
2.3 OBJECTIVES FOR THE BODY COMPOSITION STUDY 
2.3.1 Primary objective 
a. To evaluate and compare the body composition of HIV-exposed and HIV–
unexposed, preterm VLBW and ELBW infants. 
i. To evaluate the body composition in terms of fat mass and fat-free mass 
(muscle mass, bone mass and water mass). 
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2.3.2 Secondary objectives 
b. To evaluate the effects of the treatment duration of HAART of HIV-infected mothers 
on the body composition of HIV-exposed, preterm, VLBW and ELBW infants. 
c. To evaluate the effect of nutritional intake on the body composition of HIV-exposed 
and HIV–unexposed, preterm, VLBW and ELBW infants. 
i. To evaluate the effect of breast milk fortification on body composition.  
ii. To evaluate the effect of feeding intolerances and days that infants are nil 
per os on the body composition. 
2.3.3 Null hypotheses  
The following null hypotheses will guide the body composition study: 
a. H0: There will be no difference in the body composition of HIV-exposed and HIV–
unexposed, preterm, VLBW and ELBW infants. 
b. H0: The treatment duration of HAART of HIV-infected mothers will have no effect 
on the growth and body composition of HIV-exposed, preterm, VLBW and ELBW 
infants.  
c. H0: Nutritional intake has no effect on the body composition of HIV exposed and –
unexposed, preterm, VLBW and ELBW infants. 
2.4 CONCEPTUALISATION 
The conceptual framework of the study is outlined in Figure 2.1. As shown in this diagram, 
the aim of the body composition study was to assess the body composition and nutritional 
intake of HIV-exposed and HIV-Unexposed, preterm, VLBW and ELBW infants. Paediatric 
anthropometrical measurements included the weight, length and skinfold thickness at two 
sites (triceps and subscapular) in conjunction with nine other body dimensions which 
included: circumferences (head, chest, mid-upper arm, mid-thigh and mid-calf) and 
lengths (upper arm, lower arm, supine length and crown-rump length).  
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Figure 2.1: Conceptual framework of the study 
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2.5 SETTING 
Wards G1, G2, J3 and G8 at Tygerberg Children’s Hospital (TBCH) situated in 
Tygerberg Academic Hospital (TAH) were selected for data collection.  
2.6 STUDY DESIGN 
The study was a descriptive cross-sectional study with an analytical component. 
2.7 STUDY POPULATION 
The study population consisted of male and female preterm and very-low birth weight 
infants that were HIV-exposed and HIV-unexposed. These patients were born at TBCH 
and admitted or transferred to wards G1, G2, J3 and G8.  
2.7.1 Sample size 
According to the 2013 and 2014 live birth statistics of TBCH, 801 and 815 infants were 
born with a birth weight of < 1 500 g respectively. Furthermore 283 ELBW infants 
(<1 000 g) were born in 2013 and 2014. According to the 2013 and 2014 live birth 
statistics from the Prevention of Mother to Child Transmission (PMTCT) clinic at TAH, 
116 and 136 infants, respectively, were born with a birth weight of < 1 500 g. The 
ELBW infants (< 1 000 g) statistics show 86 live births in 2013 and 77 in 2014. 
Infants with a birth weight of < 1 200 g were included in this study. The sample size 
was estimated according to the statistics mentioned above, the inclusion and exclusion 
criteria (refer to 2.7.2) and the recommendations of a statistician. The study population 
consisted of 113 participants in total, with 83 HIV-unexposed and 30 HIV–exposed 
preterm VLBW and ELBW infants.  
A power analysis for two-way analysis of variance (ANOVA) with two levels for each 
factor with a power of 90% to detect interaction effect sizes of δ = 0.40 yielded samples 
of size n = 67 in each of the two groups. An additional 20% was added to each group 
to accommodate patient loss due to early discharge.  
After three months of data collection the researchers and primary investigators realised 
that only 20% of the study infants already included were HIV-exposed infants. Owing 
to the limited allocated time frame for data collection and financial constraints, the 
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researchers decided to consult with the statistician and review the sample size for the 
HIV-exposed infants. A power analysis for one-way analysis of variance (ANOVA) with 
a one-levelled factor with a power of 90% to detect interaction sizes of δ = 0.49 yielded 
a sample size n=23 in the HIV-exposed group. An additional 30% was added to this 
group to accommodate patient loss due to early discharge. Refer to Figure 2.2 for a 
description of the sample sizes.  
Figure 2.2: Description of sample size 
2.7.2 Sample selection 
The sample was selected from a population of consecutive preterm infants (< 37 
weeks gestation) with a birth weight of < 1 200 g who were admitted or transferred to 
wards G1, G2, J3 and G8 at TBCH. 
The inclusion and exclusion criteria that was used is outlined below. 
 Inclusion criteria 
The following inclusion criteria were used for preterm or low birth weight infants: 
i. All male and female HIV-exposed and HIV-unexposed preterm infants with a 
gestational age of 25–37 weeks, 
ii. All preterm infants with a very-low birth weight and/or extremely-low birth weight 
(≥ 500 g–≤1 200 g).  
Preterm infants ≤ 37 weeks gestational, ≤ 1 200 g 
and born or admitted to TGBH in ≤ 48 hours. 
(G1,G2,G8,J3)
n = 113
HIV-exposed 
n = 30
HIV-unexposed 
n = 83
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iii. All preterm infants receiving nutritional support in the form of enteral nutrition 
[EN: breast milk and supplementation thereof (FM85), formula feed) and 
parenteral nutrition (TPN)]. 
iv. Infants from multiple gestations (twins, triplets, etc.) were included but they were 
noted as being from multiple births.  
v. Written parental consent to the study.  
 Exclusion criteria 
The following exclusion criteria were used for preterm or low birth weight infants: 
i. Birth weight < 500 g. 
ii. Preterm infants with a birth age of < 25 weeks’ gestation. 
iii. Infants with major congenital malformations and/ or developmental disabilities. 
iv. Preterm infants who had other disorders/conditions that could have affected 
body composition (oedema, myopathy) 
v. Preterm infants with major gastro-intestinal abnormalities.  
vi. Preterm infants who had a positive polymerase chain reaction (PCR) test at 
birth. 
vii. Unavailability of mother of preterm infant within 48 hours post birth (due to 
illness, adoption, etc.)  
 Exit criteria  
Participants were exited under the following circumstances:  
i. Day 28 of the study completed. 
ii. Transferred to neonatal or paediatric intensive care unit (NICU/PICU).  
iii. Discharged within the 28 days of recruitment. 
iv. Confirmed necrotising enterocolitis (NEC): Bells stage II or III.  
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v. Mothers admitted to ICU or those who had given their infant/s up for adoption.  
vi. If the mother of an eligible infant could still not be found after 48 hours. 
vii. Death. 
2.8 SUBJECT RECRUITMENT 
i. The researchers visited ward G2 (recruitment ward) every morning and looked 
at the admissions book for new admissions or births. 
ii. New births were screened to determine whether they had adhered to the 
inclusion criteria. 
iii. If the preterm infant met the criteria, their mothers were visited by the researcher 
in the labour wards. 
iv. The researchers explained the consent form to the mothers in detail (Addendum 
A).  
v. A mother had 48 hours to consider partaking in the study and to either provide 
consent or not. 
vi. As mentioned in the study methodology, preterm infants were included in the 
study during their first 48 hours of life. If, for some reason, the mother was not 
present at or during the first visit to the ward, the researchers returned to the 
ward later that day or the next morning so as to include all eligible preterm 
infants. 
2.8.1 Establishment of the HIV-exposed and HIV-unexposed groups 
i. All admitted preterm VLBW infants in ward G2 in TBCH who conformed to the 
inclusion and exclusion criteria with informed parental consent formed part of 
the total study population. Assessments continued for those patients who were 
transferred to wards G1, G8 and J3 unit during the study period. 
ii. The HIV-exposed group consisted of infants of consenting HIV-infected mothers 
who had a confirmed HIV-infected rapid-test result, as obtained from the 
PMTCT-programme during the prenatal period.  
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iii. The HIV-unexposed group consisted of infants of all consenting HIV-uninfected 
mothers. 
The researchers were Masters of Nutrition/Dietetics students. The nature of the study 
and procedure of the data collection was explained to the parent/primary caregiver of 
the potential participant by the researchers. Each potential participant was requested 
to complete a consent form. Thereafter, the researchers using the data collection forms 
obtained the relevant information.  
The time frame allocated for data collection was approximately five months. This was 
based on the live birth statistics received form Tygerberg Hospital and the effect of the 
follow-up period. However, data was collected for a period of six months, from May 
2016 to October 2016.  
2.9 METHODOLOGY: MEASUREMENTS, METHODS AND 
INSTRUMENTS  
For this study, infants were weighed on a daily basis and length, head circumference 
and skinfolds were measured on the infants on five occasions during the 28-day follow-
up period. Furthermore, infants were assessed on a daily basis and clinical, medical 
and nutritional data was collected. The specific measurements, methods and 
instruments used to collect the data will be discussed in further detail below. 
The researchers underwent training pertaining to study procedures at the University of 
Stellenbosch by the department of Human Nutrition, therefore ensuring accuracy of 
measurements and methods.  
2.9.1 Anthropometric measurements  
All measurements were done on preterm infants on day 1 of life (or no later than the 
first 48 hours). No anthropometric measurements were done for the time period that 
infants received nasal continuous positive airway pressure (NCPAP). The following 
anthropometric measurements were done:  
 Weight 
All study infants, irrespective of whether or not these infants were incubated, were 
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weighed daily by the nursing staff. Daily weights were recorded from each participant’s 
medical file by the researcher. All scales were calibrated on Mondays with the use of 
500 g weights. Any significant weight changes were queried and the measurements 
were repeated under the supervision of the researcher  
The weight of each infant was determined as follows:1 
i. An electronic scale (SECA 354) was used, with an accuracy of 0.001 kg. 
ii. All instruments were calibrated before beginning the measurements. 
iii. Infants were weighed without any clothing or a nappy. If a nappy was worn, the 
weight was corrected by subtracting the weight of the nappy. 
iv. Infants were placed in the middle of the scale and the baby had to lie still before 
the reading was taken. 
v. The measurements were read to the nearest 0.001 kg. 
 Length 
Infants were measured on day 1 of life; thereafter, the length was measured weekly. 
Upon exiting the study (day 28), the length was measured again. Therefore, five 
measurements, on days 1, 7, 14, 21 and 28, were taken. The researcher, with the help 
of the infant’s mother, if needed, performed the length measurements. If there were 
any weekly discrepancies of more than 1 cm growth, the length was recorded for a 
second time.  
If weekly lengths were taken by nursing staff, those values were also recorded and if 
there were discrepancies of > 0.5 cm against the researcher’s recording, a second 
measurement was done. Using the nursing staff’s recordings was viewed as a quality 
control measure for this study.1 
The length of each infant was measured according to the following criteria: 2 
i. A SECA 207 measuring rod was used, with an accuracy of 0.1 cm.  
ii. Crown-heel length was obtained by placing the SECA 207 measuring rod over 
the infant who was lying on a smooth flat surface.  
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iii. The participant’s head was placed in the Frankfurt plane (a line between the 
lowest point on the margin of the orbit, the bony socket of the eye, and the 
tragion, the notch above the tragus, of the ear) in the centre of the SECA 207 
measuring rod, and the shoulders were held down on the smooth flat surface in 
a straight line by the researcher or mother. This ensured that the infant’s body 
lay parallel to the long axis of the SECA 207 measuring rod.  
iv. The measuring rod was positioned with the slide at the infant’s head.  
v. The researcher, using her right hand, slid the measuring rod in the direction of 
the infant’s feet and held the infant steady using her left hand.  
vi. The researcher then fully extended the infant’s right leg and held the infant’s 
foot at a right angle to the smooth flat surface.  
vii. The measuring slides on the SECA 207 measuring rod were then moved 
towards the infant’s foot by applying constant pressure to the measuring slides 
until they met the infant’s right heel at a right angle.  
viii. The measurement was then read from the number counter (inside of measuring 
rod) to the nearest 0.1 cm.  
2.9.2 Body composition measurements 
Body composition was assessed through skinfold thickness at two primary sites: 
triceps and subscapular. The measurements were taken in the respective wards by 
the researchers or research assistants. Each infant’s skinfold thicknesses were 
measured on day 1 of the study, and subsequently measured on a weekly basis. Upon 
exiting the study (day 28), the skinfold thickness was measured again. Five 
measurements, on days 1, 7, 14, 21 and 28, were thus recorded. 
No skin fold measurements were done for the time period that infants had a weight of 
≤ 700 g. Two skinfold measurements were taken at each skinfold site, weekly. If the 
results differed by more than > 0.5 mm a third measurement was taken.3 
The Dauncey anthropometric method was used to determine total fat mass and fat-
free mass by assessing skinfold thickness at two sites (triceps and subscapular) in 
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conjunction with nine other body dimensions. The body dimensions included: 
circumferences (head, chest, mid-upper arm, mid-thigh and mid-calf) and lengths 
(upper arm, lower arm, supine length and crown-rump length).4 5 
The following skinfold thickness measurements were performed:  
 Subcutaneous adipose tissue fat mass  
Fat mass was determined by the use of Holtain skinfold callipers, with a calibration 
sensitivity of 0.1 mm and divisions of 0.2 mm. The same pair of callipers was used for 
all of the measurements and was calibrated before each measurement period. 
Measurements were repeated on the right hand side of the body. Only two 
measurements at each body site were assessed owing to the fragility of the study 
population and to cause minimal invasion.a  6 7 8  
The researcher or research assistant, with the help of the infant’s mother/caregiver, if 
needed, performed skinfold thickness measurements. 
The skinfold thickness of each infant was measured according to the following criteria:  
A) Triceps skinfold (TSF/TS)5 6 7 9 10 
i. A Holtain calliper determined SSSF/SBS to the nearest 0.1mm. 
ii. TSF/TS was measured in the posterior midline of the left arm, over the 
triceps muscle, at the midway point between the lateral projection of the 
acromion process of the scapula and the inferior margin of the olecranon 
process of the ulna, while the participants’ arm was placed at his/hers side. 
iii. Once located, the measurement site was marked with a pen.  
                                            
a 
After examining the study population the researchers decided not to conduct SFT measurements on infants’ with a birth weight 
of ≤  700 g, owing to their high vulnerability. Even though other research stipulated that these measurements are safe to conduct.  
Stellenbosch University  https://scholar.sun.ac.za
 36 
 
B) Subscapular skinfold (SSSF/SBS)5 6 7 9 10  
i. A Holtain calliper determined SSSF/SBS to the nearest 0.1mm. 
ii. SSSF/SBS was measured on the right side, below the tip of the inferior angle 
of the scapula. The SSSF/SBS was picked up on a diagonal, inclined infero-
laterally at a 45° angle versus the horizontal plane in the natural cleavage line 
of the skin.  
iii. Once located, the measurement site was marked with a pen. 
The researcher picked up skin from the marked areas of measurement with her thumb 
and index finger, making sure to pick up the full thickness of the skin and taking care 
to exclude any underlying tissue9 10. This elevated a double fold of subcutaneous 
adipose tissue that was approximately 1 cm proximal to the site at which the skinfold 
was measured. The calliper was placed at this site, while the researcher still elevated 
the double fold of subcutaneous adipose tissue, to measure the subcutaneous adipose 
tissue for three seconds8 9 11. The average of the two skinfold thickness measurements 
were calculated to the nearest 0.1 mm and used as the actual skin fold thickness for 
that site in the study7 8 10.  
The nine body dimensions: circumferences (head, chest, mid-upper arm, mid-thigh and 
mid-calf) and lengths (upper arm, lower arm, supine length and crown-rump length) of 
each infant were measured on day 1 of the study, and subsequently measured on a 
weekly basis. Upon exiting the study (day 28), the nine body dimensions were 
measured again. Five measurements, on days 1, 7, 14, 21 and 28, were thus recorded.  
The following circumference measurements were performed: 
C) Circumferences4 5 
The circumferences of each infant were measured according to the following criteria: 
Head circumference  
If weekly head circumferences were taken by nursing staff, those values were also 
recorded and in the case of discrepancies of >  0.5 cm against the researcher’s 
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recording; a second measurement was done. Using the nursing staff’s recordings was 
viewed as a quality control measure for this study..  
The head circumference of each infant was measured according to the following 
criteria: 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used. 
ii. All head coverings were removed. 
iii. The measuring tape was placed on the supraorbital ridge and on the occiput. 
iv. The tape was on the same plane on both sides of the head. 
v. Measurements were read to the nearest millimetre. 
Chest circumference12 13 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used.  
ii. All clothes covering the chest area were removed. 
iii. The patient was held in a supine position with arms parallel to the body.  
iv. The measuring tape was placed at the level of the xiphoid nipples during the 
mid-stage of expiration of breath.  
v. The measuring tape was fitted snugly around the chest without compressing the 
skin. 
vi. Measurements were read to the nearest 0.1 cm.  
Mid-point of the arm (recumbent position)14 15 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used. 
ii. All clothes covering the arm area were removed. 
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iii. The patient was held in a supine position with the right arm bent at a 90 ° angle 
at the elbow and the right palm facing up. 
iv. The lateral projection of the acromion process of the scapula was located and 
marked.  
v. The zero end of the measuring tape was held at this mark and extended down 
to the posterior surface of the arm to the inferior margin of the olecranon process 
of the ulna (bony part of the mid-elbow). 
vi. The tape was kept in position and located half the distance from the acromion 
to the olecranon process. (mid-point of the upper arm) 
vii. Measurements were read to the nearest 0.1 cm. 
viii. The measurement was marked with a cosmetic pen.  
Mid-upper arm circumference (MUAC)14 15 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used.  
ii. All clothes covering the arm area were removed. 
iii. The patient was held in a supine position with the arms loosely parallel to the 
body.  
iv. The measuring tape was wrapped around the right arm at the level of the upper 
arm mid-point mark.  
v. The tape was positioned perpendicular to the long axis of the upper arm. 
vi. The measuring tape was fitted snugly around the arm without compressing the 
skin. 
vii. Measurements were read to the nearest 0.1 cm. 
Mid-thigh circumference13 16 
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i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used. 
ii. All clothes and diapers covering the right thigh area were removed. 
iii. The patient was held in a supine position with the arms parallel to the body and 
legs fully extended in a straight line.  
iv. The measuring tape was placed at the inguinal fold anteriorly, to lie at the level 
of the lowest crease in the gluteal region posteriorly, with the tape lying 
perpendicular to the to the long axis of the lower limb.  
v. The measuring tape was fitted snugly around the thigh without compressing the 
skin. 
vi. Measurements were read to the nearest 0.1 cm. 
Mid-calf circumference13 16 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used. 
ii. All clothes covering the right lower leg area were removed. 
iii. The patient was held in a supine position with the arms parallel to the body and 
legs fully extended in a straight line.  
iv. The measuring tape was placed at the level of the largest circumference of the 
calf. 
v. The measuring tape was fitted snugly around the calf without compressing the 
skin. 
vi. Measurements were read to the nearest 0.1 cm. 
The following length measurements were performed: 
D) Length measurements4 5 
Crown-rump length (Cl) 
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i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used.  
ii. All clothes and diapers covering the crown rump area were removed. 
iii. The patient was in a prone position with the arms loosely parallel to the body.  
iv. The measuring tape was placed at the vertex of the cranium to the mid-point 
between the apices of the buttocks.  
v. Measurements were read to the nearest 0.1 cm.  
Upper arm length14 15 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used. 
ii. All clothes covering the right arm area were removed. 
iii. The patient was held in a supine position with the right arm bent at a 90° angle 
at the elbow and the right palm was facing up. 
iv. The lateral projection of the acromion process of the scapula was located and 
marked.  
v. The zero end of the measuring tape was held at this mark and extended down 
the posterior surface of the arm to the inferior margin of the olecranon process 
of the ulna (bony part of the mid elbow). 
vi. Measurements were read to the nearest 0.1 cm.  
Lower arm length4 
i. A standard non-stretchable measuring tape with 0.5 cm and 1 cm dimensions 
was used. 
ii. All clothes covering the right arm area were removed. 
iii. The patient was held in a supine position with the arms loosely parallel to the 
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body.  
vii. The measuring tape was placed at the tip of the olecranon process (bony part 
of the mid elbow) to the tip of the lateral ulna styloid process.  
viii. Measurements were read to the nearest 0.1 cm.  
Thigh and lower leg length 4 
= Supine length–crown rump length 
= S−Cl 
2.10 DATA COLLECTION FORMS 
The data collection forms consisted of the following forms: the patient medical 
background, daily monitoring and anthropometric data. Refer to Addendum B for the 
data collection forms. All forms had been pre-coded. The coding list was supplemented 
as new possibilities or options occurred.  
2.10.1 Patient medical background data collection form  
This form was used to collect medical background information of the infants as well as 
the mothers. The researchers documented this information upon the infants’ entry into 
the study. The maternal information was divided into three sections and included 
general information, medical information and medication received. The infant 
information also consisted of these three sections. The investigator or research 
assistants documented this information upon the infant’s entry into the study. 
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Table 2.1: Maternal medical background information 
Maternal information 
General information  Age. 
 Race. 
 Lifestyle information (Smoking and the use 
of ethanol and narcotics).  
 Gravida/parity. 
 Mode of delivery. 
 Maternal HIV status.  
 Maternal CD4 cell count. 
 Whether the mother was be enrolled on 
the PMTCT scheme and the duration of 
enrolment. 
 Maternal tuberculosis history and 
treatment. 
 Maternal syphilis (Venereal Disease 
Research Laboratory [VDRL] test) history 
and treatment. 
Medical information Whether the following conditions were 
applicable to the mother:  
 Hypertension/preeclampsia. 
 Diabetes.  
 Antepartum and post-partum 
haemorrhage. 
 Abruptio placentae. 
Maternal medication  Maternal antibiotics and steroids given prior 
to/during labour. 
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Table 2.2: Infant medical background information  
Infant information 
General information  Gender.  
 Date of birth. 
 Apgar counts. 
 Birth weight, length and head 
circumference. 
 Gestational ages – dates.  
 Foot length. 
 Infant syphilis (VDRL test) status and 
whether being treated. 
Medical information  Respiratory complications. 
Whether the infant underwent any of the 
following: 
 Cranial ultrasound. 
 Phototherapy. 
Infant medication  The following medications were noted:  
 Nevirapine. 
 AZT.  
 Surfactant. 
 Antibiotics. 
 Corticosteroid.  
 Other. 
Blood sample collections Whether the following blood samples had been 
collected:  
 CRP.  
 Full blood count. 
 Blood culture.  
 HIV PCR.  
2.10.2 Daily monitoring form 
The daily monitoring forms assessed the nutritional intake and output of patients. 
Furthermore, some treatments such as phototherapy and blood products received 
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were noted. All medications, intravenous fluids and blood transfusions administered to 
the study infants were documented on the medical form by the investigator or research 
assistants. Only medical information that was directly linked to body composition was 
recorded. Antiretroviral treatment was documented for the HIV-exposed infants. The 
daily clinical assessments of the study infants were done by the attending doctors and 
were documented by the investigator or research assistants.  
2.10.3 Nutritional intake  
The standard feeding protocol of the ward was applied during the study. The time of 
initial feeding was at the discretion of the attending physician. The daily volume of milk 
feeds was determined according to the feeding protocol of the institution. According to 
ward protocol, feeds were increased in daily increments of 25 ml/kg/d. Furthermore, 
per ward protocol, infants of HIV-infected mothers received pasteurised expressed 
breast milk. Infants of HIV-uninfected mothers received unpasteurised breast milk 
(expressed or breastfed). The breast milk of HIV-infected mothers was pasteurised 
using the Pretoria flash method. Pasteurisation is standard protocol in the ward; 
therefore it did not form part of the methodology of this study. 
Breast milk fortifier was introduced when infants reached daily feeds of above 
100 ml/kg. Fortification of feeds was, however, dependent on feeding tolerance and 
may have differed from one individual to another. The dietary intake of all study infants 
was documented on a feed monitoring form. Any feeding intolerance was documented. 
The following data was captured on the daily monitoring form:  
 Feeding route of the infant. 
 Volume/amount of breast milk, formula, TPN, Neonatelyte (glucose-electrolyte-
containing solution) and saline provided to the infant. 
 Supplementation with FM85 (a breast milk fortifier) and medium-chain 
triglyceride) oil, multivitamin and iron supplementation. 
 Urinary output.  
 Stool frequency and colour/consistency. 
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 Phototherapy and blood products received. 
 Medication administered. All the medications that the infants received were 
noted. 
 Any feeding intolerance was documented. The attending doctor noted the 
presence of a feeding intolerance in the patient folder. Furthermore, for the 
purposes of this study, a feeding intolerance was identified when vomiting and 
aspirates occurred. The colour and frequency of vomits and aspirates was 
noted. Also, abdominal distension, stool volume and consistency were reported 
on. 
2.11 DATA CAPTURING 
Data capturing was done using Microsoft Excel 2007®.  
2.12 DATA ANALYSIS 
The data analysis for the different aspects of data collection is discussed in detail 
below: 
2.12.1 Data analysis: Body composition measurements  
 Skinfold thickness measurement  
For the analyses of skinfolds, the average of the two measurements at each site was 
used, unless a third measurement was taken. In that case, if two of the three 
measurements differed by less than the prescribed amount (< 0.5 mm), the average 
of those two measurements was used; otherwise, the average of all three 
measurements was used.3 
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VOLUME OF SUBCUTANEOUS FAT 4  5 
Crown rump length – Cl 
Diameter of head – d 
Supine length – l 
Length of upper arm and lower arm (Arm length) – a 
Skinfold calliper measurement – S 
Thickness of subcutaneous fat layer - = (S − 0.2 cm) 
Trunk = (Cl − d) 
Trunk = (Subscapular skin fold − 0.2 cm) 
Arm = Leg = (Triceps skin fold − 0.2 cm) 
0.9 = The density factor of human fat  
Trunk circumference = Cc (Chest circumference) 
The following were measured to determine FM and FFM in the preterm infant: 
A) Volume of fat covering trunk (ml) 
A = (Crown rump length minus diameter of head) ×  (Circumference of trunk) ×
 (Subscapular skin fold − 0.2 cm) 
A = (trunk) × (Cc) × (trunk) 
B) Volume of fat covering upper limbs (ml) 
B = (Length of upper arm + length of lower arm) × (Circumference of upper arm ×
 (Tricep skinfold −0.2 cm) 
B = (a) × (MUAC) × arm 
C) Volume of fat covering lower limbs (ml) 
C =  (Supine length −  crown rump length) ×  ½ (circumference of mid-thigh + 
circumference of × calf) × (Triceps skinfold – 0.2 cm)  
C = (l-Cl) × ½ (Circumference of mid-thigh + Circumference of calf) × Leg 
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D) Total body fat (FM) 
D = (A + 2B + 2C) × 0.9 
E) Total fat-free mass (FFM) 
E = Body weight − FM 
F) Percentage of FM 
F = (FM/Total body weight) × 100 
2.13 STATISTICAL ANALYSIS  
Microsoft Excel® was used to capture the data and STATISTICA version 11 (StatSoft 
Inc. (2013) STATISTICA (data analysis software system), www.statsoft.com.) was 
used to analyse the data. Summary statistics were used to describe variables such as 
the daily intake data of infants, routine examinations, medication, intravenous fluids, 
blood transfusions and mode of delivery. 
Distributions of variables were presented with histograms and/or frequency tables. 
Medians or means were used as the measures of central location for ordinal and 
continuous responses and standard deviations and quartiles as indicators of spread. 
The relation between nominal variables was investigated with contingency tables and 
appropriate chi-square tests, such as the likelihood ratio chi-square test. A 𝑝-value of 
𝑝 < 0.05 represents statistical significance in hypothesis testing and 95% confidence 
intervals were used to describe the estimation of unknown parameters. 
2.14 PILOT STUDY  
Local ethical consent was obtained and a pilot study was performed in May 2016 to 
streamline all data collection procedures. Pilot study participants were recruited for a 
period of one week.  
2.15 FINANCIAL DISCLOSURE  
There were no financial disclosures for this study.  
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2.16 ETHICAL CONSIDERATIONS  
The protocol was submitted to the Human Research Ethics Committee of the Faculty 
of Health Sciences, Stellenbosch University and TAH for approval. All the investigators 
adhered to Good Clinical Practice (GCP) guidelines during the study period. All 
participating mothers were informed about the study in their first language (Afrikaans, 
English or Xhosa). Each participant (the study infant’s mother) received a copy of the 
consent form once recruited and written consent was obtained for participation in the 
study. In some instances, participants were given 48 hours to consider partaking in the 
study before the written consent form was signed. Each participant received a copy of 
the consent form. Participating in the study was voluntary. Participants were free to 
leave the study at any time and would not be penalised or prejudiced in any way for 
doing so. 
Confidentiality and anonymity were maintained during this study. All infants received 
an allocated participant number. The HIV status of the mother and her infant were 
treated with confidentiality and were not revealed to any persons other than the 
patient’s doctor, the research assistant and the investigator.  
Participation in this study did not affect the quality of care that infants and mothers 
received during or after the study. Appropriate medical care provided to HIV-infected 
mothers as determined by the provincial protocol for the treatment of HIV/AIDS was 
adhered to. Refer to Addendum C for the ethics approval notification. 
2.17 RISK TO BENEFIT RATIO 
Available literature stipulated that one of the best methods for determining body 
composition of the preterm infant in terms of fat mass and fat-free mass is the use of 
the Dauncey anthropometric model, which includes skinfold thickness at two primary 
sites and nine body dimensions. This body composition method is accurate, safe, 
inexpensive, non-invasive and can be performed at the bedside, avoiding excessive 
disturbance to these fragile infants. 
2.18 VULNERABLE STUDY POPULATION 
Limited literature exists on the assessment of neonatal body composition and only a 
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few studies have focused on the growth and development of preterm infants.2 3 
Research shows that preterm infants should achieve growth rates similar to the term 
infant. In other words, the preterm infant should grow at the same rate in size, 
anthropometrically and in body composition extra-utero as infants who are still growing 
in utero.5 6 7 8 However, generally infants do not meet these growth rates, resulting in 
growth failure and debilitating outcomes. After examining the study population, the 
researchers decided not to conduct SFT measurements on infants with a birth weight 
of ≤ 700 g, because of their high vulnerability, even though other research stipulated 
that these measurements were safe to conduct.  
2.19 CONFIDENTIALITY AND QUALITY OF CARE  
Confidentiality and anonymity were maintained during this study. All infants received 
an allocated participant number that was used for data capturing. The HIV status of 
the mother and her infant were treated with confidentiality and were not revealed to 
any persons other than the nursing staff, the patient’s doctor, the researchers and the 
investigator.  
Participation in this study did not affect the quality of care that infants and mothers 
received during or after the study.  
2.20 INSURANCE 
The protocol provided insurance for research-related adverse events (Addendum D).  
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2.21 BUDGET 
Table 2.3 indicates the study budget.  
Table 2.3: Study budget 
Item Description Unit cost Total cost 
Printing Printing of consent forms and 
data collection forms 
 R 700.00 
Research 
equipment 
1×SECA 207 model measuring 
rod.  
R2 365 R2 365.00 
Human resources Statistician  R400/hr × 10 
hours 
 
R 4 000.00 
 
Research assistant R6 000/month – 
3 hours per day 
R 6 000.00 
Total cost R 13 065.00 
*Funding has been received for this project. Funders: Early Career Development Fund, Stellenbosch University and the Harry 
Crossley Foundation.  
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Figure 0.5 Figure A1 
 
  
Stellenbosch University  https://scholar.sun.ac.za
 66 
 
ORIGINAL ARTICLE 2: 
How does the nutritional intake affect the body composition of 
HIV-exposed and HIV-unexposed preterm, very- and extremely-
low birth weight infants? 
 
This article is under review by the journal of Breastfeeding Medicine.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 67 
 
How does nutritional intake affect the body composition of HIV-exposed and 
HIV-unexposed preterm, very- and extremely-low birth weight infants? 
 
Running title: Nutritional intakes on preterm body composition  
 
Strydom Klara, Author 1,* , BSc Diet. Nel Daniel Gerhardus, Co-author 5,**, PhD. 
Dhansay Muhammad Ali, Co-author 3,4,**, MBChB, DCH, MMed (Paed), FC Paed (SA). 
van Niekerk Evette, Co-author 5,**, PhD Nutrition.  
Affiliations: 
1 Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape 
Town. PO Box 19063; Francie Van Zijl Drive. Tygerberg 7505. South Africa. Email: klaras@sun.ac.za  
2 Department of Statistics and Actuarial Sciences, Stellenbosch University. Email: dgnel@sun.ac.za  
3 South African Medical Research Council, Burden of Diseases Research Unit, Cape Town. Francie Van 
Zijl Drive, Parow Valley, Cape Town, South Africa 7501. Email: Email: AliDhansay@mrc.ac.za  
4 Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch 
University. PO Box 19063; Francie Van Zijl Drive. Tygerberg 7505. South Africa. Email: 
AliDhansay@mrc.ac.za  
5 Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape 
Town. PO Box 19063; Francie Van Zijl Drive. Tygerberg 7505. South Africa. Email: evettev@sun.ac.za  
 
* First author and corresponding author 
** Co-author 
 
Address correspondence to: Klara Strydom, Division of Human Nutrition; Faculty of Medicine and Health 
Sciences; Stellenbosch University. PO Box 19063; Francie Van Zijl Drive. TYGERBERG 7505. South 
Africa. Telephone: +27 021 938 9474. Fax +27 933 299. klaras@sun.ac.za  
 
Word count abstract: 245 
Word count text: 3870 
Number of tables: 4 
Number of figures: 1 
Number of supplementary tables: 1 
Number of supplementary figures: 1 
 
Funding: The Early Career Development Fund, Stellenbosch University and the Harry Crossley 
Foundation supported this study.  
Keywords: body composition; breast milk fortifier; HIV-exposure; nutritional intakes; NPO; preterm 
infants. 
 
Stellenbosch University  https://scholar.sun.ac.za
 68 
 
ABSTRACT 
Background: Human breast milk (HBM) is considered inadequate in meeting protein 
requirements, especially for very low birth weight (VLBW) infants, which could affect 
body composition. 
Objectives: To determine the effect of HBM on body composition of HIV-exposed and 
unexposed preterm VLBW and extremely-low birth weight (ELBW) infants. 
Furthermore, to ascertain the effect of breast milk fortification, and days nil per os 
(NPO) has on body composition. 
Methods: A descriptive cross-sectional study was conducted. Preterm infants with a 
birth weight of ≤1 200 g were included. Infant nutritional intakes and body composition 
measurements were recorded during the 28-day follow-up period. 
Results: 110 of 113 preterm infants received HBM and 91 infants received fortified 
HBM. HIV-exposed and unexposed infants receiving fortified HBM displayed 
differences in fat mass percentage (FM%) (0.88% vs. 1.36%; 𝑝 = 0.01) and (0.97% 
vs.1.49%; 𝑝 =  0.03) and fat-free mass percentage (FFM%) (98.98% vs. 98.68% 𝑝 = 
0.03) and (99.02% vs. 98.49%; 𝑝 =0.02), on day 21 and 28, respectively. Infants kept 
NPO displayed differences in FM% on day 7, 21 and 28 (0.9% vs 1.3%; 𝑝 = 0.03), 
(0.99% vs 1.4%; 𝑝 = 0.02) and (0.9% vs 1.6% 𝑝 = 0.0004) as well as differences in 
FFM% (99.1% vs 98.4% 𝑝 = 0.0005) on day 28 of life.  
Conclusion: There were no significant differences in the body composition of infants 
who received HBM vs. fortified HBM. However, significant differences in body 
composition were reported between HIV exposure groups for infants who received 
fortified HBM. Infants who were kept NPO were generally smaller, shorter, and had 
lower FM% and more FFM%.  
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INTRODUCTION 
Over the past two decades, South Africa has experienced a serious HIV epidemic and 
is home to the world’s largest HIV population.1 HIV-infected pregnant mothers on 
highly active antiretroviral therapy (HAART) have a considerably higher risk (13–34%) 
of delivering an infant preterm.2 3  
A recent study conducted in Africa by Adeteyo et al.4 found that HIV-exposed 
uninfected (HIV-EU) infants had poorer growth than HIV-unexposed uninfected (HIV-
UU) infants during infancy. Previous literature confirms that HIV-EU infants grew more 
poorly and had increased early mortality and morbidity rates compared with HIV-UU.4 
5 6 For the purposes of this article, the terms HIV-EU and HIV-UU infants will be referred 
to as HIV-exposed and HIV-unexposed infants, respectively.  
The aggressive nutritional management recommended for preterm and small for 
gestational age (SGA) infants by the American Association of Pediatrics to achieve 
appropriate fetal growth rates and body composition, could result in an increased risk 
of cardiovascular diseases and metabolic syndrome later on in life. These risks are 
related to high early postnatal weight gain.7 8 This was supported in a meta-analysis by 
Johnson et al.9 detailing the relationship between nutritional intakes and body 
composition in preterm infants. Nutritional intakes include micronutrients and 
macronutrients (energy and protein) and their effect on the successful growth and body 
composition of preterm infants at term-equivalent age. Preterm infants, especially 
those born with a very low birth weight (<1.5 kg; VLBW), are a challenge to feed 
because of the high recommended daily allowance of energy, protein and nutrients 
required to achieve in-utero growth rates.8 10  
Human breast milk (HBM) alone is considered inadequate to meet the nutritional 
requirements of preterm infants during early neonatal life, especially in infants born 
with very low birth weight (VLBW).11 When fed in amounts that satisfy energy 
requirements, HBM provides only about 60% of the protein requirements.12 13Therefore, 
HBM from mothers with preterm infants is not nutritionally adequate and must be 
fortified to ensure adequate growth and body composition in terms of (fat mass) FM 
and (fat-free mass) FFM. There are three main fortification strategies namely: standard 
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fortification, super fortification and individualised (adjustable and targeted fortification). 
These strategies range from simple, quick, safe and inexpensive to complex, 
sophisticated and expensive.14 15 16 17 Supplementation of HBM with a fortifier (energy, 
protein, vitamins and minerals) is common practice in many neonatal intensive care 
units (NICUs) to achieve nutritional requirements and successful intrauterine growth 
rates in preterm infants, while the many benefits of HBM such as better 
neurodevelopmental outcomes and a decrease in late-onset sepsis and necrotising 
enterocolitis (NEC) continue to be recorded.10 12 18  
The Baby Friendly Hospital Initiative (BFHI) was launched by the World Health 
Organization (WHO) and United Nations Children’s Fund as a global initiative to 
protect, promote and support breastfeeding practices by adhering to and implementing 
the minimum global criteria contained in “The ten steps to successful breastfeeding” 
guidelines.19 These guidelines are critical to the prevention of mother-to-child 
transmission (PMTCT) programme.20 21 22 The attending doctor should only prescribe a 
formula feed once all other options to administer HBM have been exhausted, such as 
when the mother is unable to produce or express breast milk, also known as mother’s 
own milk (MOM), and donor breast milk (DBM) is unavailable. 
There is a gap in published research regarding the relationship between HIV, breast 
milk intake, body composition and preterm infants and the effect thereof on the quality 
of growth and body composition, in terms of FM and FFM.9 23 24 The purpose of the 
study was to evaluate the effect of HBM intake (and the fortification thereof) and the 
body composition of HIV-exposed and HIV-unexposed preterm VLBW and ELBW 
infants.  
MATERIALS AND METHODS 
Study design and setting 
This descriptive cross-sectional study, which formed part of a larger cohort, was 
conducted from 16 May to 22 October 2016, in the Neonatal Unit of Tygerberg 
Children’s Hospital (TBCH) situated in Tygerberg Academic Hospital (TAH), Cape 
Town, South Africa. 
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Sample size 
The sample sizes needed of the study populations were determined according to the 
live birth statistics for infants born with a birth weight of < 1 500 g (VLBW) at the 
institution. A power analysis for two-way analysis of variance (ANOVA) with a power 
of 90% to detect interaction effects of δ = 0.49 (regarded as a medium effect size) 
yielded a required sample size n = 23 in each of the exposure groups. The total sample 
size of n = 113 preterm infants consisted of n = 83 HIV-unexposed preterm infants and 
n = 30 HIV-exposed preterm infants.  
Participants  
The study population, comprised of all HIV-exposed and HIV-unexposed preterm 
infants, who adhered to the inclusion criteria and whose mother gave written consent, 
were included in the study. The inclusion criteria stipulated the following: all male and 
female preterm infants born at TBCH with a gestational age (GA) ≥ 25 weeks and < 37 
weeks and a birth weight ≥ 500 g≤1 200 g born at TBCH. 
Outcomes 
The primary outcome of the study was to determine the effect of HBM intakes on the 
body composition of HIV-exposed and HIV-unexposed preterm, VLBW and ELBW 
infants. This evaluation also included the effect of BM fortification, feeding intolerances 
and days on which infants were nil per os (NPO). 
Methods 
Participants were included in this study for a 28-day follow-up period (day 1 was 
considered as the first 24 hours of life). The researchers collected the maternal medical 
background of each infant with inclusion. Infant clinical, medical and nutritional data 
were collected on a daily basis, and anthropometric and skinfold measurements were 
taken weekly.  
The researchers documented all fluid input and output from the patients’ fluid balance 
charts. The daily clinical assessments were done by the attending doctors and were 
recorded by the researchers or research assistants. For the duration of the study, milk 
feeds were advanced was according to the standard ward protocol and feeds were 
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increased in daily increments of approximately 25-30 ml/kg/d. The time of initial feeding 
was at the discretion of the attending physician.  
The primary nutritional intake prescribed for preterm infants (according to the national 
consolidation guidelines regarding the PMTCT of HIV)20 22 for this research study was 
HBM, which included: MOM, DBM, pasteurised breast milk (PBM), and HBM fortified 
with a standard agent known as FM85.25 Furthermore, in line with ward protocol, infants 
of HIV-infected and HIV-uninfected mothers received PBM or DBM or unpasteurised 
BM (expressed, donor or breastfed), respectively. The BM of HIV-infected mothers 
was pasteurised using the Pretoria pasteurisation method,26 which was standard 
protocol in the ward.  
The ward protocol prescribed the fortification of MOM in TBCH25 for breastfed preterm 
infants who were born <  34 weeks gestational age and weighed <  1 800 g, and 
breastfed preterm infants who did not grow at a rate of 15 g/kg/day and had to receive 
full fluid requirements (150–180 ml/kg/day). For the duration of the study, the standard 
protocol applied, namely the BM fortifier was added at a ratio of 1 g to 20 ml MOM. 
The standard addition of 5 g of fortifier to 100 ml MOM increased the energy and 
protein concentration from ±67 Kcal to 85 Kcal/100ml BM and 1,2 g to 2,2 g/100 ml, 
respectively. 25 
Additionally, the following data were assessed and recorded daily: feeding route, the 
volume of HBM, formula, total parenteral nutrition (TPN), Neonatalyte (glucose-
electrolyte-containing solution) and saline provided to the infant, standard BM fortifier 
and medium-chain triglyceride oil, multivitamin supplementation, phototherapy and 
blood products received, medication administered, urinary output, stool frequency and 
colour/consistency, and feeding intolerance frequency.  
The researcher assessed body composition by measuring skinfold thickness at two 
primary sites: triceps and subscapular. The skinfold thickness measurements of each 
infant were taken on day 1 of the study, and subsequently measured on a weekly basis. 
Upon exiting the study (day 28), the skinfold thickness was measured again. Five 
measurements were thus recorded: on days 1, 7, 14, 21 and 28. Skinfold thickness 
was determined by the use of Holtain skinfold callipers, with a calibration sensitivity of 
Stellenbosch University  https://scholar.sun.ac.za
 73 
 
0.1 mm and divisions of 0.2 mm. The same pair of callipers was used for all 
measurements and was calibrated before each measurement period. All skinfold 
measurements were taken on the right hand side of the body and only two 
measurements at each body site were assessed owing to the fragility of the study 
population and to ensure minimal invasion.27 28 29 30 In cases where the results differed 
by more than > 0.5 mm, a third measurement was taken. No skin fold measurements 
were done while infants weighed ≤ 700 g.  
The Dauncey anthropometric method was used to determine total FM and FFM by 
assessing skinfold thickness at two sites (triceps and subscapular) in conjunction with 
nine other body dimensions. These body dimensions were circumferences (head, 
chest, mid-upper arm, mid-thigh and mid-calf) and lengths (upper arm, lower arm, 
supine and crown-rump length).31 32 
Ethical approval 
Ethical approval was granted by the Health Research Ethics Committee of the Faculty 
of Medicine and Health Sciences, University of Stellenbosch and Tygerberg Academic 
Hospital, Ethics reference #N15/10/102.  
Statistical analysis 
Data analyses were performed using Statistica version 13 (Dell Inc. (2016). Dell 
Statistica (data analysis software system.) in Stellenbosch, South Africa. When 
comparing continuous variables between two groups (anthropometric and body 
composition measurements for HIV-exposure), one-factor ANOVA was used; if 
residuals were not normally distributed, a nonparametric test, the Mann-Whitney test, 
was used to confirm conclusions for ANOVA. Nominal variables (e.g. GA and sex) 
were compared between groups with contingency tables using the maximum likelihood 
chi-square test. Descriptive statistics were reported in terms of the mean, standard 
deviation (SD) and maximum and maximum values. Confidence intervals of 95% were 
used to report the mean of each group and a 𝑝-value of < 0.05 was used to determine 
statistical significance in this study. 
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RESULTS 
A total of 131 preterm infants conformed to the inclusion criteria and of these, 18 infants 
(14%) were excluded: eight (6%) of the exclusions were due to the mother being 
unable to give consent for medical or social reasons; six infants (5%) died before 
consent was obtained, three mothers (2%) declined participation and one infant (1%) 
was transferred to the NICU. The final study population consisted of 113 preterm 
infants; however, two of these infants died before enteral feeds were initiated and one 
infant exited the study due to being transferred to the NICU. Therefore, a total of 110 
infants [HIV-exposed (n = 29) and HIV-unexposed infants (n = 81)] received MOM, 
DBM or PBM at a given point in time during the 28-day follow-up study (Supplementary 
Figure 1). 
Table 1 below indicates the HBM composition 33 and nutritional intake of HIV-exposed 
and HIV-unexposed infants. No significant difference was noted in the HBM volume 
(ml/kg/day), energy density (kcal/kg/day) and macronutrient concentration, in terms of 
protein and fat (g/kg/day), in HIV-exposed and HIV-unexposed preterm infants.  
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Table 1: Human breast milk composition and nutritional intakes of HIV-exposed 
and HIV-unexposed preterm infants 
 HIV-exposed Infants 
N= 29 (26%) 
HIV-unexposed Infants 
N=81 (74%)  
𝒑 
 
Volume of intake (ml/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
0.00 ±0.00 
69.76 ±38.55 
153.43 ±49.3 
150.60 ±58.54 
155.79 ±58.78 
 
0.28 ±1.28 
88.78 ±46.56 
148.88 ±53.15 
146.88 ±61.48 
143.245 ±65.02 
 
0.23 
0.09 
0.71 
0.79 
0.45 
Day of life receiving full feed (days) 12.5 ±3.71 11.375 ±3.31 0.19 
 
Human breast milk energy and macronutrient intake 
 
Energy (kcal/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
0.00 ±0.00 
46.74 ±25.83 
102.80 ±33.03 
100.90 ±8.29 
104.39 ±39.39 
 
0.19 ±0.89 
59.48 ±31.19 
99.75 ±35.61 
98.41 ±5.16 
96.97 ±42.89 
 
0.23 
0.09 
0.71 
0.79 
0.45 
Protein (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
0.00 ±0.00 
1.53 ±0.85 
3.38 ±1.09 
3.31 ±1.29 
3.43 ±1.29 
 
0.01 ±0.03 
1.95 ±1.02 
3.75 ±1.17 
3.23 ±1.35 
3.15 ±1.41 
 
0.23 
0.09 
0.71 
0.79 
0.44 
Fat (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
0.00 ±0.00 
3.21 ±1.77 
7.06 ±2.27 
6.93 ±2.69 
7.17 ±2.70 
 
0.013 ±0.06 
4.08 ±2.14 
6.85 ±2.44 
6.76 ±2.83 
6.59 ±2.95 
 
0.23 
0.09 
0.71 
0.79 
0.45 
    
Values are means (?̅?) and ±Standard Deviations (±SD) unless otherwise indicated. 
* Statistically significant when (𝑝 =< 0.05) 
Infants in both groups were generally initiated with minimal feeds on day 2–3 of life. 
Even though the HBM volume was similar between the two groups for the duration of 
the study period, it was noted that infants in the HIV-exposed group received slightly 
more HBM from day 14 of life onwards than the HIV-unexposed group. The 
macronutrient intake is directly proportional to the volume of HBM; therefore, HIV-
unexposed infants generally had lower energy, protein and fat intakes when compared 
to HIV-exposed infants.  
The HIV-exposed and HIV-unexposed preterm infants were compared per birth weight 
category (VLBW and ELBW) by a two-way ANOVA. According to this analysis, there 
was no statistically significant difference in the HBM composition and nutritional intakes 
throughout the 28-day follow-up period between the two groups. 
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Fortified breast milk 
For the duration of this study, the standard fortification formulation, which was in 
existence then, was used. From 2017, however, a reformulation has been 
implemented in South Africa.16 21  
Of the 110 infants who received HBM, 91 (83%) received fortified HBM. Of these 
infants, 25 (27%) and 66 (73%) were HIV-exposed and HIV-unexposed preterm 
infants, respectively (Table 2). There was no significant difference (𝑝 =  0.48) between 
the two groups in the mean number of days the infants received the BM fortifier. The 
HIV-exposed group did however receive the BM fortifier for fewer days 8.63 (±7.14) 
and for a maximum of 19 days compared with HIV-unexposed infants who received 
the fortifier for 9.64 (±6.73) days and for a maximum of 21 days.  
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Table 2: Human breast milk fortification and nutrient intakes of HIV-exposed and 
HIV-unexposed preterm infants  
 HIV-exposed 
Infants  
N=25 (26%) 
HIV-unexposed 
infants 
N=70 (74%) 
𝒑 
 
 
Fortifier (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
0.00 ±0.00 
0.00 ±0.00 
4.33 ±4.37 
4.956 ±4.73 
6.76 ±5.21 
 
 
0.00 ±0.00 
0.08 ±0.47 
4.73 ±4.32 
5.16 ±4.44 
5.12 ±4.68 
 
 
– 
0.44 
0.69 
0.85 
0.20 
 
NOD receiving a fortifier ?̅?, ±SD 
 
8.64 ±7.14 
 
9.64 ±6.73 
 
0.48 
 
 
Fortifiers energy and macronutrient intake 
 
 
Energy (kcal/kg/day)  ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
0.0 ±0.00 
0.0 ±0.00 
15.07 ±15.20 
17.76 ±16.47 
23.51 ±18.12 
 
0.00 ±0.00 
0.00 ±0.00 
16.45 ±15.02 
17.95 ±15.45 
17.25 ±15.93 
 
 
– 
– 
0.69 
0.85 
0.16 
Protein (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
0.00 ±0.00 
0.00 ±0.00 
0.87 ±0.87 
0.99 ±0.19 
1.35 ±1.04 
 
0.00 ±0.00 
0.00 ±0.00 
0.95 ±0.86 
1.03 ±0.11 
1.02 ±0.94 
 
– 
– 
0.69 
0.85 
0.20 
Fat (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
0.00 ±0.00 
0.00 ±0.00 
0.02 ±0.02 
0.02 ±0.02 
0.03 ±0.02 
 
0.00 ±0.00 
0.00 ±0.00 
0.02  ±0.02 
0.02  ±0.02 
0.02  ±0.02 
 
– 
–0.69 
0.85 
0.13 
 
 
Fortified breast milk energy and macronutrient intake  
 
 
Energy (kcal/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
0.00 ±0.00 
0.00 ±0.00 
145.94 ±19.06 
153.26 ±19.20 
151.47 ±26.28 
 
 
 
0.00 ±0.00 
0.00 ±0.00 
141.54 ±2.68 
147.015 ±16.21 
149.95 ±14.02 
 
 
 
– 
– 
0.41 
0.25 
0.80 
Protein (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
 
0.00 ±0.00 
0.00 ±0.00 
5.41 ±0.87 
5.76 ±0.84 
5.75 ±1.16 
 
0.00 ±0.00 
0.00 ±0.00 
5.29 ±0.77 
5.53 ±0.66 
5.69 ±0.53 
 
– 
– 
0.61 
0.31 
0.99 
Fat (g/kg/day) ?̅?, ±SD 
Day 1 
Day 7 
Day 14 
Day 21 
Day 28 
 
0.00 ±0.00 
0.00 ±0.00 
8.32 ±0.87 
8.53 ±0.83 
8.28 ±1.18 
 
0.00 ±0.00 
0.00 ±0.00 
7.96 ±0.88 
8.17 ±0.89 
8.21 ±0.85 
 
– 
– 
0.17 
0.20 
0.81 
Values are means (?̅?) and ±Standard Deviations (±SD) unless otherwise indicated. 
*Statistically significant when (𝑝 =< 0.05) 
NOD; Number of days 
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For the duration of the study, there were no statistically significant differences in body 
composition, in terms of skinfold thickness measurements, fat mass percentage (FM%) 
and fat-free mass percentage (FFM%), between infants who received fortified HBM 
and those who did not. However, it was noted that, for the duration of the study, infants 
who received the fortifier were generally smaller and did not grow at a rate of 
15 g/kg/day (Supplementary Table 1). 
Comparisons for a two-way ANOVA for infants receiving the fortified HBM and HIV-
exposure could not be determined from day 7 onwards as there were no HIV-exposed 
infants in the group “infants receiving HBM alone.” Therefore the anthropometric and 
body composition measurements were determined for infants receiving fortified BM 
only and HIV-exposure (Table 3).   
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Table 3: Weekly anthropometric and body composition measurements of infants 
receiving fortified breast milk 
 Infants receiving fortified breast milk 
N = 91 (83%) 
𝒑 
 
 
 
 
 
HIV-exposed 
N = 25 (28%) 
 
HIV-unexposed 
N = 66 (72%) 
 
⌃  Day 1 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
934.40 ±155.46 
35.58 ±2.76 
2.62 ±0.59 
2.5 ±0.47 
1.21 ±1.09 
98.79 ±1.09 
 
996.37 ±146.72 
36.84 ±2.79 
2.75 ±0.49 
2.48 ±0.38 
1.29 ±0.87 
98.71 ±0.85 
 
0.07 
0.06 
0.12 
0.95 
0.49 
0.49 
 
⌃  Day 7 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
904.20 ±139.03 
35.53 ±1.74 
2.42 ±0.37 
2.26 ±0.40 
0.89 0.65 
99.11 ±0.65 
 
942.41 ±152.99 
36.69 ±1.68 
2.62 ±0.38 
2.35 ±0.34 
1.24 ±0.69 
98.90 ±1.17 
 
0.27 
0.05* 
0.03* 
0.19 
0.13 
0.21 
Day 14 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
919.16 ±179.60 
35.83 ±1.78 
2.52 ±0.33 
2.34 ±0.26 
1.10 ±0.60 
99.04 ±1.36 
 
999.29 ±159.59 
36.66 ±1.89 
2.63 ±0.39 
2.39 ±0.37 
1.13 ±0.69 
99.14 ±1.60 
 
0.04* 
0.07 
0.30 
0.55 
0.86 
0.84 
Day 21 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
1012.96 ±196.43 
36.66 ±1.96 
2.53 ±0.38 
2.31 ±0.45 
0.88 ±0.62 
98.98 ±0.97 
 
 
1112.45 ±190.36 
37.55 ±1.63 
2.75 ±0.40 
2.58 ±0.43 
1.36 ±0.73 
98.68 ±0.798 
 
 
0.02* 
0.09 
0.02* 
<0.01* 
0.01* 
0.03* 
Day 28 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
1026.20 ±144.17 
36.59 ±1.64 
2.55 ±0.41 
2.39 ±0.40 
0.97 ±0.74 
99.02 ±0.74 
 
1203.92 ±215.74 
37.99 ±1.79 
2.91 ±0.59 
2.71 ±0.52 
1.49 ±0.85 
98.49 ±0.85 
 
<0.01* 
<0.01* 
<0.01* 
0.01* 
0.03* 
0.02* 
Values are means (?̅?) and ±Standard Deviations (±SD) unless otherwise indicated. 
*Statistically significant when (𝑝 =<0.05) 
**Extremely statistically significant when (𝑝 =< 0.001) 
⌃  These values are based on unfortified breast milk, refer to Table 2.  
Fat-free mass percentage; FM%, Fat mass percentage; Subscapular skinfold thickness; TSF, Triceps skinfold thickness 
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Significant differences were found for infants who received fortified HBM and HIV 
exposure for weight and length [on days 14, 21 and 28 ( 𝑝 =0.04, 𝑝 =0.02 and 
( <  𝑝 = 0.01 and day 28 < 𝑝 =  0.01) of life, respectively]. Significant differences were 
also found between exposures for triceps skinfolds (TSF), subscapular skinfolds 
(SSSF), fat mass% (FM%) and fat-free mass% (FFM%) [on day 21 and 28 (𝑝 = 0.02 
and < 𝑝 = 0.04), (< 𝑝 =0.01 and 𝑝 = 0.01), (𝑝 = 0.01 and 𝑝 = 0.03) and (𝑝 = 0.03 and 
𝑝 = 0.02) of life, respectively] (Figure 1).  
Figure 0.1 
Formula and total parenteral nutrition (TPN) 
During the 28-day follow-up study period, five infants (4%) received infant formula for 
an average of 7.6 days and 11 infants (10%) received TPN for an average of five days. 
Owing to the small number of infants who received these nutritional intakes for a short 
period of time, no conclusive evidence regarding body composition could be 
determined. However, as expected, the 10 infants (91%) who received TPN were 
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classified as ELBW and had a significantly lower (𝑝 = 0.0012) mean birth weight 
822.73 g (±132 g) when compared with infants who did not receive TPN during the 28-
day follow-up period. Infants who received TPN displayed a consistent trend of being 
leaner with smaller TSF and SSSF thicknesses, lower FM% and higher FFM% for the 
duration of the study.  
All five infants who received formula were HIV-unexposed. Only one HIV-exposed 
infant (9%) received TPN and the remainder, i.e. 10 (91%) were HIV-unexposed 
infants, therefore adhering to BFHI and PMTCT guidelines. Of the HIV-unexposed 
infants who received TPN, seven (70%) completed the 28-day follow-up study, one 
infant was diagnosed with NEC Bells stage II and two infants passed away. 
The effect of Nil per os (NPO)  
Table 4 depicts the anthropometric and body composition measurements of all 113 
preterm infants included in this sub-study, divided into the total number of days infants 
were kept NPO at any given time during the 28-day follow-up period. For the purposes 
of this study, feeding intolerance was recorded with the occurrence of a vomit or 
aspirate. A total of 41 infants (36%) were NPO due to suspected intolerance during the 
study period. Of these infants, more than three quarters (76%) were kept NPO for ≤ 3 
days and the remainder for > 4–≤8 days. No infants were kept NPO for 6 days.  
Infants who were NPO at any given point during the study revealed that, generally, the 
longer total number of days they were kept NPO, the smaller, shorter and leaner they 
were and the higher their FFM% was. These infants displayed significant differences 
in FM% on day 7 (𝑝 = 0.04), day 21 (𝑝 = 0.04) and day 28 (𝑝 = 0.02) of life as well as 
significant differences in FFM% on day 21 (𝑝 = 0.02) and day 28 (𝑝 = 0.03) of life. 
Skinfold thickness was measured concurrently with FM%, and infants who were kept 
NPO had significant differences in TSF thicknesses on day 21 (𝑝 = 0.02) and day 28 
( 𝑝 = 0.04) of life, as well as significantly different SSSF thicknesses on day 28 
(𝑝 =0.02) of life (Table 4).  
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Table 4: The effect of nil per os (NPO) on the anthropometry and body composition of preterm infants  
 Infants who were 
not NPO 
N = 72 (64%) 
Infants who were NPO 
N = 41 (36%) 
 NPO for 0 days 
N = 72 (64%) 
NPO for 1 day 
N = 14 (34%) 
NPO for 2 days 
N = 10 (24%) 
NPO for 3 days 
N = 7 (17%) 
NPO for 4 days 
N = 3 (7%) 
NPO for 5 days 
N = 3 (7%) 
NPO for 7 days 
N = 2 (5%) 
NPO for 8 days 
N =  2 (5%) 
𝒑 
 
Day 1 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
985.14 ±162.23 
36.55 ±3.12 
2.74 ±0.49 
2.46 ±0.40 
1.26 ±0.81 
98.75 ±0.81 
 
962.86 ±178.56 
35.79 ±3.19 
2.81 ±0.55 
2.32 ±0.26 
1.27 ±0.89 
98.73 ±0.89 
 
 
963.00 ±173.21 
35.60 ±1.78 
2.57 ±0.35 
2.29 ±0.44 
0.96 ±0.83 
99.04 ±0.83 
 
967.14 ±62.11 
35.46 ±1.05 
2.66 ±0.97 
2.56 ±0.56 
1.31 ±1.66 
98.7 ±1.66 
 
920.00 ±135.28 
34.74 ±0.64 
2.63 ±0.70 
2.38 ±0.43 
1.15 ±1.3 
98.85 ±1.29 
 
890.00 ±251.198 
34.72 ±2.59 
--- 
2.60 ±0.92 
--- 
--- 
 
1065.00 ±49.5 
37.28 ±1.03 
2.75 ±0.212 
2.95 ±0.07 
1.49 ±0.66 
98.51 ±0.66 
 
680.00 ±28.29 
34.5 ±0.71 
--- 
--- 
--- 
--- 
 
0.41 
0.41 
0.57 
0.46 
0.69 
0.69 
Day 7 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
952.18 ±154.1 
36.68 ±1.63 
2.64 ±0.42 
2.36 ±0.36 
1.29 ±0.66 
98.86 ±1.17 
 
948.64 ±183.5 
36.61 ±1.96 
2.57 ±0.49 
2.30 ±0.45 
0.92 ±0.70 
99.07 ±0.70 
 
845.71 ±175.68 
34.58 ±3.74 
2.29 ±0.28 
2.17 ±0.40 
0.49 ±0.52 
99.51 ±0.52 
 
897.143 ±81.79 
35.73 ±1.03 
2.36 ±0.31 
2.32 ±0.58 
0.53 ±0.29 
99.47 ±0.29 
 
830.00 ±105.83 
--- 
2.22 ±0.33 
2.07 ±0.23 
--- 
--- 
 
988.00 ±110.31 
34.98 ±2.18 
2.63 ±0.35 
2.33 ±0.59 
1.57 ±1.24 
98.43 ±1.24 
 
1065.00 ±49.49 
35.70 ±0.21 
2.85 ±0.64 
2.90 ±0.14 
1.43 ±1.00 
98.57 ±1.00 
 
640.00 ±14.14 
31.63 ±0.32 
--- 
--- 
--- 
--- 
 
0.08 
0.09 
0.10 
0.12 
0.04 * 
0.06 
 
Day 14 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
1009.56 ±116.68 
36.65 ±1.96 
2.63 ±0.35 
2.41 ±0.34 
1.21 ±0.60  
99.04 ±1.51 
 
 
952.08 ±200.44 
36.66 ±2.11 
2.69 ±0.50 
2.31 ±0.36 
0.87 ±0.66 
99.14 ±0.66 
 
 
983.17 ±111.33 
36.84 ±0.87 
2.60 ±0.33 
2.38 ±0.45 
0.84 ±0.74 
100.37 ±2.95 
 
 
930.00 ±35.59 
36.49 ±0.58 
2.45 ±0.33 
2.26 ±0.39 
0.98 ±0.95 
99.02 ±0.95 
 
 
856.67 ±113.72 
35.20 ±1.06 
2.67 ±0.55 
2.13 ±0.23 
0.83 ±1.17 
99.17 ±1.17 
 
 
920.00 ±236.43 
34.93 ±3.38 
2.45 ±0.35 
2.43 ±0.04 
0.89 ±0.74 
99.11 ±0.74 
 
 
1080.00 ±77.78 
36.65 ±0.07 
3.05 ±0.07 
2.73 ±0.25 
1.77 ±0.16 
97.52 ±0.85 
 
 
675.00 ±91.92 
32.23 ±0.88 
--- 
--- 
--- 
--- 
 
 
0.16 
0.30 
0.32 
0.46 
0.42 
0.34 
 
Day 21 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
1131.98 ±192.70 
37.58 ±1.74 
2.76 ±0.36  
2.60 ±0.41 
1.38 ±0.61 
98.62 ±0.61 
 
 
1029.18 ±215.99 
37.47 ±1.78 
2.48 ±0.53 
2.25 ±0.49 
0.922 ±0.94 
99.08 ±0.94 
 
 
1108.17 ±153.38 
37.74 ±1.07 
2.90 ±0.30 
2.63 ±0.42 
1.55 ±0.61 
98.45 ±0.61 
 
 
1022.33 ±103.13 
37.29 ±0.831 
2.41 ±0.42 
2.33 ±0.49 
0.52 ±0.79 
99.48 ±0.79 
 
 
905.00 ±117.58 
35.78 ±1.59 
2.37 ±0.15 
2.07 ±0.13 
0.53 ±0.06 
99.47 ±0.06 
 
 
1026.67 ±272.27 
36.12 ±3.14 
2.43 ±0.45 
2.45 ±0.56 
0.77 ±1.05 
99.77 ±1.53 
 
 
1130.00 ±56.59 
37.33 ±0.18 
3.00 ±0.00 
2.70 ±0.71 
1.71 ±0.29 
96.93 ±1.63 
 
 
720.00 ±155.56 
32.83 ±0.32 
--- 
--- 
--- 
--- 
 
 
0.09 
0.29 
0.02 * 
0.12 
0.04 * 
0.02 * 
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 Infants who were 
not NPO 
N = 72 (64%) 
Infants who were NPO 
N = 41 (36%) 
 NPO for 0 days 
N = 72 (64%) 
NPO for 1 day 
N = 14 (34%) 
NPO for 2 days 
N = 10 (24%) 
NPO for 3 days 
N = 7 (17%) 
NPO for 4 days 
N = 3 (7%) 
NPO for 5 days 
N = 3 (7%) 
NPO for 7 days 
N = 2 (5%) 
NPO for 8 days 
N =  2 (5%) 
𝒑 
 
 
Day 28 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
1205.05 ±218.61 
37.91 ±1.77 
2.93 ±0.57 
2.79 ±0.49 
1.622 ±0.79 
98.38 ±0.79 
 
 
1127.73 ±244.75 
37.33 ±2.37 
2.73 ±0.52 
2.47 ±0.41 
1.13 ±0.75 
98.87 ±0.75 
 
 
1108.25 ±142.68 
37.78 ±1.45 
2.80 ±0.29 
2.35 ±0.06 
1.31 ±0.49 
98.69 ±0.46 
 
 
1141.50 ±120.29 
37.82 ±0.98 
2.33 ±0.45 
2.24 ±0.45 
0.56 ±0.79 
99.45 ±0.79 
 
 
989.00 ±74.72 
36.23 ±1.24 
2.35 ±0.33 
2.12 ±0.14 
0.67 ±0.52 
99.34 ±0.52 
 
 
1178.33 ±317.19 
36.63 ±4.49 
2.28 ±0.53 
2.40 ±0.71 
0.30 ±0.68 
--- 
 
 
1177.50 ±102.53 
37.85 ±0.92 
2.65 ±0.49 
2.55 ±0.49 
1.08 ±0.37 
98.91 ±0.37 
 
 
735.00 ±134.4 
34.08 ±0.32 
--- 
--- 
--- 
--- 
 
 
0.18 
0.40 
0.04 * 
0.02 * 
0.02 * 
0.03 * 
Values are means (?̅?) and ±Standard Deviations (±SD) unless otherwise indicated. 
* Statistically significant when (𝑝 = < 0.05) 
--- Indicates that no measurements were obtained for the following reasons: Length, infants received NCPAP therefore length measurements were unable to 
be conducted; TSF and SSSF, the researchers did not conduct skinfolds on infants if they appeared critically ill or had a weight ≤ 700 g; FM% and FFM%, 
unable to calculate values according to the Dauncey anthropometric method if all anthropometric and body composition measurements were not conducted. 
Fat-free mass percentage; FM%, fat mass percentage; NPO, nil per os; Subscapular skinfold thickness; TSF, Triceps skinfold thickness
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DISCUSSION 
This study represents one of the first to assess the nutritional intakes and the its effects 
on the quality of growth and body composition of HIV-exposed and HIV-unexposed 
preterm infants in a tertiary academic hospital in a resource-poor setting of South 
Africa.  
Very few study infants received nutritional intakes other than HBM or fortified HBM and 
for a very short period of time, thereby adhering to the BFHI and PMTCT guidelines.21 
Conclusive evidence could not be determined for the effect of nutritional intakes, such 
as formula milk or TPN, and the possible effect of these, on the body composition of 
HIV-exposed and HIV-unexposed preterm infants.  
The European Society of Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) recommends enteral and parenteral energy intakes of 110–
135 kcal/kg/day and 110–120 kcal/kg/day, respectively and a protein intake of 
3.5-4 g/kg/day for VLBW preterm infants.34 According to clinical guidelines,25 VLBW 
and ELBW preterm infants are expected to reach full fluid requirements (150–
180 ml/kg/day) between day ±10–14 of life. HIV-exposed preterm infants achieved full 
fluid requirements by day 12.5 (±3.71) of life, whereas the HIV-unexposed preterm 
infants achieved full fluid requirements on day 11.375 (±3.31) of life. The majority of 
the study infants (n = 19 and n = 91) received nutritional intakes from HBM only and 
fortified HBM respectively, during the 28-day follow-up period. Therefore, the effect of 
nutritional intakes on body composition was primarily focused on HIV-exposed and 
HIV-unexposed preterm infants who received only HBM and fortified HBM. 
K Strydom, E van Niekerk and M.A Dhansay35 conducted one of the first studies in 
Africa to assess the body composition of HIV-exposed and HIV-unexposed preterm 
infants. This study found that HIV-exposed preterm infants had significantly lower birth 
weights and poorer growth rates, and presented with a significantly leaner body 
composition in terms of FM%, lower skinfold thickness measurements and FFM% 
when compared with their HIV-unexposed counterparts.  
A Cochrane review by Brown36 comprising fourteen randomised controlled trials and 
1 071 preterm infants addressed multi-nutrient fortification of HBM for preterm infants. 
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This review found that multi-nutrient fortification of HBM had small but statistically 
significant increases in growth rates (weight, length and head circumference) for 
preterm infants during hospital admission, but there was a lack of data on the long-
term effects for growth and development. A recent review on fortification strategies of 
HBM for improved in-hospital growth of preterm infants conducted in a resource-poor 
setting such as South Africa, concluded that standard fortification did not lead to 
suitable in-hospital growth for preterm infants, and alternative fortification strategies 
should be considered.12 In our study, the inclusion criteria comprised the smallest and 
most preterm infants (GA ≤37 weeks and a birth weight ≤1 200 g) born in the 
institution. It was anticipated that these infants would generally have been smaller and 
not grow at the required rate of 15 g/kg/day and therefore would require 
supplementation of fortified HBM according to the fortifying HBM indications. According 
to the simplified energy and protein requirement guidelines commonly used in TBCH, 
it is recommended that preterm infants receive 110–150 Kcal/kg/day energy and a 
minimum of 9% protein of total energy.25 When comparing the composition and 
nutritional intakes, these requirements are met when HBM is fortified with a standard 
agent (Table 2). It is however noted that the HBM composition used in our study was 
based on the average composition of preterm MOM. 33 
There were no significant differences in body composition in terms of FM% and FFM% 
of infants who received fortified HBM and infants who did not. However, it was found 
that infants who were receiving fortifier generally had smaller skin fold measurements, 
indicating less FM% and higher FFM% compared with infants who did not receive 
fortifier (Supplementary Table 1). There were no HIV-exposed infants who received 
BM alone from day 7 onwards. This could be because HIV-exposed preterm infants 
had poorer growth rates when compared with their HIV-unexposed counterparts. When 
comparing HIV-exposure and infants who receive fortified HBM, it was noted that the 
HIV-exposed infants were generally smaller, shorter and leaner for the duration of the 
study when compared with the HIV-unexposed infants. Significant differences were 
found in terms of TSF, SSSF, FM% and FFM%, especially nearer to the end of the 
study, on days 21 and 28 of life.  
A review by Hay and Thureen37 stated that preterm FFM growth was dependent on 
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protein intake and insufficient nutrition and that decreased protein intakes could lead 
to muscle mass breakdown. Therefore, while growth alone is an important factor and 
requires increased amounts of amino acids and protein included in the nutritional 
intakes of preterm infants it is also essential for cell and tissue replication and growth.38 
37 39 
This study noted that the weight and body composition of preterm infants who were 
kept NPO at any given point in time during the 28-day study period generally had a 
negative association and displayed significant differences in FM% on day 7 (𝑝 =  0.04), 
day 21 (𝑝 = 0.04) and day 28 (𝑝 = 0.02) of life, and significant differences in FFM% on 
day 21 (𝑝 = 0.02) and day 28 (𝑝 = 0.03) of life. This study also found that infants who 
were NPO for the longest duration, a total number of 8 days during the 28-day study 
period, were the smallest; weighing generally <700 g for the duration of the study. 
Therefore the researchers were unable to conduct skinfold thickness measurements 
using the Dauncey anthropometric method and consequently body composition 
measures in terms of FM and FFM were inconclusive. Limited literature exists 
elucidating the relationship between preterm infants being kept NPO and the effect it 
could have on weight, growth and body composition.40 For this reason, a more 
comprehensive study should be conducted in this area.  
Recommendations for future studies include a longer follow up period to identify the 
effects nutritional intake has on the long-term growth and body composition of HIV-
exposed and HIV-unexposed preterm infants. This study made use of reference values 
for the calculation of nutrient content for the feeds that were prescribed to the infants. 
None of these feeds (BM, DMB, PBM or fortified HBM) were analysed for nutrient 
content. Future studies should consider milk analyses to determine the exact quantity 
of micronutrients, energy and macronutrients in terms of protein and fat. The strengths 
of this study are that it was one of the first studies in Africa to assess the effects of 
nutritional intakes on the growth and body composition of HIV-exposed and HIV-
unexposed preterm infants.  
CONCLUSION 
This descriptive cross-sectional study of HIV-exposed and HIV-unexposed preterm 
VLBW and ELBW infants was conducted at an institution that has been BFHI 
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accredited since 2005. For this reason, the majority of the study infants received 
nutritional intakes from HBM and fortified HBM. HIV-unexposed preterm infants 
achieved full fluid requirements earlier than HIV-exposed preterm infants. Preterm 
infants receiving fortified HBM were smaller and presented with a poorer growth rate 
of <15 g/kg/day. There were no significant differences in body composition of infants 
receiving HBM or fortified HBM. Significant differences in weight, skinfold thickness 
and body composition measurements (in terms of FM% and FFM%) were found for 
HIV-exposed and HIV-unexposed preterm infants who received fortified HBM. This 
study found that infants who were kept NPO for any duration during the 28-day follow-
up period were generally smaller, shorter, had lower FM% and higher FFM%.  
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SUPPLEMENTARY DATAFigure 0.2 Supplementary figure 1 
Supplementary Figure 1. Flow diagram of infants included in the study 
 
 
 
 
 Supplementary Table 1: Weekly anthropometric and body composition measurements of infants 
receiving only human breast milk or fortified human breast milk 
Infants not eligible for the 
study
n= 3
Infants eligible for the 
study
n= 131
Infants enrolled
n= 113
HIV-exposed
n= 30
Received BM 
n=29
Not received 
BM n=1
HIV-unexposed
n= 83
Received BM
n=81
Not received 
BM n=2
Infant outcomes
Completed 28-Day follow-up n= 70
Transferred n=21
Death n=14
NICU n=5
Discharged n=2
NEC Bell's II n=1
Withdrawal n= 0
Infants who did not 
participate in the study
n= 18
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Values are means (?̅?) and ±Standard Deviations (±SD) unless otherwise indicated. 
* Statistically significant when (𝑝 = < 0.05) 
** Extremely statistically significant when (𝑝 = < 0.001) 
⌃  These values are based on unfortified breast milk, refer to Table 2.  
Fat free mass percentage; FM%, fat mass percentage; Subscapular skinfold thickness; TSF, Triceps skinfold thickness 
 Infants receiving 
fortified breast milk 
N = 91 (83%) 
Infants receiving 
breast milk alone 
N = 19 (17%) 
𝒑 
 
Day 1 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
979.34 ±17.06 
36.50 ±2.83 
2.72 ±0.51 
2.49 ±0.40 
1.27 ±0.91 
98.73 ±0.91 
 
936.83 ±150.89 
34.89 ±2.67 
2.72 ±0.60 
2.22 ±0.43 
1.03 ±0.79 
98.97 ±0.79 
 
0.27 
0.017 * 
0.99 
0.009* 
0.30 
0.30 
⌃Day 7 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
932.62 ±149.59 
36.41 ±1.75 
2.57 ±0.38 
2.32 ±0.36 
1.16 ±0.69 
98.96 ±1.07 
 
926.23 ±211.25 
34.66 ±2.91 
2.66 ±0.72 
2.44 ±0.71 
1.08 ±0.76 
98.92 ±0.76 
 
0.89 
0.014 * 
0.54 
0.39 
0.79 
0.93 
Day 14 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
979.13 ±165.65 
36.44 ±1.89 
2.60 ±0.38 
2.37 ±0.34 
1.13 ±0.66  
99.11 ±1.54 
 
1065.0 ±203.72 
36.53 ±3.49 
2.69 ±0.35 
2.48 ±0.39 
1.04 ±0.67 
98.96 ±0.67 
 
0.27 
0.93 
0.62 
0.51 
0.80 
0.85 
Day 21 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
 
1085.72 ±196.32 
37.30 ±1.76 
2.69 ±0.41  
2.50 ±0.45 
1.22 ±0.73 
98.76 ±0.85 
 
1178.60 ±224.64 
37.36 ±2.82 
2.74 ±0.31 
2.70 ±0.52 
1.36 ±0.65 
98.64 ±0.65 
 
0.31 
0.95 
0.77 
0.34 
0.68 
0.76 
Day 28 of life ?̅?, ±SD 
Weight (g)  
Length (cm)  
TSF (mm)  
SSSF (mm)  
FM (%)  
FFM (%) 
 
1156.27 ±211.88 
37.56 ±1.86 
2.80 ±0.57 
2.17 ±0.51 
1.33 ±0.84 
98.66 ±0.85 
 
1277.50 ±344.419 
38.35 ±2.90 
2.58 ±0.32 
2.78 ±0.34 
1.09 ±0.49 
98.91 ±0.49 
 
0.27 
0.42 
0.43 
0.54 
0.57 
0.56 
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CHAPTER 4  
 
SUMMARY, CONCLUSION AND RECOMMENDATIONS 
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4.1 SUMMARY OF STUDY OBJECTIVES AND DESIGN 
 
“FROM LITTLE ACORNS MIGHTY OAKS GROW”  
 - ANONYMOUS- 
 
In 2010, “an estimated 14.9 million babies worldwide were born preterm, and this figure 
rises every year”. Fifty-two percent of global live births occur in sub-Saharan Africa and 
South Asia, and of these 60% are preterm deliveries (Lancet 20121). HIV is highly 
prevalent in South Africa and HIV-infected pregnant mothers have a considerably higher 
risk (13–34%) of delivering an infant preterm.1 2 HIV-exposed infants seem to have poorer 
growth and greater early mortality and morbidity rates than their HIV-unexposed 
counterparts.3 4 Changes in body fat distribution, as well as glucose and bone metabolism 
in HIV-positive children can increase their risk of future morbidities.5  
There is an evident gap in documented research regarding nutritional interventions and 
the effect thereof on the quality of growth and body composition of the preterm infant,6 7 8 
9 especially in the context of HIV infection.9 10 According to published research, the best 
method for assessing preterm body composition, in terms of fat mass (FM) and fat-free 
mass (FFM), is Dauncey’s anthropometric model.11 12 13 14 The use of this method to 
determine body composition is accurate, safe, inexpensive, non-invasive and can be 
performed at the patient’s bedside11 12 13 14, thereby avoiding excessive disturbance to 
these fragile infants.12  
Human breast milk (HBM) is globally accepted as the optimal and ideal nutritional 
intervention for full-term and preterm infants The benefits of HBM include better 
neurodevelopmental outcomes, improved gastrointestinal function, improvements in host 
defence and a decrease in late-onset sepsis and necrotising enterocolitis (NEC).15 16 17 18  
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The composition of preterm and term milk changes over time: HBM from mothers with 
preterm infants is initially higher in protein and fat, when compared with term milk.19 20 21 
22 A study by Hsu et al.18 examined the change in macronutrient and micronutrient 
composition of preterm milk over a four-week post-partum period. The results showed that 
the composition of fat increased gradually but plateaued after two-weeks post-partum. 
Research has shown that the composition of protein decreases slowly over the following 
weeks of lactation.22 As preterm milk is low in calcium, the bone mineral density and bone 
mass of preterm infants may be of concern in the long term. 
Olhager and Forsum23 stated that despite its benefits, preterm milk alone does not meet 
the increased nutritional requirements of infants born with a very-low birth weight (VLBW), 
as preterm milk provides only approximately 60% of their protein requirements.24 25 
Therefore, HBM from mothers with preterm infants is not nutritionally adequate and must 
be fortified to ensure adequate growth. It is particularly challenging to feed and meet the 
nutritional requirements of these infants owing to the high recommended daily allowance 
of energy, protein and other nutrients to achieve in-utero growth rates, in conjunction with 
the slow feeding progressions, small feeding volumes, feeding intolerance and 
gastrointestinal immaturity.15 16 18 26 27 28  
When there is an insufficiency in mother’s own milk (MOM) or if MOM is unavailable, 
pasteurised donor breast milk (DBM) is the first line of nutritional intervention for preterm 
infants.29 Donor breast milk usually comes from a mother who has an abundance of milk, 
more than her own infant can consume, and is from mothers with more mature milk (later 
on in lactation). The composition of DBM is lower in fat and protein and requires 
fortification to achieve the nutritional requirements of VLBW infants to ensure adequate 
growth. Supplementation of HBM with a fortifier (protein, nutrients, vitamins and minerals) 
is common practice in many neonatal intensive care unit (NICUs) to achieve the nutritional 
requirements and successful intrauterine growth rates in preterm infants, while the 
benefits of HBM are continually derived.24 25 30  
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The primary objective of the study was to evaluate and compare body composition in 
terms of the FM and FFM of HIV-exposed and HIV–unexposed, preterm, VLBW and 
extremely-low birth weight (ELBW infants). 
The secondary research objectives were as follows: 
i. To evaluate the effect of HIV-infected mothers’ treatment duration of highly active 
antiretroviral therapy (HAART) on the body composition of HIV-exposed, preterm, 
VLBW and ELBW infants. 
ii. To evaluate the effect of nutritional intake according to the ward protocol on the 
body composition of HIV-exposed and HIV–unexposed, preterm, VLBW and ELBW 
infants. 
iii. To evaluate the effect of breast milk fortification on the body composition of HIV-
exposed and HIV–unexposed, preterm, VLBW and ELBW infants.  
iv. To evaluate the effect of feeding intolerances and days that infants are nil per os 
(NPO) on the body composition of HIV-exposed and HIV–unexposed, preterm, 
VLBW and ELBW infants. 
A cross-sectional descriptive study with an analytical component was conducted in the 
neonatal units of Tygerberg Children’s Hospital (TBCH), Cape Town, South Africa 
between May 2016 and October 2016. Participants were included if the following inclusion 
criteria were met: (i) all male and female HIV-exposed and HIV-unexposed preterm infants 
with a gestational age of 25–37 weeks; (ii) birth weight (≥  500 g–≤  1 200 g); (iii) receiving 
nutritional support in the form of enteral nutrition and/or parenteral nutrition [EN: breast 
milk and supplementation thereof (FM85), formula feed) and parenteral nutrition (TPN)]; 
and (iv) written parenteral consent. Infants from multiple gestations meeting these criteria 
were included in the study. Infants were exited from the study if the following occurred: (i) 
day 28 of the study completed; (ii) transferred to neonatal or paediatric intensive care unit 
(NICU/PICU); (iii) discharged within the 28 days of recruitment; (iv) confirmed NEC: Bells 
stage II or III; (v) mothers admitted to intensive care unit (ICU) or those who gave their 
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infant/s up for adoption; (vi) if the mother of an eligible child could not be found after 48 
hours of recruitment; and (vii) death.  
Participants were included in this study for a 28-day follow-up period. Maternal medical 
background, infant clinical, medical and nutritional data were collected on a daily basis by 
the researcher. These included: medical information, medications, supplementation and 
all fluid input and output. Maternal antiretroviral (ARV) treatment was documented for the 
HIV-exposed preterm infants. The daily clinical assessments were done by the attending 
doctors and were documented. Furthermore, the following data was assessed and 
recorded daily: supplementation with medium-chain triglyceride oil, multivitamin and iron 
supplementation, phototherapy and blood products received, medication administered, 
urinary output, stool frequency, colour and consistency and the occurrence, frequency, 
colour and consistency of feeding intolerances.  
The researcher assessed the daily infant nutritional intakes, which included feeding route 
and volume of breast milk, infant formula, TPN, Neonatelyte (glucose-electrolyte-
containing-solution) and saline. The time of initial feeding was at the discretion of the 
attending physician. Infants of HIV-infected mothers received pasteurised expressed 
breast milk (PBM), which was pasteurised using the Pretoria flash method. Infants of HIV-
uninfected mothers received unpasteurised breast milk. The protocol for the fortification 
and supplementation with FM85 (breast milk fortifying agent available in South Africa) was 
applied for the duration of the study.  
All anthropometric and body composition measurements were conducted on day 1 of the 
preterm infants’ life and subsequently on a weekly basis: days 7, 14, 21 and 28 of life. 
Anthropometric measurements included: daily weights (g) and weekly lengths (cm). Body 
composition was determined using the Dauncey anthropometric method. Fat mass (FM) 
and FFM were determined by assessing skinfold thickness at two primary sites (triceps 
and subscapular) in conjunction with nine body dimensions: circumferences (head, chest, 
mid-upper arm, mid-thigh and mid-calf) and lengths (upper arm, lower arm, supine and 
crown-rump). No anthropometric measurements were conducted if the infant was 
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receiving nasal continuous positive airway pressure (NCPAP) and no skinfold 
measurements were done for the period that infants had a weight ≤700 g. 
Of the 131 preterm infants initially meeting the inclusion criteria, eight mothers were 
unable to give consent for medical or social reasons, three mothers declined consent, one 
infant was transferred to the NICU before inclusion and six infants died before consent 
was obtained. This left a sample size of 113 preterm infants in this descriptive cross-
sectional study. Of these, 30 infants (27%) were HIV-exposed and 83 (73%) were HIV-
unexposed.  
Of the 113 infants enrolled in the study, 70 (62%) completed the 28-day follow-up study 
period. Reasons for not completing the 28-day follow-up were: 21 were transferred to 
other hospitals, five were sent to the NICU, two were discharged, one was diagnosed as 
NEC Bells II and 14 deaths occurred. There were no withdrawals from the study. 
There were ten pairs of twins in the study; therefore the maternal study population 
comprised a total of 103 mothers. Of these, 27 (26%) were HIV-infected and 76 (74%) 
were HIV-uninfected.  
4.2 ADDRESSING STUDY OBJECTIVES 
In this section, each objective will be described and interpreted within the context of the 
results of the research.  
4.2.1 Body composition and HIV-exposure 
To our knowledge, this is one of the first studies to assess the body composition, in terms 
of FM and FFM, of HIV-exposed and HIV-unexposed preterm infants (refer to glossary of 
terms for definitions). Existing literature on body composition and HIV focuses 
predominantly on: HIV-exposed uninfected (HIV-EU) infants, HIV-infected and HIV-
unexposed infants, children and adults. In this study, HIV-exposed infants were born 
significantly more preterm (p = 0.01; GA 25–28 weeks), and were generally smaller, 
shorter and leaner at birth when compared with the HIV-unexposed infants. HIV-exposed 
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preterm infants presented with significantly lower birth weights and lengths [929 g 
(±155g); (p = 0.05)] and [35.1 cm (±2.8 cm); (p = 0.01)], respectively.  
As expected31 an almost equal weight loss was seen in the first week of life for both the 
HIV-exposed and HIV-unexposed groups [–58.5g (±60.6g) and –58.2g (±60.15g); 
(𝑝 = 0.32)]. This study found that HIV-exposed preterm infants generally had a lower FM% 
for the duration of the study and were found to have significantly smaller triceps skinfold 
(TSF) and sub-scapular skinfold (SSSF) thicknesses [on day 7, day 21, day 28 (𝑝 = 0.03, 
𝑝 = 0.02 and 𝑝 = <0.01) and day 21 and day 28 (𝑝 = <0.01 and 𝑝 = <0.01) of life, 
respectively]. This indicates a significantly lower FM% and a significantly higher FFM% 
when compared with HIV-unexposed preterm infants on day 21 (𝑝 = 0.01 and 𝑝 = 0.03) 
and day 28 (𝑝 = 0.03 and 𝑝 = 0.03) of life. This study failed to show significant differences 
in FM%, FFM% and TSF thickness measurements for HIV-exposures for the duration of 
the study (day 1–28 of life). However, significant differences (𝑝 = 0.01) in SSSF thickness 
were found for HIV-exposures for the duration of the study (day 1–28 of life).  
Environmental factors (maternal socio-economic environment and nutritional status) could 
have an effect on early life programming and determine or influence an infant’s risk of 
developing diseases later on in life.32 Barker et al.33 and Hales et al.34 conducted studies 
which reported that infants born with lower birth weights died of ischemic heart disease 
later on in life and had a higher prevalence of type 2 diabetes when compared with adults 
who were born with a normal weight at birth.35 Barker et al.36 37 further went on to study 
small for gestational age (SGA) and preterm birth and the effects these had on the risk of 
diseases later on in life. They reported that the low birth weight of infants born prematurely 
could be an indicator for developing lifestyle diseases later on, such as obesity, type 2 
diabetes, hypertension and cardiovascular disease (CVD). Existing literature on body 
composition and HIV predominantly focuses on older children and adults and there is 
limited literature regarding early life programming and HIV.  
A longitudinal observation study found that when compared with the National Health and 
Nutrition Examination Survey (NHANES) standards, HIV-EU children <  2 years had 
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significantly smaller TSF and SSSF thicknesses, indicating significantly lower fat stores.38 
Even though the researchers were unable to compare the results of this study to available 
literature it was found that our results were supportive of this trend in body composition. 
The current study indicated that HIV-exposed infants generally had smaller body 
composition measurements (TSF, SSSF and FM%) at weekly measurements on day 1, 
7, 14, 21 and 28 of life, indicating that they were leaner for the duration of the study. (Refer 
to article 1: The effect of maternal HIV status and treatment duration on body composition 
of HIV-exposed and HIV-unexposed preterm, very- and extremely-low birth weight infants, 
and Table 2: Weekly anthropometric and body composition measurements.) The 
researcher therefore rejects the null hypothesis (see 2.3.3) as clear differences existed in 
the body composition of HIV-exposed and HIV-unexposed preterm, VLBW and ELBW 
infants. HIV-exposed infants were smaller and leaner than HIV-unexposed infants. The 
researchers further hypothesise that early life programming affects the long-term 
outcomes of HIV-exposed preterm infants.  
4.2.2 Effect of HIV-infected mothers’ treatment duration on body composition 
Research reveals that HIV-infected infants, children and adults benefit from HAART.39 
Even though HAART is advantageous for maternal health and for the prevention of 
mother-to-child transmission (PMTCT), antenatal HAART has been associated with 
increased preterm delivery.1 2 40 HIV as a disease and HIV treatment are associated side 
effects such as altered fat distribution, especially an increase in central adiposity, which 
can be a risk factor for morbidities such as CVD and metabolic syndrome.10 39 To our 
knowledge, the relationship between body fat distribution and the body composition of 
HIV-infected or HIV-exposed preterm infants receiving antiretroviral therapy (ART) as 
prophylaxis has not yet been determined. 
This study included 27 HIV-infected mothers who were all on HAART at the time of 
delivery. This concurs to the most recent South African national consolidated guidelines 
for PMTCT released in April 2015.41 42 The HIV-status of all mothers included in this study 
was known at the time of delivery and all HIV-infected study mothers had received HAART 
for ≥ 4 weeks at delivery. According to the guidelines, in 2011, mother-to-child 
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transmission (MTCT) decreased to 2.7%.41 In this study none of the HIV-exposed preterm 
infants had a positive polymerase chain reaction (PCR) test for the duration of the study. 
Even though the researchers only recorded the PCR at birth and did not conduct any 
follow-up PCR tests, the low transmission rates and positive statistics are very 
encouraging, indicating that Tygerberg academic hospital (TAH) is implementing and 
adhering to PMTCT governmental guidelines and policies.  
All HIV-infected mothers had received HAART at the time of delivery. Thirteen mothers 
(48%) received HAART for ≥ 4–< 20 weeks and 14 (52%) received HAART for ≥20 
weeks. This study failed to show significant differences between the duration mothers 
received HAART and TSF, SSSF, FM% and FFM% measurements at birth among HIV-
exposed infants. However, this study found that HIV-exposed preterm infants whose 
mothers received HAART ≥20 weeks were generally heavier and had larger TSF and 
SSSF thickness measurements, indicating increased FM% and lower FFM% at birth when 
compared with infants whose mothers were on HAART for ≥ 4–< 20 weeks. Increased 
skinfold measurements and FM% indicates an altered body fat distribution which could 
increase the risk factors for future morbidities of these infants.5 10 Low maternal CD4 count 
(< 200 cells/µL) was associated with heavy birth weights, higher FM% and lower FFM%. 
The researcher therefore accepts the null hypothesis (see 2.3.3) that HIV-infected 
mothers’ treatment duration of HAART will have no effect on the growth and body 
composition of HIV-exposed, preterm, VLBW and ELBW infants. However, this could be 
due to small samples and detection as it is clear that, clinically, there was a significant 
difference in weight as infants born to mothers on HAART ≥ 20 weeks were almost 100g 
heavier at birth when compared with infants born to mothers on HAART ≥ 4–< 20 weeks. 
For the scope of this study and for the purposes of addressing the hypothesis, the 
researchers only compared the weight and body composition of treatment durations at 
birth.  
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4.2.3 Nutritional intakes and body composition 
This study represents one of the first to assess the nutritional intakes and the effect thereof 
on the quality of growth and body composition of HIV-exposed and HIV-unexposed 
preterm infants. There is increasing interest in the relationship between nutritional status 
during early infancy and childhood and the increased risk of adverse health effects as 
adults.23 28 31 43 44  
Tygerberg Children’s Hospital has been an accredited Baby Friendly Hospital Initiative 
since 2005 and implements the PMTCT national consolidated guidelines.41 42 Only five 
(4%) of the included infants received infant formula for an average of 7.6 days and 11 
infants (10%) received TPN for an average of five days. This study failed to provide 
conclusive evidence on the effects of nutritional intakes, such as infant formula and TPN, 
and their possible effect on the body composition of HIV-exposed and HIV-unexposed 
preterm infants.  
Human breast milk is globally known to provide the optimal nutritional intake for infants. 
However, breast milk from mothers with preterm infants is considered nutritionally 
inadequate and must be supplemented with a fortifying agent to ensure adequate growth 
of these infants of > 15 g/kg/day.23 24 25 30 45 One hundred and ten infants [HIV-exposed 
(n = 29) and HIV-unexposed (n = 81)] received expressed breast milk (EBM), DBM or 
PBM at a given point in time during the 28-day follow-up study. In this current study, no 
significant differences in body composition in terms of FM% and FFM% were noted for 
HIV exposure. The majority of study infants (n=110) received nutritional intakes from 
breast milk only (n = 19) and fortified breast milk (n = 91), during the 28-day follow-up 
period. The indication for the use of a fortifier was the infants were generally smaller, and 
did not grow at the required rate of 15 g/kg/day. There were no significant differences in 
body composition in terms of FM% and FFM% of infants who received fortified breast milk 
and infants who did not. These findings are in agreement with a recent review conducted 
in South Africa, which concluded that standard fortification strategies of human breast milk 
did not lead to sufficient in-hospital growth of preterm infants. The authors recommended 
that the super fortification strategy or patient-specific requirements should be 
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implemented, as it would lead to higher protein intakes and adequate growth of the 
preterm infant.24 46 The researcher, therefore, fails to reject the null hypotheses (see 2.3.3) 
that there is no difference in body composition between VLBW and ELBW preterm infants 
who receive breast milk only and infants who receive fortified breast milk.  
For the purposes of this study, the researcher followed ward protocol for the fortification 
of HBM in TBCH. The fortifier was FM85 and the standard fortification strategy was used.45 
46  
The term ‘feeding intolerance’ is commonly used in the literature, but there is little 
consensus regarding its definition. Fanaro47 defined a feeding intolerance as a 
“combination of clinical signs suggesting an inability by the subject to tolerate enteral 
nutrition”. Moore and Wilson48 conducted a concept analysis in an attempt to find a 
universally accepted definition for the term. All known definitions from dictionaries, 
medical textbooks, literature and biomedical databases were used to compose the most 
comprehensive definition: “a feeding intolerance in the premature infant is the inability to 
digest enteral feedings presented as GRV (gastric residual volume) more than 50%, 
abdominal distension or emesis or both, and the disruption of the patient’s feeding plan.” 
For the purposes of this study, feeding intolerance was recorded with the occurrence of 
vomiting or aspiration, at which stage infants were NPO. 
A total of 41 infants (36%) were NPO because of a suspected intolerance during the 28-
day study period. Infant’s who were NPO at any given point during the study, but 
especially for longer durations, were found to be generally lighter, shorter, leaner and had 
a higher FFM%. Significant differences in body composition were found for infants who 
were kept NPO during the 28-day follow-up period. These infants displayed significant 
differences in FM% on day 7 (𝑝 = 0.04), day 21 (𝑝 = 0.04) and day 28 (𝑝 = 0.02) of life 
as well as significant differences in FFM% on day 21 (𝑝 = 0.02) and day 28 (𝑝 = 0.03) of 
life. Skinfold thickness was congruent with FM% and infants that were NPO had significant 
differences in TSF thickness on day 21 (𝑝 = 0.02) and day 28 (𝑝 = 0.04) of life, as well as 
significantly different SSSF thicknesses on day 28 (𝑝 = 0.02) of life. (Refer to article 2: 
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How does nutritional intake affect the body composition of HIV-exposed and HIV-
unexposed preterm, very- and extremely-low birth weight infants? and Table 4: The effect 
of nil per os (NPO) on the anthropometry and body composition of preterm infants.) This 
study concludes that keeping an infant NPO and providing inadequate nutrition during 
early life may be associated with an increase in morbidity, poor development 
(neurologically and physiologically) and impaired cognitive performance later on in life.23 
26 49 The researcher therefore rejects the null hypothesis (see 2.3.3) as preterm infants 
who were NPO were smaller, had lower FM% and higher FFM% than infants who were 
not NPO at any point during the study. Limited literature exists elucidating the relationship 
between preterm infants being kept NPO and the effect it could have on weight changes. 
50  
It is increasingly evident that preterm infants who are NPO or not meeting their nutritional 
requirements do not achieve growth rates in relation to size, anthropometry and body 
composition when compared with their term counterparts at term-equivalent age. 
Therefore, these infants are at risk of developing adverse outcomes later on in life such 
as neurodevelopmental delays, decreased immunity and stunting.43 51 52 53 On the other 
hand, infants who experience rapid catch-up growth and intra-abdominal adiposity could 
be at risk of developing metabolic syndrome and CVD later on in life.6 7 8 26 54 55  
Recent literature has reported that the risk of diseases such as obesity, CVD and type 2 
diabetes is influenced by more than just an excess energy intake and sedentary lifestyle. 
The very early life of an infant in-utero and the environment that he or she is exposed to 
could influence the infant’s risk of disease later on in life.56 57 Maternal risk factors during 
pregnancy could also have an effect on an infant’s early life programming in the prenatal 
period. Environmental factors such as maternal obesity, gestational diabetes and smoking 
have been found to be precursors to obesity later on in life. This study found that infants 
whose mothers smoked cigarettes during pregnancy were heavier and had a higher FM% 
and lower FFM% at birth than infants whose mothers did not smoke. (Refer to article 1: 
The effect of maternal HIV status and treatment duration on body composition of HIV-
exposed and HIV-unexposed preterm, very- and extremely-low birth weight infants.) 
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Previous literature has reported that infants of mothers who smoked during pregnancy 
were considerably more likely to be SGA.58 59 However, more recently studies have linked 
smoking during pregnancy with childhood and adult obesity.60 61 62 63 The researchers 
hypothesise that prenatal smoking is a risk factor for fetal growth restriction and lower birth 
weights and subsequently can be associated with the risk of developing obesity later on 
in life. 
Infants of mothers who had received HAART for 20 weeks or longer were generally 
heavier and had higher FM% and lower FFM% at birth when compared with infants whose 
mothers were receiving HAART  4–20 weeks. This study also found that infants whose 
mothers had CD4 counts < 200 cells/µL were the heaviest at birth and had the highest 
FM% when compared with infants whose mothers had higher CD4 counts (CD4 ≥ 200–
< 500 cells/µL and CD4  ≥ 500 cells/µL). (Refer to article 1: The effect of maternal HIV 
status and treatment duration on body composition of HIV-exposed and HIV-unexposed 
preterm, very- and extremely-low birth weight infants.). Infants of mothers who are HIV-
positive could be exposed to a maternal immunosuppressed environment in-utero which 
could cause epigenetic changes and oxidative stress, thereby increasing the risk of 
metabolic and cardiovascular diseases. (Refer to article 1: The effect of maternal HIV 
status and treatment duration on body composition of HIV-exposed and HIV-unexposed 
preterm, very- and extremely-low birth weight infants.) 
The thrifty phenotype hypothesis states that maternal undernutrition results in endocrine 
changes (insulin resistance) that decrease nutrient supply to the somatic cells of the fetus 
and rather nourish the heart and brain. The fetus adapts to this environment in-utero and 
when born into a world of abundance, the increased insulin resistance could result in the 
infant developing obesity and type 2 diabetes later on in life. 64 65 Body composition 
studies indicate that babies with higher abdominal FM% and lower overall FFM%, known 
as ‘thin-fat babies’, are at a higher risk of developing type 2 diabetes later on in life. 
Therefore, the thrifty phenotype hypothesis extends further than only maternal 
undernutrition and could include environmental factors, which result in altered body 
composition of preterm infants.66 
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This study found that infants who were exposed to environmental factors such as smoking, 
low CD4 counts and were exposed to chronic medication (HAART ≥ 20 weeks) had 
increased birth weights and higher FM%. These infants are already pre-disposed due to 
their low birth weights to risk factors later on in life. HIV-exposed preterm infants were 
found to be the smallest and leanest, and therefore have an even higher increased risk of 
developing diseases such as obesity, type 2 diabetes and CVD later on in life.  
4.3 LIMITATIONS OF THE STUDY 
The following limitations could have impacted the quality of results of this descriptive 
cross-sectional study: 
i. Owing to the slow enrolment of HIV-exposed preterm infants and a limited time 
frame for data collection, the statistician recalculated the sample size for the HIV-
exposed group. Refer to Chapter 2: Methodology section 2.6.1 Sample size  
ii. When infants were receiving NCPAP no anthropometric measurements (weight, 
length, head circumferences) were conducted for this time period. This was a 
limitation to the current study, as all anthropometric and body composition 
measurements were needed to determine FM% and FFM% using the Dauncey 
anthropometric method on the five occasions during the study period (Day 1, 7, 14, 
21 and 28).  
iii. Owing to the fragility and friability of the preterm infants’ skin, no skinfold 
measurements were conducted for the time period that infants had a weight of 
≤  700 g. This was a limitation to the current study, as all anthropometric and body 
composition measurements were needed to determine FM% and FFM% using the 
Dauncey anthropometric method on the five occasions during the study period (Day 
1, 7, 14, 21 and 28).  
iv. During the 28-day recruitment period 21 infants were transferred to other hospitals 
before the end of the 28-day follow-up period.  
The following data and results could have been collected to further strengthen the 
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results of the study: 
i. Pre-existing maternal body composition and environmental factors could have 
been accounted for and would have presented interesting body composition 
results.  
ii. Body composition measurements, in terms of weight, TSF, SSSF, FM%, FFM%, of 
HIV-exposed and HIV-unexposed infants at 6 months would have helped to 
determine the quality of catch-up growth and body composition and to draw 
associations with HIV-exposure.  
iii. A secondary PCR at 10 weeks could have been used to determine HIV MTCT risk 
and assess the effects on body composition. 
iv. Recording maternal viral loads at birth could have further indicated maternal HIV 
stage. This information may have been interesting for identifying the effect of 
maternal HIV viral loads on the body composition of HIV-exposed infants.  
v. Reference values were used for the calculation of nutrient content for the feeds 
(HBM, DBM, PBM or fortified breast milk) that were prescribed to the infants. 
Analysing the micronutrient, energy and macronutrients content (in terms of protein 
and fat) could have led to a better understanding of the quality of growth and body 
composition distribution in terms of FM% and FFM%.  
4.4 RECOMMENDATIONS 
4.4.1 Practical recommendations to address the research question 
i. To the researchers’ best knowledge, this was the first study to assess the body 
composition of HIV-exposed and HIV-unexposed, VLBW and ELBW preterm 
infants. More studies should be conducted using different body composition 
assessment methods such as the gold standard; air displacement 
plethysmography (ADP), using the PEA POD, and dual-energy X-ray 
absorptiometry to confirm the differences in body composition of these infants. 
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ii. The effect of HIV, the immunosuppressed state of an HIV-positive mother and the 
treatment duration and exposure on the growth and body composition of HIV-
exposed preterm VLBW and ELBW infants should be explored.  
4.4.2 Recommendations for future research 
i. A prospective study should investigate long-term outcomes of body composition in 
HIV-exposed and HIV-unexposed preterm infants. An important research question 
that remains is: What are the long term outcomes of body composition and the 
effect of the quality of catch-up growth in HIV-exposed and HIV-unexposed preterm 
infants and the incidence of morbidities associated with central obesity such as 
CVD and metabolic syndrome?  
ii. A longer follow up study period may have contributed to the identification of the 
long-term effects such as maternal HIV status and treatment duration on the body 
composition of HIV-exposed and unexposed VLBW and ELBW preterm infants, as 
well as the effects nutritional intake has on the long-term growth and body 
composition of HIV-exposed and HIV-unexposed preterm infants. 
iii. Future studies should conduct milk analyses on the nutritional intake samples 
(breast milk, donor breast milk, pasteurised breast milk and fortified breast milk) 
infants received to determine the micronutrient, energy and macronutrient 
composition and the effect these could have on the quality of growth and body 
composition of preterm infants.  
iv. Analysing the breast milk composition of HIV-positive and HIV-negative mothers 
should be examined and their possible effect on the growth and body composition 
of HIV-exposed and HIV-unexposed preterm infants.  
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4.5 KEY POINTS 
 
  
Key points to take home 
 
 
1.  
 
Mothers receiving HAART could have an increased risk of preterm delivery 
2.  At birth, HIV-exposed uninfected preterm infants are significantly smaller (in 
weight and length), generally leaner (in terms of FM%) and do not gain weight 
as well in the first 28 days of life, when compared with HIV-unexposed preterm 
infants. 
3.  HIV-exposed preterm infants have significantly leaner body composition in terms 
of FM% and skinfold thickness (triceps and biceps) on day 21 and day 28 of life. 
4.  The treatment duration of maternal HAART affects the postnatal body 
composition of preterm infants. 
5.  HIV-unexposed preterm infants reach full fluid requirements earlier [day 11.375 
(±3.31) of life] than HIV-exposed preterm infants [day 12.5 (±3.71 of life)]. 
6.  Preterm infants receiving fortified breast milk were smaller and presented with a 
poorer growth rate < 15 g/kg/day. 
7.  No significant differences in body composition were found in infants receiving 
HBM vs. fortified HBM. 
8.  The duration infants are kept NPO has an effect on their growth and body 
composition as these infants were generally smaller, shorter, had lower FM% 
and higher FFM%. 
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ADDENDUM A: CONSENT FORMS (ENGLISH, AFRIKAANS, ISIXHOSA 
BIG$HMO$STUDY-ICF/$VERSION$2$ 1!
 
 
 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT:  
Body composition, Growth and nutritional intake of HIV exposed premature, very- and 
extremely-low birth weight infants in Tygerberg hospital, Western Cape- Gut Microbiome and 
Human Milk Oligosacchardise composition.  
BIG HMO study 
 
REFERENCE NUMBER:  N15/10/12 
PRINCIPAL INVESTIGATOR: Dr. Evette Van Niekerk, Prof Ali Dhansay 
RESEARCHERS: Klara Strydom, Thea Lodewyks 
ADDRESS:   
Division of Human Nutrition,  
Faculty of Medicine and Health Sciences,  
Tygerberg campus 
Third floor 
Tygerberg, Stellenbosch University  
CONTACT NUMBERS: +27 21 938 9474, +27 82 418 4906 
 
1. INVITATION 
You are being invited to take part in a research project. Please take some time to read the 
information here, which will explain the what the project is about. Please ask the study staff any 
questions about any part of this project that you do not fully understand. It is very important that 
you are completely happy and that you clearly understand what this research is about and how 
you and your baby could be involved. Also, your participation is entirely voluntary and you are 
free to say that you do not want to take part in the study. If you say no, this will not affect you or 
your infant in any bad way whatsoever.  You are also free to say at any time that you do not 
want to take part in the study anymore, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be performed according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
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2$ BIG$HMO$STUDY-ICF/$VERSION$2!
 
2. WHAT IS THIS RESEARCH STUDY ALL ABOUT? 
It is known that babies who are born prematurely (born early) grow differently to babies that are 
born at full term (born at the right age). This could mean that babies are not growing right for 
their age, resulting in a longer stay in hospital. Premature infants are difficult to feed. The type 
and quality of feeds can have an effect on how the baby grows. Growth is important for brain 
development and for the babies to reach general milestones (sitting, crawling, walking etc.). 
Preterm babies are known for having more total fat mass than babies who are born at the right 
age. This could mean that these premature babies stand a chance of getting or becoming: 
obese (very fat), diabetes (sugar) and heart problems when they are older.   
Breast milk stimulates the growth of “good” germs in the gut or intestines of babies. Studies 
have shown that the “good” germs in breast milk can help the baby to grow better and prevent 
“bad” germs from making the baby sick and not grow properly. The live “good” germs that we 
want to look at are called Prebiotics. In this study we want to see how much of the “good” germs 
grow in the babies gut or intestine that are fed breast milk and if the amount of “good” germs 
has an effect on the overall growth of your baby.  
Babies who are born very early are admitted to Ward G2 in Tygerberg Children’s Hospital. Very 
small premature babies who weigh less than 1200g, born to mothers who are HIV-positive or 
HIV-negative will take part in the study. With this study we want to find out the following:  
i. The growth and body composition (the percentage of fat, muscle, bone and water in the 
body) of the HIV-exposed and HIV–unexposed, premature babies.  
ii. The effect of the feeds (breastmilk, breastmilk with a supplement (FM85) and formula 
feed) that the babies get as food have on their growth and body composition.  
iii. The effect that the amount of time the HIV-infected mothers have been on HAART 
medication has on the growth and body composition of HIV-exposed, preterm and 
extremely low birth weight (ELBW; ≤1200g) babies. 
iv. To evaluate the effects of oligosaccharide composition on the babies good gut germs 
and the effects it has on growth and body composition.  
2.1. How will you and your baby participate in the study? 
! If your baby has a birth weight lower than ≤1200g your baby will be admitted to Ward G2 
while you will be admitted to Ward J5 or J2. We will visit you in the ward after the birth of 
your baby to explain the study to you and to invite you and your baby to take part in the 
study. We will give you a letter which explains the study and if you agree to take part, 
you must sign a consent form.  Within a few days after the birth of your baby, you will be 
transferred to stay with your baby in ward G2. Once your baby is bigger, you and your 
baby will be transferred to ward G8 or J2 in Tygerberg Children’s Hospital where you will 
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stay until your baby is ready to be transferred to another hospital where you will remain 
until your baby weighs more than 1800g and is ready to go home. 
! Babies will be in the study for the first 28 days after birth.  
 
2.2. What will happen to me if I do take part? 
Small premature babies are too weak to suckle on the breast. The mother has to express milk 
from her breast which is then given to the baby by means of a thin plastic tube that goes from 
the baby’s mouth to the baby’s stomach. The nurses in G2 baby ward will teach you how to 
express breast milk for your baby. As part of the study, we want to measure the quality of some 
of the good components in your breast milk. The most important one is oligosaccharride which 
also helps to protect your baby against infection. We will therefore need a 2ml sample of your 
breast milk at specific times. 
The first milk sample we will need from you is on day 1 of life, then on day 7,14, 21, 28 of life. 
These 5 milk samples will be collected in a sterile container and frozen before being tested in 
the laboratory.  
Information from your hospital file will be used in the study such as how your baby was 
delivered, what medications you received during your pregnancy, etc. All pregnant women in 
the Western Cape are tested for HIV during pregnancy. As it is important for us to know your 
HIV status, we will obtain your HIV status from your hospital folder.  
2.3. What will happen to the baby if I give consent?  
Breast milk allows “good” bacteria to grow in your infants guts and intestines. As part of the 
study, we want to measure the quality of some of the “good” bacteria that grows in baby’s gut 
and intestines by measuring the amount “good” bacteria in the stool. The “good” bacteria helps 
to protect your baby against infection and helps them to grow properly. We will therefore need a 
1g sample of your babies stool at specific times. 
The first stool sample we will need from your baby is the first stool on day 1 of life, then on day 
7,14, 21, 28 of life. These 5 stool samples will be collected in a sterile container and frozen 
before being tested in the laboratory.  
Your baby’s folder will be read by the researcher every day and the results of the laboratory 
tests (blood tests etc.), feeds and medication the baby receives will be written down. Small 
babies are weighed every day to see if they are getting enough feeds and growing properly. 
Your baby will be weighed daily by the nursing staff. On a weekly basis the following will also be 
done: 
i. Please refer to figure 1 for the following measurements that will be taken on your 
baby:  
A: Head circumference 
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B and D: Cylindrical circumferences 
C: Length 
E: Foot length 
Figure 1: Measurements that will be taken of your baby 
  
E 
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ii. Skinfold thickness: Only the fat layer under your skin is picked up, at different parts 
of the body, and it is precisely measured using a calliper to see how much fat makes 
up your baby’s body. Refer to figure 2.  
 
 
 
 
 
 
Figure 2: Skinfold thickness 
 
3. WHY HAVE YOU BEEN INVITED TO PARTICIPATE? 
You have been chosen because you gave birth to a very small baby, that was born too early 
and was admitted to ward G2 at Tygerberg Children’s Hospital (TCH).   
 
4. WILL YOU BENEFIT FROM TAKING PART IN THIS RESEARCH? 
You will benefit from knowing that you were an important contributor in giving the medical team 
(Doctors, nurses, dietitians and researchers) important information about the growth, body 
composition and nutritional intake (feeds) of VLBW and ELBW premature babies.  
5. ARE THERE ANY RISKS OR DISCOMFORTS INVOLVED IN YOUR TAKING PART IN 
THIS RESEARCH? 
There are no risks involved if you take part in this study. Your baby will be treated exactly the 
same as any of the other small babies admitted to ward G2 at Tygerberg Children’s Hospital. All 
the measurements that will be done has been proven to be safe by other studies. Your baby 
might be a bit uncomfortable when moved to take the measurements but all the measurements 
taken are safe and the researchers will not hurt your baby. The researchers have received the 
right training to measure your baby.  
 
6. IF YOU DO NOT AGREE TO TAKE PART, WHAT ALTERNATIVES DO YOU HAVE? 
It is your choice whether you would like you and your baby to take part in this study or not. If 
you decide not to take part in the study it will not affect the care given to you or your baby. 
Additionally you are allowed to say, at any point without giving a reason, that you do not want 
yourself and your baby to take part in the study. Your and your baby’s  routine health care will 
not be negatively affected. 
Stellenbosch University  https://scholar.sun.ac.za
 120 
 
 
6$ BIG$HMO$STUDY-ICF/$VERSION$2!
 
 
7. WHO WILL HAVE ACCESS TO YOUR MEDICAL RECORDS? 
Only the researcher, research assistant and persons directly involved with the study will have 
access to your and your baby’s medical records. All information will always be kept confidential 
and private. The researcher and research assistant will treat all information collected as strictly 
confidential and private and no information that can identify you or your baby will be given to 
any person who is not directly involved with the study.  
 
8. WHAT WILL HAPPEN IN THE UNLIKELY EVENT OF SOME FORM OF INJURY 
OCCURRING AS A DIRECT RESULT OF YOUR TAKING PART IN THIS RESEARCH 
STUDY? 
It is very rare that something will go wrong. Throughout the study common methods will be 
used, therefore making the chances that something goes wrong, very small. 
 
9. WILL YOU BE PAID TO TAKE PART IN THIS STUDY AND ARE THERE ANY COSTS 
INVOLVED? 
No, you will not be paid to take part in the study. You will also not have to pay for anything, if 
you do take part in the study. 
 
10. IS THERE ANYTHING ELSE THAT YOU SHOULD KNOW OR DO? 
! You can contact the principal investigator or researchers at +27 21 938 9474, +27 82 
418 4906 if you have any further queries or encounter any problems. 
! You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any worries or complaints that have not been properly addressed by the researcher. 
! You will receive a copy of this information and consent form for your own records. 
 
11. INSURANCE 
This study does have insurance, for a period from 1st January 2016 - 31st December 2016,  for 
the unlikely event of something going wrong during the study.  
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled Growth, body composition and nutritional intake of HIV exposed premature, 
very- and extremely-low birth weight infants in Tygerberg hospital, Western Cape.. 
I declare that: 
· I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
· I have had a chance to ask questions and all my questions have been properly 
answered. 
· I understand that taking part in this study is voluntary and I have not been forced to 
take part. 
· I may choose to leave the study at any time and will not be penalised or 
discriminated in any way. 
· I may be asked to leave the study before it has finished, if the researcher feels it is 
in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
 
 
 ................................ ................................ ....   ................................ ................................ .. 
Signature of participant Signature of witness 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
· I explained the information in this document to ………………………………….. 
· I encouraged him/her to ask questions and took adequate time to answer them. 
· I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
· I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below). 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
 
 
 ................................ ................................ ....   ................................ ................................ .. 
Signature of investigator Signature of witness 
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Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
· I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
· We encouraged him/her to ask questions and took adequate time to answer them. 
· I conveyed a factually correct version of what was related to me. 
· I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….(2015). 
 
 
 
 ................................ ................................ ....   ................................ ................................ .. 
Signature of interpreter Signature of witness 
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DEELNEMERINLIGTINGSBLAD EN -TOESTEMMINGSVORM 
 
 
TITEL VAN DIE NAVORSINGSPROJEK: 
Liggaamsamestelling, Groei en voedingsinname van MIV blootgestelde premature, lae 
geboorte gewig babas in Tygerberg Hospitaal, Wes-Kaap. Derm Mikrobiome en Menslike Melk 
Oligosakkaried samestelling. 
BIG HMO studie 
 
VERWYSINGSNOMMER: N15/10/12 
 
HOOFNAVORSER: Dr. Evette Van Niekerk, Prof Ali Dhansay 
Navorsers: Klara Strydom, Thea Lodewyks 
ADRES: 
Afdeling van Menslike Voeding,  
Fakulteit van Gesondheidswetenskappe,  
Tygerberg kampus 
Derde vloer 
Tygerberg, Stellenbosch Universiteit  
KONTAKNOMMER: +27 21 938 9474, +27 82 418 4906 
 
1. UITNODIGING 
Jy word genooi om deel te neem aan ’n navorsingsprojek.  Lees asseblief hierdie inligtingsblad 
op jou tyd deur aangesien die detail van die navorsingsprojek hierin verduidelik word.  As daar 
enige deel van die navorsingsprojek is wat jy nie heeltemal verstaan nie, is jy welkom om die 
navorsingspersoneel of dokter daaroor te vra.  Dit is baie belangrik dat jy heeltemal moet 
verstaan waaroor die navorsingsprojek gaan en hoe jy en jou baba daarby betrokke kan wees.  
Jou deelname is jou keurse en dit is ook jou besluit as jy wil nee sê.  Jy sal op geen manier sleg 
beïnvloed word as jy sou weier om deel te neem aan die studie nie.  Jy mag ook op enige 
stadium van die navorsingsprojek onttrek, selfs al het jy nou ja gesê. 
 
Hierdie navorsingsprojek is deur die Gesondheidsnavorsingsetiekkomitee (GNEK) van die 
Universiteit Stellenbosch goedgekeur en sal gedoen word volgens die etiese riglyne en 
beginsels van die Internasionale Verklaring van Helsinki en die Etiese Riglyne vir 
Navorsing van die Mediese Navorsingsraad (MNR). 
 
2. WAT BEHELS HIERDIE NAVORSINGSPROJEK? 
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Dit is bekend dat premature babas (vroeg gebore word) anders groei as babas wat volterm 
gebore (gebore op die regte tyd) word. Dit kan tot gevolg hê dat hierdie babas nie reg groei vir 
hulle ouderdom nie en dus langer in die hospitaal moet bly. Premature babas is ook moeilik om 
te voed. Die tipe en kwaliteit van voedings kan ‘n verskil maak aan die groei van die baba. Groei 
is belangrik vir brein ontwikkelling en om algemene mylpale te bereik (soos sit, kruip, stap ens). 
Premature babas is geneig om meer totale vet massa te hê as babas wat op die regte tyd 
gebore is en dit kan lei tot obesiteit (baie vet), diabetes (suiker) en ook hart probleme as hulle 
ouer is.  
Borsmelk stimuleer die groei van "goeie" kieme in die derm of ingewande van babas. Studies 
het getoon dat die "goeie" kieme in borsmelk die baba kan help om beter te groei en te keer dat 
“slegte” kieme die baba siek maak wat kan veroorsaak dat die baba nie goed groei nie. Hierdie 
lewende "goeie" kieme waarna ons wil kyk word Prebiotika genoem. In hierdie studie wil ons 
sien die hoeveelheid van "goeie" kieme in die derm of ingewande van babas wat slegs borsmelk 
ontvang en ons wil ook kyk of die hoeveelheid “goeie” kieme ‘n effek sal he aan die algemeene 
groei van jou baba.  
 
Babas wat vroeg gebore word word opgeneem in Saal G2 in Tygerberg Kinder hospitaal. Baie 
klein premature babas wat minder as 1200g weeg en wie se moeders MIV+ of MIV- is gaan 
deelneem aan hierdie studie. Met hierdie studie wil ons die volgende uitvind word: 
i. Die groei en liggaamsamestelling (persentasie vet, spier, been en water in die lyf) van MIV-
blootgestelde en MIV-nie-blootgestelde premature babas. 
ii. Die effek van die voedings (borsmelk, borsmelk met supplement (FM85) en formule) wat hierdie 
babas kry op hulle groei en liggaamsamestelling. 
iii. Die effek van die tydperk (hoe lank) die MIV-postiewe mamma op HAART behandelings is, op 
die groei en liggaamssamestelling van MIV-blootgestelde, premature, BLGM (kleiner as 
≤1200g) babas.  
iv. Die effek van oligosakkaried samestelling op die baba se goeie kieme in die derm te evalueer 
asook die effek wat dit het op die groei en liggaam samestelling van die baba.. 
 
 
2.1. Hoe gaan ek en my baba deelneem in die studie? 
· As jou baba ‘n geboorte gewig het van minder as ≤1200g gaan jou baba opgeneem word in 
saal G2 terwyl jy opgeneem gaan word in saal J5 of J2. Ons sal jou besoek in die saal nadat jou 
baba gebore is om die studie aan jou te verduidelik en jou en jou baba uit te nooi om aan die 
studie deel te neem. Ons sal vir jou ‘n brief gee wat die studie verduidelik en as jy instem om 
deel te neem, moet jy hierdie brief teken. Binne ‘n paar dae nadat jou baba gebore is sal jy 
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geskuif word na saal G2 om by jou baba te wees. Sodra jou baba groter is gaan jy en jou baba 
geskuif word na saal G8 or J2 in die Tygerberg Kinderhospitaal. Daar sal julle bly totdat jou 
baba gereed is om na ‘n ander hospitaal oorgeplaas te word. Julle sal gereed wees om huis toe 
te gaan as jou baba meer as 1800g weeg.  
· Babas sal deel wees van hierdie studie vir die eerste 28 dae na geboorte. 
 
2.2. Wat gaan met my gebeur as ek aan die studie deel neem? 
Klein premature babas is te swak om te drink aan die bors. Die ma moet haar bors uitmelk en 
die melk word dan aan die baba gegee deur middel van 'n dun plastiese pyp wat strek vanaf die 
baba se mond na die baba se maag. Die verpleegsters in Saal G2 sal jou leer om jou borsmelk 
uit te melk vir jou baba. As deel van die studie, wil ons die gehalte van sommige van die goeie 
komponente in jou borsmelk meet. Die belangrikste een is oligosakkariede wat ook help om jou 
baba te beskerm teen infeksies. Ons sal dus 'n 2ml monster van jou bors melk benodig op 
spesifieke tye.  
 
Die eerste melk monster word van jou benodig op dag 1 van die laktasie, dan op dag 7, 14, 21 
en weer op dag 28 van die baba se lewe. Hierdie 5 melkmonsters sal geneem word in 'n steriele 
houer en gevries word voordat dit getoets word in die laboratorium.  
Inligting uit jou hospitaal leêr gaan gebruik word soos hoe jou baba gebore is, watter medisyne 
jy gekry het gedurende swangerskap ens. Alle swanger vroue in die Wes-Kaap word getoets vir 
MIV tydens swangerskap. Omdat dit vir ons belangrik is om jou MIV status te weet, sal ons dit 
ook uit jou hospitaal leêr kry. 
 
2.3. Wat gaan met my baba gebeur as ek toestemming gee? 
Borsmelk stimuleer die groei van "goeie" kieme in die derm of ingewande van babas. 
As deel van die studie, wil ons die gehalte van sommige van die “goeie” kieme in jou baba se 
stoelgang meet. Die  “goeie” kieme beskerm jou baba teen infeksies en help hulle om te groei. 
Ons sal dus 'n 1g monster van jou baba se stoelgang benodig op spesifieke tye. Die eerste 
stoelgangmonster wat van jou baba benodig sal wees is die heel eerste stoelgang op dag 1 van 
die baba lewe, dan op dag 7, 14, 21 en weer op dag 28 van die baba se lewe. Hierdie 5 
stoelgangmonsters sal geneem word in 'n steriele houer en gevries word voordat dit getoets 
word in die laboratorium.  
 
Jou baba se leêr gaan elke dag deur die navorser gelees word en resultate van laboratorium 
toetse (bloed toetse ens), voedings en die medisyne wat jou baba kry gaan neergeskryf word. 
Klein babas word elke dag geweeg om te sien of hulle genoeg melk kry en goed genoeg groei. 
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Jou baba gaan elke dag geweeg word deur die verpleeg personeel. Op ‘n weeklikse basis gaan 
daar ook die volgende gedoen word: 
 
i. Kyk asseblief na figuur 1 om te sien watter metings op jou baba gedoen gaan word: 
A: kop omtrek 
B en D: silindriese omtrekke (Bv. Boarm omtrek ens.) 
C: Baba se lengte 
E: Voet lengte 
 
 
Figuur 1: Metings wat op jou baba gedoen gaan word 
E 
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ii. Velvou dikte: net die vet lagie onder jou baba se vel word opgelig, op verskillende plekke op 
sy/haar lyf en dit word gemeet deur ‘n kaliper te gebruik. Die doel van die meting is om te sien 
hoeveel vet jou baba se liggaam het. (Sien figuur 2) 
 
Figuur 2: Velvou dikte 
 
3. HOEKOM IS EK GEVRA OM DEEL TE NEEM? 
Jy is gekies om deel te neem aan die studie omdat jy ‘n baie klein baba, wat vroeg gebore is 
gehad het en opgeneem is in Saal G2 in die Tygerberg Kinder Hospitaal (TKH). 
 
4. SAL U VOORDEEL TREK DEUR DEEL TE NEEM AAN HIERDIE NAVORSINGSPROJEK? 
Jy gaan voordeel trek uit die wete dat jy ‘n belangrike bydra gemaak deur vir die mediese span 
(dokters, verpleegsters, dieetkundiges en navorsers) belangrike inligting te gee oor die groei, 
liggaamsamestelling en voedingsinname (voedings) van baie lae gewig babas. 
 
5. IS DAAR ENIGE RISIKO'S VERBONDE AAN U DEELNAME AAN HIERDIE 
NAVORSINGSPROJEK? 
Daar is geen risiko’s verbonde as jy sou kies om aan hierdie studie deel te neem nie. Jou baba 
gaan presies dieselfde hanteer word as enige ander klein baba wat opgeneem word in Saal G2 
in die Tygerberg Kinder Hospitaal. Al die metings wat geneem gaan word is bewys as veilig 
deur ander studies. Jou baba mag dalk ‘n bietjie ongemaklik wees wanneer hy/sy beweeg word 
om die metings te neem, maar al die metings is veilig en die navorsers sal nie jou baba 
seermaak nie. Die navorsers het die regte opleiding gekry om jou baba te kan meet. 
 
6. WATTER ALTERNATIEWE IS DAAR INDIEN U NIE INSTEM OM DEEL TE NEEM NIE? 
Dit is jou keuse of jy en jou baba wil deel neem of nie. As jy besluit om nie deel te neem nie 
gaan dit nie beïnvloed hoe goed daar na jou en jou baba gekyk word nie. Verder is jy welkom 
om enige tyd in die studie te sê, sonder ‘n verduideliking, dat jy en jou baba nie meer wil 
deelneem nie.  Jou en jou baba se gesondheidsorg gaan nie negatief beïnvloed word nie. 
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7. WIE SAL TOEGANG HÊ TOT U MEDIESE REKORDS? 
Net die navorser, navorsingsassistent en persone wat direk betrokke is met die studie sal 
toegang hê tot jou en jou baba se mediese rekords. Alle inligting sal altyd konfidensieël en 
privaat gehou word. Die navorser en navorsingsassistent sal alle inligting wat uit jou leêr 
geneem is streng konfidensieël en privaat hanteer en jou of jou baba sal nie geïdentifiseer kan 
word op grond van die inligting nie. Die inligting sal ook nie beskikbaar wees vir enige persoon 
wat nie direk betroke is met die studie nie. 
 
8. WAT SAL GEBEUR IN DIE ONWAARSKYNLIKE GEVAL VAN ’N BESERING WAT MAG 
VOORKOM AS GEVOLG VAN U DEELNAME AAN HIERDIE NAVORSINGSPROJEK? 
Die kans is baie klein dat iets verkeerd sal gaan. Deur die hele studie gaan algemene metodes 
gebruik word wat dus die kans dat iets verkeerd kan gaan baie klein maak. Al is die kans vir 
beserings so klein, is die studie en die navorsers gedek deur versekering.  
 
9. SAL U BETAAL WORD VIR DEELNAME AAN DIE NAVORSINGSPROJEK EN IS DAAR 
ENIGE KOSTE VERBONDE AAN DEELNAME? 
Jy sal nie betaal word om deel te neem aan die studie nie.Jy hoef ook nieks te betaal om deel 
te neem nie. . 
 
10. IS DAAR ENIGIETS ANDERS WAT U MOET WEET OF DOEN? 
· Jy kan die hoofnavorser kontak by +27 21 938 9474, +27 82 418 4906  indien jy enige verdere 
vrae het of enige probleme ondervind. 
· Jy kan die Gesondheidsnavorsingsetiek administrasie kontak by 021-938 9207 indien jy oor 
enige iets bekommerd is of ‘n klagte het wat nie goed genoeg deur jou navorser hanteer is nie. 
· Jy sal ’n afskrif van hierdie inligtings- en toestemmingsvorm ontvang vir jou eie rekords. 
 
11. VERSEKERING 
Hierdie studie het versekering, vir die tydperk van 1 Januarie 2016 tot 31 Desember 2016, vir 
die onwaarskynlike situasie wat daar iets verkeerd gaan in die studie. 
 
Verklaring deur deelnemer 
Met die ondertekening van hierdie dokument onderneem ek, 
…….....................……….....……...……….., om deel te neem aan ’n navorsingsprojek getiteld  
Groei, liggaamsamestelling en voedingsinname van MIV blootgestelde premature, lae 
geboorte gewig babas in Tygerberg Hospitaal, Wes-Kaap.  
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Ek verklaar dat: 
· Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat voorlees het 
en dat dit in ’n taal geskryf is wat ek verstaan en gemaklik mee is. 
· Ek geleentheid gehad het om vrae te stel en dat al my vrae goed beantwoord is. 
· Ek verstaan dat deelname aan hierdie navorsingsprojek my keuse is en dat daar 
geen druk op my geplaas is om deel te neem nie. 
· Ek te eniger tyd aan die navorsingsprojek mag onttrek en dat ek nie op enige wyse 
daardeur benadeel sal word nie. 
· Ek gevra mag word om van die navorsingsprojek te onttrek voordat dit afgehandel is 
indien die navorser van opinie is dat dit in my beste belang is, of indien ek nie die 
ooreengekome navorsingsplan volg nie. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2016. 
 
 
 ................................ ................................ ....   ................................ ................................ .. 
Handtekening van deelnemer Handtekening van getuie 
 
 
Verklaring deur navorser 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
· Ek die inligting in hierdie dokument verduidelik het aan 
……………………................... .......................... ……….. 
· Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit 
te beantwoord. 
· Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo 
bespreek, voldoende verstaan. 
· Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik is, moet die 
tolk die onderstaande verklaring teken.) 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2016. 
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 ................................ ................................ ....   ................................ ................................ .. 
Handtekening van navorder Handtekening van getuie 
 
 
Verklaring deur tolk 
 
Ek (naam) …………………………………...……………… verklaar dat: 
 
· Ek die navorser (naam) ………............................. …………………. bygestaan het om 
die inligting in hierdie dokument in Afrikaans/Xhosa aan (naam van deelnemer) 
…………………………….................. ....... te verduidelik. 
· Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het om dit 
te beantwoord. 
· Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is. 
· Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle verstaan 
en dat al sy/haar vrae bevredigend beantwoord is. 
 
 
Geteken te (plek) ..............................…………….. op (datum) …………....……….. 2016. 
 
 
 ................................ ................................ ....   ................................ ................................ .. 
Handtekening van tolk Handtekening van getuie 
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INCWADANA ENGOLWAZI NGOMTHATHI-NXAXHEBA KUNYE NEFOMU YEMVUMELWANO 
 
ISIHLOKO SEPROJEKTHI YOPHANDO: 
Ukukhula, okuqulathwe ngumzimba nendlela ezitya ngayo iintsana ezizelwe phambi 
kwexesha ebezikwindawo enabantu abaneNtsholongwane kaGawulayo, aiintsana ezincinci 
kakhulu ngokwasemzimbeni ukuzalwa kwazo kwisibhedlele saseTygerberg, eNtshona Koloni 
– Uhlobo lweGut Microbiome nook kufumaneka kwiikhabhohayidreyithi ezifumaneka kuBisi loMntu 
(Oligosacchardise).  
Uphando lweBIG HMO 
 
 
INOMBOLO YONXULUMANO: N15/10/12 
UMPHANDI OYINTLOKO: UGqr. Evette Van Niekerk, uNjing Ali Dhansay 
RESEARCHERS: UKlara Strydom, UThea Lodewyks 
IDILESI: 
Icandelo loKutya kwaBantu   
Isebe leeNzuluwazi ngezoNyango nezeMpilo 
Ikhampasi yaseTygerberg 
Umgangatho wesithathu 
Iyunivesithi yaseStellenbosch, eTygerberg 
IINOMBOLO ZOQHAGAMSHELWANO: +27 21 938 9474, +27 82 418 4906 
 
1. ISIMEMO 
Uyamenywa ukuba athathe inxaxheba kwiprojekthi yophando. Nceda thatha ixesha lokufunda 
ulwazi oluvezwe apha, oluzakuthi luchaze iinkcukacha zale projekthi. Nceda buza nayiphina imibuzo 
emalunga nayiphina indawo ongayiqondiyo ngokupheleleyo kubasebenzi besi sifundo okanye 
kugqirha. Kubaluleke kakhulu ukuba waniliseke ngokupheleleyo yinto yokuba ucacelwe kakuhle 
ukuba yintoni ebangwa sesi sifundo kwaye ungabandakanyeka njani. Kwakhona, ukuthatha kwakho 
inxaxheba ukwenza ngokuzithandela unganyanzelwa kwaye ukhululekile ukuba ungarhoxa 
ekuthatheni inxaxheba. Ukuba uthi hayi, oku akusayi kuchaphazela ukungavumi kwakho 
nangayiphina indlela. Ukwakhululekile ukuba uyeke kwesi sifundo, nkqu nokokuba uyavuma 
ukuthatha inxaxheba. 
 
Olu phando luvunywe ziinqobo ezisesikweni zeKomiti yoPhando Lomntu kwiYunivesithi 
yaseStellenbosch kwaye luza kwenziwa ngokwemigaqo esesikweni lophando elamkelekileyo 
kwiSaziso sehlabathi sika-Helsinki, iMigaqo eLungileyo yoMzantsi Afrika yokuSebenza eKliniki 
kunye neBhunga lezoPhando ngamaYeza (MRC) iMigaqo yeNqobo yezoPhando. 
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2. SIMALUNGA NANTONI ESI SIFUNDO SOPHANDO?  
Kuyazeka ukuba iintsana ezizalwa phambi kwexesha zikhula ngendlela eyahlukileyo kwiintsana 
ezizalwa ngexesha elifanelekileyo. Oku kungathetha ukuba iintsana azikhuli ngendlela efanele 
iminyaka yazo, oko kubangele ukuba zihlale ixesha elide esibhedlele. Iimveku eziselwe phambi 
kwexesha kunzima ukuzondla. Uhlobo nomgangatho woko zikutyayo kungayichaphazela indlela 
indlela ezikhula ngayo iintsana. Ukukhula kubalulekile ukuze nengqondo ikhule kwaye zikwazi 
iintsana ukufikelele kwiindlela zokukhula gabalala (ukuhlala, ukukhasa, ukuhamba njlnjl). Iintsana 
zaphambi kwexesha zaziwa ngokuba namafutsha amaninzi kuneentsana ezizalwa ngexesha 
elifanelekileyo. Oku kungathetha ukuba ezi ntsana zizelwe phambi kwexesha zingatyeba ngaphaya 
kokuba kufanelekile (zityebe kakhulu), zibenesifo seswekile neengxaki zentliziyo xa zindala.  
Ubisi lwebele luvuselela ukukhula kweentsholongwane “ezilungileyo” kumetyiso okanye 
kumathumbu osana. Uphando lubonakalise ukuba iintsholongwane “ezilungileyo” ezikubisi lwebele 
zingalunceda usana lukhule ngcono kwaye lukhusela iintsholongwane “ezingalunganga” ukuba 
zingalugulisi usana naxa lungakhuli ngokufanelekileyo. Iintsholongwane “ezilungileyo” eziphilayo 
esifuna ukuzijonga zibizwa ngokuba ziiPrebiotics. Kolu phando sifuna ukujonga ukuba zikhula 
kangakanani na iintsholongwane “ezilungileyo” kumetyiso okanye kumathumbu eentsana ezifumana 
ubisi lwebele nokuba ubungakanani beentsholongwane “ezilungileyo” buneempembelelo ekukhuleni 
jikelele kosana lwakho.   
 
Iintsana ezizalwa msinya kakhulu ziye zilaliswe kwaWadi G2 kwiSibhedlele saBantwana 
eTygerberg. Iintsana ezincinci kakhulu (ezizelwe phambi kwexesha) zinobukhulu obungaphantsi 
kwe-1200g, zizalwa ngoomama abaneNtsholongwane kaGawulayo okanye abangenayo 
iNtsholongwane kaGawulayo ziza kuthatha inxaxheba kolu phononongo. Ngolu phononongo sifuna 
ukufumanisa oku kulandelayo:  
i. Ukukhula noko kukhoyo emzimbeni (ipesenti yamafutha, izihlunu, amathambo namanzi 
asemzimbeni) kwiintsana ezizelwe phambi kwexesha zabo baneNtsholongwane 
kaGawulayo nabangenayo.  
ii. Iimpembelelo zokutya (ubisi lwebele, ubisi lwebele oluhamba nezinye izongezeleli zondlo 
(FM85) nobisi lwebhotile) okutyiwa ziintsana ezibangela ukukhula noko kusemizimbeni 
yazo.  
iii. Iimpembelelo zexesha oomama abachatshazelwe yiNtsholongwane kaGawulayo 
besebenzisa amayeza e-HAART ekukhuleni noko kusemzimbeni wosana oluchaphazeleke 
yiNtsholongwane kaGawulayo, ukuzalwa phambi kwexesha, neentsana ezincinci kakhulu 
emzimbeni xa zizalwa (ELBW; zingaphantsi kwe-1200g). 
iv. Ukuvavanya iimpembelelo zoko kukhoyo kwiikhabhohayidreyithi (oligosaccharide) 
ezikwiintsholongwane “ezilungileyo” ezikumetyiso wosana neempembelelo zoko ekukhuleni 
kwalo nakwizinto ezikhoyo kumzimba walo.  
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3. Niza kuyithatha njani inxaxheba wena nosana lwakho kolu phononongo? 
! Ukuba usana lwakho linobunzima bomzimba ongaphantsi kwe-1200g usana lwakho luza 
kulaliswa kwaWadi G2 ngeli xesha uza kulaliswa kwaWadi J5 okanye J2. Siza kuya kuwe 
ewadini emva kokubeleka kwakho usana lwakho sikucacisele ngophononongo kwaye sikucele 
wena nosana lwakho ukuba nithathe inxaxheba kuphononongo. Siza kukunika ileta 
ekucacisela ngophononongo kwaye ukuba uyavuma ukuthatha inxaxheba, kufuneka utyikitye 
ifomu yesivumelwano. Kwiintsuku nje ezimbalwa emva kokuzalwa kosana lwakho, uza 
kuthunyelwa uyohlala nosana lwakho kwawadi G2. Xa usana lwakho lulukhulu, wena nosana 
lwakho niza kusiwa kwawadi G8 okanye J2 kwiSibhedlele saBantwana eTygerberg apho uza 
kuhlala lude usana lwakho lukulungele ukusiwa kwesinye isibhedlele apho uza kuhlala khona 
lude usana lwakho lubenobukhulu obungaphezu kwe-1800g kwaye lulungele ukugoduka. 
! Iintsana ziza kuba kolu phononongo kwiintsuku ezingama-28 emva kokuba zizelwe.  
 
4. Kuza kwenzeka ntoni kum ukuba ndithatha inxaxheba? 
Iintsana ezincinci ezizelwe phambi kwexesha zibuthathaka kakhulu ukuba zinganxanxa zifunxe 
ibele. Umama kufuneka alicudise ibele lakhe akhuphe ubisi oluye lunikwe usana ngombhobho 
weplastiki obhityileyo osuka kumlomo wosana usiya kwisisu sosana. Oonesi abakwiwadi 
labantwana i-G2 baza kukufundisa ukuba ulucudisa njani ubisi ebeleni usenzela usana. 
Njengenxalenye yophando, sifuna ukuthelekisa umgangatho wokunye okulungileyo okufumaneka 
kubisi lwakho lwebele. Eyona ibalulekileyo yi-oligosaccharride ekwanceda ukukhusela usana lwakho 
lungosuleleki zizifo. Ngoko ke siza kufuna isampuli ye-2ml kubisi lwakho lwebele ngamaxesha 
athile. 
Isampuli yokuqala yobisi esiza kuyifuna kuwe iza kuba yeyosuku loku-1, yosuku lwesi-7. Lwe-14, 
lwama-21, lwama-28 luzelwe. Ezi sampuli zi-5 zobisi ziza kuqokelelwa zifakwe kwinkonkxa 
enezicoci necocekileyo ifakwe kwisikhenkcezisi phambi kokuba luhlolwe elebhu.  
Iinkcukacha ezifumaneka kwifayile yasesibhedlele ziza kusetyenziswa kuphononongo ezifana 
nokuba ubeleke njani, ngawaphi amayeza owafumeneyo ngoku ubukhulelwe, njlnjl. Bonke 
ababhinqileyo abakhulelweyo eNtshona Koloni bayahlolwa ukuba abanayo na iNtsholongwane 
kaGawulayo, siza kuyifumana imeko yakho kaGawulayo kwifayile yakho yasesibhedlele.  
 
5. Kuza kwenzeka kusana xa ndinika imvume yam?  
Ubisi lwebele luvumela iintsholongwane “ezilungileyo” zikhule kumetyiso okanye kumathumbu 
osana lwakho. Njengenxalenye yophando, sifuna ukuthelekisa umgangatho wezinye 
iintsholongwane “ezilungileyo ezikhulayo kumetyiso okanye kumathumbu osana lwakho ngokujonga 
umlinganiselo wobungakanani beentsholongwane “ezilungileyo” kwilindle lakhe. Iintsholongwane 
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“ezilungileyo” zinceda ukukhusela usana lwakho ekosulelekeni zizifo kuzincede zikhule ngendlela 
efanelekileyo. Ngoko ke siza kufuna isampuli ye-1g yelindle losana lwakho ngamaxesha athile. 
Isampuli yelindle yokuqala esiza kuyifuna kusana lwakho lilindle lokuqala losuku lokuqala lwesi-7. 
Lwe-14, lwama-21, lwama-28 luzelwe. Ezi sampuli zi-5 zobisi ziza kuqokelelwa zifakwe kwinkonkxa 
enezicoci necocekileyo ifakwe kwisikhenkcezisi phambi kokuba luhlolwe elebhu.  
Ifayile yosana lwakho iza kufundwa ngumphandi yonke imihla kwaye iziphumo zohlolo lwaselebhu 
(uhlolo lwegazi njlnjl.), ukutya namayeza afunyanwa lusana lwakho aza kubhalwa phantsi. Iintsana 
ezincinci ziza kubekwa esikalini yonke imihla kujongwe ukuba ingaba zifumana ukutya okwaneleyo 
na kwaye zikhula ngokufanelekileyo na. usana lwakho luza kubekwa esikalini ngamanesi. Rhoqo 
ngeveki kuza kwenziwa oku kulandelayo: 
i. Nceda ujonge iSazobe 1 kule milinganiselo ilandelayo eza kujongwa kusana lwakho:  
A: Ububanzi bentloko 
U-B no-D: Umlinganiselo ojonga ubude nobubanzi 
C: Ubude 
E: Ubude bonyawo 
Isazobe 1: Umlinganiselo oza kuthathwa kusana lwakho 
 
ii. Ubukhulu kububanzi besikhumba: Ngumaleko wamanqathe kuphela phantsi kofele 
ojongwayo, kwiindawo ezahlukeneyo emzimbeni, kwayo oko kujongwa ngqo umlinganiselo 
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kusetyenziswa isixhobo esibizwa ngokuba yi-calliper ukujonga ubungakanani bamanqathe 
akhoyo emzimbeni wosana lwakho. Jonga kwisazobe 2.  
 
 
 
 
 
 
Isazobe 2: Ubukhulu kububanzi besikhumba 
  
6. KUTHENI UMENYIWE UKUBA UTHATHE INXAXHEBA?  
Uye wakhethwa kuba ubeleke usana oluncinci kakhulu, oluzelwe phambi kwexesha kakhulu lwaze 
lwalaliswa kwawadi G2 kwiSibhedlele saBantwana saseTygerberg (TCH).   
 
 
7. INGABA UZA KUZUZA EKUTHATHENI INXAXHEBA KOLU PHANDO?  
Uza kuxhamla ngokwazi ukuba ube negalelo elibalulekileyo ngokunika iqela labonyango (ooGqirha, 
amanesi, iingcali ngokutya nabaphandi) iinkcukacha ezibalulekileyo malunga nokukhula, 
okuqulathwe ngumzimba nendlela ezitya ngayo iintsana ezizelwe phambi kwexesha zeVLBW ne-
ELBW.  
 
8. INGABA ZIKHO IINGOZI EZIBANDAKANYEKAYO EKUTHATHENI KWAKHO INXAXHEBA 
KOLU PHANDO?  
Akukho mngcipheko okhoyo ngokuthatha kwakho inxaxheba kolu phononongo. Usana lwakho luza 
kuphatheka ngendlela enye efanayo neyezinye iintsana ezilaliswa kwawadi G2 kwiSibhedlele 
saBantwana saseTygerberg. Konke ukuthathwa komlinganiselo nobunzima okuza kwenziwa 
kuqinisekisiwe ukuba kukhusselekile lolunye uphononongo. Usana lwakho lungangaphatheki 
kakuhle xa luyothatha imilinganiselo kodwa yonke imilinganiselo ethathwayo ikhuselekile kwaye 
abaphandi soze balwenzakalise usana lwakho. Abaphandi bafumene uqeqesho olufanelekileyo 
lokuthatha umlinganiselo kusana lwakho.  
 
9. UKUBA AWUVUMI UKUTHATHA INXAXHEBA, LOLUPHI OLUNYE UNYANGO ONALO?  
Nguwe onokuzikhethela ukuba ingaba wena nomntwana wakho niyafuna na ukuthatha inxaxheba 
kolu phononongo. Ukuba ugqiba ukuthatha inxaxheba kuphononongo oko akuzokuchaphazela 
wena nosana lwakho. Okunye, uvumelekile, nanini na nokuba awunasizathu, ukuba awufuni wena 
nomntwana wakho ukuthatha inxaxheba kuphononongo. Indlela oqhele ukukhathalelwa ngayo 
kwezempilo wena nosana lwakho ayizi kuchaphazeleka kakubi.  
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10. NGUBANI UZA KUFUMANA INGXELO YAKHO YAMAYEZA?  
Ngumphandi kuphela, abancedisi kuphando nabantu ababandakanyeka ngqo kolu phononongo 
abazokwazi ukuzifumana iingxelo zakho nezosana lwakho. Zonke iinkcukacha ziza kusoloko 
zigcinwe ziyimfihlo bucala. Abaphandi nabancedisa kuphando baza kuzithatha zonke iinkcukacha 
ezifunyenweyo njengeziyimfihlo kwaye akukho zinkcukacha ezinokubangela waziwe ukuba 
ungubani wena okanye umntwana wakho aza kunikwa nabani na ongabandakanyekiyo ngendlela 
ethe ngqo kolu phononongo.  
 
11. KUZA KWENZEKA NTONI KWIMEKO YESIGANEKO ESINGALINDEKANGA 
SOKWENZAKALA NGENXA YOKUTHATHA KWAKHO INXAXHEBA KWESI SIFUNDO 
SOPHANDO?  
Kunqabe kakhulu ukuba kubekho into engahambi kakuhle. Kulo lonke uphononongo kuza 
kusetyenziswa iindllea eziqhelekileyo, ngoko ke oko kuza kwenza amathuba amancinci okuba 
kungakho into embi enokwenzeka.  
 
12. INGABA UZA KUHLAWULWA NGOKUTHATHA INXAXHEBA KWESI SIFUNDO KWAYE 
INGABA KUKHO IINDLEKO EZIBANDAKANYEKAYO?  
Hayi, awuzi kuhlawulwa ngokuthatha kwakho inxaxheba kolu phononongo. Nawe akukho nto kuza 
kufuneka uyihlawule, ukuba uthatha inxaxheba kolu phononongo. 
 
13. INGABA IKHO ENYE INTO EKUMELE UYAZI OKANYE UYENZE?  
! Ungaqhagamshelana nomphandi oyintloko okanye abenza uphando ku +27 21 938 9474, 
+27 82 418 4906 ukuba unayo nayiphi na into ofuna ukuyiqonda okanye ufumana nayiphi na 
ingxaki. 
! Ungaqhagamshelana neKomiti yoPhando Lomntu kwa-021-938 9207 ukuba unenkxalabo 
okanye izikhalazo ezingasonjululwanga kakuhle ngugqirha wakho wesifundo. 
! Uza kufumana ikopi yezi nkcukacha neyefomu yesivumelwano ukuba uzigcinele. 
  
14. I-INSHORENSI 
Olu phononongo lunayo i-inshorensi esusela ngomhla woku-1 ngoJanuwari ka-2016 – kowama-31 
ngoDisemba ka-2016, xa kunokwenzeka isehlo esingaqhelekanga sento engahambanga kakuhle 
ngeli xesha kuqhutywa olu phononongo.  
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Isifungo somthathi-nxaxheba 
Ngokuytyikitya ngezantsi, Mna …………………………………..…………. ndiyavuma ukuthatha 
inxaxheba kwisifundo sophando semfuzo esibizwa ngokuba Ukukhula, okuqulathwe ngumzimba 
nendlela ezitya ngayo iintsana ezizelwe phambi kwexesha ebezikwindawo enabantu 
abaneNtsholongwane kaGawulayo, aiintsana ezincinci kakhulu ngokwasemzimbeni ukuzalwa 
kwazo kwisibhedlele saseTygerberg, eNtshona Koloni. 
 
Ndazisa ukuba: 
 
· Ndilufundile okanye ndalufunda olu lwazi kunye nefomu yemvumelwano kwaye ibhalwe 
ngolwimi endiliciko nendikhululekileyo kulo  
· Bendinalo ithuba lokuba ndibuze imibuzo kwaye yonke imibuzo yam iphendulwe 
ngokwanelisayo. 
· Ndiyakuqonda ukuba ukuthatha inxaxheba kolu phando kube kukuzithandela kwam 
kwaye andikhange ndinyanzelwe ukuba ndithathe inxaxheba. 
· Ndingakhetha ukusishiya isifundo naninina kwaye andisayi kohlwaywa okanye uqal’ 
ugwetywe nangayiphi indlela. 
· Usenokucelwa ukuba usishiye isifundo phambi kokuba siphele, ukuba ugqirha wesifundo 
okanye umphandi ukubona kuyinzuzo kuwe, okanye ukuba andisilandeli isicwangciso sesifundo, 
ekuvunyelenwe ngaso. 
 
 
Kutyikitywe e-(indawo) .........…........…………….. ngo-(usuku) ………....……….. 2016. 
 
 
 ................................ ................................ ....   ................................ ................................ ..  
Umtyikityo womthathi-nxaxheba   Umtyikityo wengqina 
 
 
Isifungo somphandi 
 
Mna (igama) ………………………………………………… ndiyafunga ukuba: 
· Ndilucacisile ulwazi olu kweli xwebhu ku-…………………..……………... 
· Ndimkhuthazile ukuba abuze imibuzo kwaye athathe ixesha elifanelekileyo ukuba 
ayiphendule. 
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· Ndiyaneliseka kukuba uyakuqonda ngokwanelisayo konke okumalunga nophando 
okuxoxwe ngasentla. 
· Ndisebenzise/andisebenzisanga toliki.  (Ukuba itoliki isetyenzisiwe kumele ityikitye 
isaziso ngezantsi. 
 
 
Kutyikitywe e-(indawo) .........…........…………….. ngo-(usuku) ………....……….. 2016. 
 
 
 ................................ ................................ ....   ................................ ................................ ..  
Umtyikityo womphandi     Umtyikityo wengqina 
 
 
Isifungo setoliki 
 
Mna (igama) ………………………………………………… ndazisa ukuba: 
· Ndicende umphandi (igama) …………………………. Ekucaciseni ulwazi olu lapha kweli 
xwebhu ku-(igama lomthathi-nxaxheba) …………………………….. ndisebenzisa ulwimi 
lwesiAfrikaans/lwesiXhosa. 
· Simkhuthazile ukuba abuze imibuzo kwaye athathe ixesha elifanelekileyo ukuba 
ayiphendule. 
· Ndimxelele eyona nto iyiyo malunga nokunxulumene nam. 
· Ndiyaneliseka kukuba umthathinkxaxheba ukuqonda ngokupheleleyo okuqulathwe 
loluxwebhu lwemvumelwano eyazisiweyo kwaye nemibuzo yakhe yonke iphendulwe 
ngokwanelisayo. 
 
 
Kutyikitywe e-(indawo) .........…........…………….. ngo-(usuku) ………....……….. 2016. 
 
 
 ................................ ................................ ....   ................................ ................................ ..  
Umtyikityo wetoliki Umtyikityo wengqina 
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ADDENDUM C: ETHICS APPROVAL 
 
 
Approval Notice
Response to Modifications- (New Application)
14-Dec-2015
Van Niekerk, Evette E
Ethics Reference #: N15/10/102
Title:
Growth, body composition and nutritional intake of HIV exposed preterm, very- and extremely-low birth weight infants
in Tygerberg hospital, Western Cape.
Dear Dr. Evette Van Niekerk,
The Response to Modifications - (New Application) received on 10-Dec-2015, was reviewed by members of Health Research Ethics Committee 1
via Expedited review procedures on 14-Dec-2015 and was approved.
Please note the following information about your approved research protocol:
Protocol Approval Period: 14-Dec-2015 -13-Dec-2016
Please remember to use your protocol number  (N15/10/102) on any documents or correspondence with the HREC concerning your research protocol.
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications, or
monitor the conduct of your research and the consent process.
After Ethical Review:
Please note a template of the progress report is obtainable on www.sun.ac.za/rds and should be submitted to the Committee before the year has expired.
The Committee will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected
randomly for an external audit.
Translation of the consent document to the language applicable to the study participants should be submitted.
Federal Wide Assurance Number: 00001372
Institutional Review Board (IRB) Number: IRB0005239
The Health Research Ethics Committee complies with the SA National Health Act No.61 2003 as it pertains to health research and the United States
Code of Federal Regulations Title 45 Part 46. This committee abides by the ethical norms and principles for research, established by the Declaration of
Helsinki, the South African Medical Research Council Guidelines as well as the Guidelines for Ethical Research: Principles Structures and Processes
2004 (Department of Health).
Provincial and City of Cape Town Approval
Please note that for research at a primary or secondary healthcare facility permission must still be obtained from the relevant authorities (Western Cape
Department of Health and/or City Health) to conduct the research as stated in the protocol. Contact persons are Ms Claudette Abrahams at Western
Cape Department of Health (healthres@pgwc.gov.za Tel: +27 21 483 9907) and Dr Helene Visser at City Health (Helene.Visser@capetown.gov.za Tel:
+27 21 400 3981). Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics
approval is required BEFORE approval can be obtained from these health authorities.
We wish you the best as you conduct your research.
For standard HREC forms and documents please visit: www.sun.ac.za/rds
If you have any questions or need further assistance, please contact the HREC office at 0219389657.
Included Documents:
Declaration K Strydom
Data collection sheet
CV K Strydom
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CV E van Niekerk
20151211 MOD Consent English
20151211 MOD Consent Afrikaans
Protocol
Payment form
Protocol Synopsis
20151211 MOD Protocol
Cover letter
20151211 MOD Cover letter
Consent form (Afrikaans)
Declaration E van Niekerk
Declaration T Lodewyks
Consent form (English)
Application form
CV MA Dhansay
Checklist
Declaration MA Dhansay
CV T Lodewyks
Confirmation of Liability and PI insurance
Sincerely,
Franklin Weber
HREC Coordinator
Health Research Ethics Committee 1
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Investigator Responsibilities
Protection of Human Research Participants
Some of the responsibilities investigators have when conducting research involving human participants are listed below:
1.Conducting the Research.  You are responsible for making sure that the research is conducted according to the HREC approved research protocol. You
are also responsible for the actions of all your co-investigators and research staff involved with this research.
2.Participant Enrolment.  You may not recruit or enrol participants prior to the HREC approval date or after the expiration date of HREC approval. All
recruitment materials for any form of media must be approved by the HREC prior to their use. If you need to recruit more participants than was noted
in your HREC approval letter, you must submit an amendment requesting an increase in the number of participants.
3.Informed Consent.  You are responsible for obtaining and documenting effective informed consent using only the HREC-approved consent documents,
and for ensuring that no human participants are involved in research prior to obtaining their informed consent. Please give all participants copies of the
signed informed consent documents. Keep the originals in your secured research files for at least fifteen (15) years.
4.Continuing Review. The HREC must review and approve all HREC-approved research protocols at intervals appropriate to the degree of risk but not
less than once per year. There is no grace period.  Prior to the date on which the HREC approval of the research expires, it is your responsibility to
submit the continuing review report in a timely fashion to ensure a lapse in HREC approval does not occur.  If HREC approval of your research
lapses, you must stop new participant enrolment, and contact the HREC office immediately.
5.Amendments and Changes.  If you wish to amend or change any aspect of your research (such as research design, interventions or procedures, number
of participants, participant population, informed consent document, instruments, surveys or recruiting material), you must submit the amendment to the
HREC for review using the current Amendment Form. You may not initiate  any amendments or changes to your research without first obtaining
written HREC review and approval. The only exception  is when it is necessary to eliminate apparent immediate hazards to participants and the HREC
should be immediately informed of this necessity.
6.Adverse or Unanticipated Events.  Any serious adverse events, participant complaints, and all unanticipated problems that involve risks to participants
or others, as well as any research-related injuries, occurring at this institution or at other performance sites must be reported to the HREC within five (5)
days of discovery of the incident. You must also report any instances of serious or continuing problems, or non-compliance with the HRECs
requirements for protecting human research participants. The only exception to this policy is that the death of a research participant must be reported in
accordance with the Stellenbosch Universtiy Health Research Ethics Committee Standard Operating Procedures www.sun025.sun.ac.za/portal
/page/portal/Health_Sciences/English/Centres%20and%20Institutions/Research_Development_Support/Ethics/Application_package  All reportable
events should be submitted to the HREC using the Serious Adverse Event Report Form.
7.Research Record Keeping.  You must keep the following research-related records, at a minimum, in a secure location for a minimum of fifteen years: the
HREC approved research protocol and all amendments; all informed consent documents; recruiting materials; continuing review reports; adverse or
unanticipated events; and all correspondence from the HREC
8.Reports to the MCC and Sponsor.  When you submit the required annual report to the MCC or you submit required reports to your sponsor, you
must provide a copy of that report to the HREC. You may submit the report at the time of continuing HREC review.
9.Provision of Emergency Medical Care.  When a physician provides emergency medical care to a participant without prior HREC review and approval,
to the extent permitted by law, such activities will not be recognised as research nor will the data obtained by any such activities should it be used in
support of research.
10.Final reports. When you have completed (no further participant enrolment, interactions, interventions or data analysis) or stopped work on your
research, you must submit a Final Report to the HREC.
11.On-Site Evaluations, MCC Inspections, or Audits.  If you are notified that your research will be reviewed or audited by the MCC, the sponsor, any
other external agency or any internal group, you must inform the HREC immediately of the impending audit/evaluation.
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ADDENDUM D: INSURANCE 
 
 
     
 
Marsh (Pty) Limited 
50 Dorp Street 
Stellenbosch,7600 
P.O Box 414  
Stellenbosch 
7599 
+27 21 834 1346 
www.marsh-africa.com 
 
An authorised financial services provider 
FSB/FSP Licence no.: 8414 
Registration no.: 1999/000348/07 
Directors: IB Skosana (Non-Executive Chairman), JJ Erwee (CEO), BR Blake (Vice Chairman)*, F Abrahams,   
R Ebrahim, S Montsi, M Pienaar, MG Sokkie  (*British) 
 
         
 
 
 
06th October  2015 
 
TO WHOM IT MAY CONCERN 
 
STELLENBOSCH UNIVERSITY:  CONFIRMATION OF INSURANCE. 
 
Growth, body composition and nutritional intake of HIV exposed preterm, very- and 
extremely-low birth weight infants in Tygerberg hospital, Western Cape 
 
This serves to confirm that the following cover has been arranged for Stellenbosch University and 
others: 
 
1. Primary General Liability (Broad form) insurance policy number 
  1000/28439 underwritten by Stalker Hutchison Admiral for a limit of R5 000 000. 
 
2. Umbrella Liability insurance policy no 1000/22890 underwritten by Stalker Hutchison Admiral 
for a limit of R150 000 000. 
 
3. Total Liability limit – R155 000 000 
 
4. Professional Indemnity insurance policy number P01380 underwritten by Stalker Hutchison 
and Admiral for a limit of ZAR 150 000 000. 
 
5. The cover mentioned above is extended to include North American extension. 
 
6. Period of insurance: 1 January 2015 to 31 December 2015 
 
 Subject to the terms, conditions and exclusions of the policy wordings. 
 
We trust that you will find the above to be in order. Please do not hesitate to contact the writer 
should you have any queries. 
 
Kind regards 
 
 
Jackie Beer 
Senior Broker 
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